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"Alice opened the door and found that it led into 
a small passage, not much larger than a rat-hole: 
she knelt down and looked along the passage into 
the loveliest garden you ever saw. How she 
longed to get out of that dark hail, and wander 
about among those beds of bright flowers and 
those cool fountains, but she could not even get 
her head though the doorway; 'and even if my 
head would go through,' thought poor Alice, 'it 
would be of very little use without my shoulders. 
Oh, how I wish I could shut up like a telescope! I 
think I could, if I only know how to begin.' For, 
you see, so many out-of-the-way things had 
happened lately, that Alice had begun to think that 
very few things indeed were really impossible." 
from "Alice's Adventures in Wonderland" 
by Lewis Carroll 
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Organoruthenium complexes of the type [(? 7 6_arene)Rull(YZ)Cl]+, where the arene is 
benzene or a benzene derivative, and YZ = chelating ligand exhibit anticancer 
activity, including activity against cisplatin resistant cancer cells. This thesis is 
concern with synthesis and characterization of novel Ru" arene anti-cancer 
complexes, containing different arenes and chelating ligands (YZ). The mechanism of 
action and cytotoxic activity of these complexes are investigated. 
Synthesis and characterization of complexes of the type [(,i6-arene)Ru(en)Cl],  where 
the arene is ortho- , meta- or para-terphenyl (o-, m- or p-terp) are reported. [(i 6-p-
terp)Ru(en)Cl] has a similar potency to cisplatin and much higher activity, against 
cancer cell lines, than o- and m-terp analogues. p-Terp complex binds to DNA rapidly 
and quantitatively and the experimental data are consistent with combined 
intercalative and monofunctional (coordination) binding mode of [( ,6-p-
terp)Ru(en)Clf. The o- and m-terp analogues bind to DNA preferentially through the 
coordination. The o- and m-terp complexes have similar collision cross-sections as a 
result of similarities in size and shape. Therefore it is difficult to separate them using 
ion-mobility in combination with mass spectrometry. Both o- and m-terp complexes 
could be separated from the p-terp analogue. 
The synthesis and characterization of Ru" arene complexes containing 2,2'-bipyridine 
(bipy), 2,2'-bipyridine-3 ,3 '-diol (bipy(OH)2) or deprotonated 2,2'-bipyridine-3 ,3 '-diol 
(bipy(OH)O) as chelating ligands and different arenes are reported as well, including 
several x-ray crystal structures. In aqueous solution only deprotonated (bipy(OH)O) 
form of the 2,2'-bipyridine-3,3'-diol are present. Hydrolyses of these complexes are 
relatively fast and when the arene is biphenyl, initial aquation is followed by partial 
vi 
arene loss. Complexes with bipy(OH)O as chelating ligands, in general exhibit good 
cytotoxicity towards A2780 human ovarian cancer cells. These activity data can be 
contrasted with those of the parent bipy complex [(,7 6-tha)Ru(bipy)C1][PF6], where tha 
= tetrahydroanthracene, which is inactive towards A2780 cells (1050 > 100 jiM). 
However [(, 6-ind)Ru(bipy(OH)2)Cl][PF6] and [(7 6-ind)Ru(bipy)Cl][PF6], where md = 
indane, bind only weakly to DNA and therefore DNA may not be the major target for 
these complexes. 
Loss of cytotoxic activity was observed for Ru" arene complexes containing different 
arenes, halides and o-phenylenediamine (o-pda) or o-benzoquinonediimine (o-bqdi) 
as chelating ligands, going from the amine complexes to its oxidized (imine) form 
(e.g. IC50 = 11 M for [(11 6-p-cym)Ru(o-pda)Cl][PF6] and IC50> 100 M for 
[(,6 
hmb)Ru(o-bqdi)Cl][PF6], where p-cym = para-cymene and hmb = 
hexamethylbenzene, against A2780 cells). The loss of activity is contributed to the 
absence of hydrolysis or to the formation of the less stable adducts with 9-
ethylguanine (9-EtG), which leads to the weakened binding to DNA. The x-ray crystal 
structures of [(16-p-cym)Ru(o-pda)C1] [PF6] and [(,1 6-hmb)Ru(o-bqdi)Cl] [PF 6] are 
reported and their differences discussed. 
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Chapter 1: Introduction 
Chapter 1 
Introduction 
"There is no subject so old that something new cannot be said about it." 
Fyodor Dostoyevsky 
Chapter 1: Introduction 
This thesis is concerned with the synthesis and characterization of Ru" arene 'piano-
stool' complexes and their potential application as anti-cancer agents. The focus of 
this work is on development of structure-activity relationships with the view to design 
more promising anticancer agents. The focus of this Chapter is on general chemistry 
of ruthenium (Ru) and its complexes. Metal-based drugs used in the treatment of 
cancer are discussed as well. 
1.1 Metals in medicine 
The elements thought to be essential for human life are: H, C, N, 0, F, Na, Mg, Si, P, 
S, Cl, K, Ca, V, Mn, Fe, Co, Ni, Cu, Zn, Se, Mo, Sn, and I. Still some of these 
biochemically essential elements can be toxic at high doses. 
Metal excesses (poisonings) as well as deficiencies have been of a particular interest 
in medicine and health science disciplines for a long period of time.' Metals are not 
biodegradable and their toxicity determination is a problem caused by a complex 
nature of interactions of metals with biological systems. 2 Use of metals in medicine 
traces back in antiquity, and began with the use of Fe, Au and As in the treatment of 
different chronic dieses. However there is a subtle balance between the therapeutic 
benefit on the one hand and the side-effects on the other hand. 
2 
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1.1.1 Metal-based drugs 
The wide range of coordination numbers and geometries, as well as the wide range of 
accessible oxidation states and thermodynamic as well as kinetic characteristics of 
metal ions, leads to metal-based compounds offering possibilities for design of 
therapeutic agents. Therefore medicinal inorganic chemistry is an expanding field and 
discoveries in inorganic and bioinorganic chemistry have had a significant impact on 
modem clinical medicine. 
In modem times, the first metal-based drug to find use in medicine was an arsenical, 
Salvarsan, used in the treatment of syphilis. 3 The later availability of penicillin made 
this drug redundant. 
Therapeutic applications of metal compounds, such as the use of platinum complexes 
in cancer chemotherapy, gallium in hypercalcemia, bismuth as anti-ulcer medication, 
and sodium nitroprusside in hypertension have been described previously, as well as 
the use of metal radionuclides in diagnosis and radiotherapy and paramagnetic metal 
complexes as contrast agents in magnetic resonance imaging. 4 
Li salts are used in neurological disorders 1 and Au drugs have proven effectiveness in 
treating rheumatoid and psoriatic arthritis as well as bronchial asthma. 5 Vanadium 
compounds have been studied for use as insulin mimetics for treating diabetes. 6 
Medical use of Co, Cs and Ra as gamma ray-emitters in radiotherapy for cancer, the 
use of Ag for treatment of bums and Hg in the form of calomel ointment as an 
antiseptic have been described.' 
3 
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1.2 Statistics and history of cancer 
Cancer is thought to be an old disease. Scientists now a day think that even dinosaurs 
may have had cancer. From looking at the remains of Egyptian mummies it has been 
found that they suffered from cancer as well. 7 The word cancer comes from the 
ancient Greek language and means crab. The Greeks thought that clusters of cancer 
cells looked like the legs of a crab. 
Cancer is a second leading cause of death, after heart diseases, in the United States. 8 
All type of cancers display characteristic uncontrolled cell division and these cells 
have the ability to invade healthy tissues. There are around 200 different types of 
cancer. Some are very common, others are rare. Development of cancer involves a 
series of complex mechanisms related to a genetic make up and exposure to certain 
risks. 
1.3 Platinum-based anticancer drugs 
The discovery of the biological activity of cisplatin 9 was followed by the extensive 
use of the drug in cancer chemotherapy. Cisplatin is highly effective in the treatment 
of testicular cancer, with a 90% cure-rate. 10 The use of cisplatin is restricted by its 
side-effects, which include nephrotoxicity, neurotoxicity and emetogenesis. 
The most widely used drugs for treatment of various types of cancers are platinum-
based drugs. A limiting factor in the use of platinum based drugs is resistance of cells 
to these drugs being developed with time." More than 3000 platinum compounds 
have been synthesized and tested for biological activity. 12  Only four platinum drugs 
are registered as marketed drugs. These are cisplatin, carboplatin, oxaliplatin and 
4 
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nedaplatin (Figure 1. 1), oxaliplatin being the only one approved by the food and drug 
administration (FDA for colorectal cancer), since the release of cisplatin and 
carboplatin." 13,14 
H 3 	CI 
—Pt.,...- - 
HP 	CI 
C is plati n 
C r1111N I-Pt-1.1 
0:: 0 
H3 .. 	 ,.O 
H3 N 	0 0 
0 
carboplatin 
H3 N.-.,.- 	.O 
LI 
H3N 	 0 
oxaliplatin 	 nedaplatin 
Figure 1.1 Chemical structures of marketed platinum anticancer drugs. 
1.4 Other metal based anti-cancer drugs 
Both the success and drawbacks of cisplatin as an anticancer drug prompted a search 
for analogous transition metal complexes. The anticancer activity of metallocene 
complexes [MCp2C12] is dependent on the metal ion, and it has been found that when 
M = Ti, V, Nb, or Mo complexes are active and when M = Ta and W complexes show 
marginal activity, while for M = Zr and Hf, complexes were found to be inactive.' 5, 16 
Titanocene and vanadocene dichloride were found to exhibit the best activity against 
lung, breast and gastrointestinal cancers in mice. 
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The tetrahedral organometallic Ti" complex titanocene dichloride [TiCp2C12] was one 
of the two Ti" complexes to enter clinical trials. The clinical trials of both budotitane 
and titanocene dichloride (Figure 1.2) have now been abandoned, whereas trials of 
some gallium complexes are still in progress. 
Au' and Au t11 complexes have been tested for anti-cancer activity in different cell 
lines, and some of these were found to exhibit good activity but their cardiovascular 











Bud otita ne 
Figure 1.2 Ti1" anticancer complexes, titanocene dichloride and budotitane. 
1.5 Mechanism of action of cisplatin 
Once in body fluids cisplatin can interact with various biomolecules,' 7 but its 
antitumour activity derives from its capability to form bifunctional DNA cross-links 
after the activation through hydrolysis. The evidence that DNA is the primary target 
for cisplatin among many potential cellular targets has been extensively discussed. 18 
The major target site for cisplatin on DNA is N7 of guanine (G) nucleobase, 19 the 
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most electron-rich site on DNA and easily accessible to the drug in the major groove 
of B-DNA. Other binding sites include N7 of adenine (A) nucleobase and N3 of 
cytosine (C). 1, 2-Intrastrand cross-links that involve G and sometimes A are the most 
common platinated adducts of DNA from cancer cells treated with cisplatin. 
In the GG intrastrand cross-linking pathway, aquation is followed by monofunctional 
adduct formation and then ring closure to give the bifunctional GG macrochelate. 19 H-
bonding formation between NH protons of cisplatin and the phosphate backbone or 
C60 of G nucleobase can play a role in stabilizing such cross-links. 20  The GG 
platination causes B-DNA to bend (by about 35_400),  and this bend is recognized by 
proteins such as High Mobility Group (HMG) proteins. HMG proteins bind strongly 
to bent platinated DNA (Figure 1.3) and this causes shielding from repair and leads to 
apoptosis.223 At the same time HMG proteins are hijacked from their normal 
function. 24 
Interstrand DNA cross-links can also cause major structural changes in DNA. These 
changes are rarer but could be important for cytotoxicity. The interstrand DNA cross-
link made by cisplatin unwinds DNA close to the platination site and bends the helix 
toward the minor groove where Pt is bound. 1° 
7 
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4fr 
Figure 1.3 Adduct formed between the nonsequence-specific domain A of HMGI 
and DNA modified by cisplatin. Colour code for cisplatin: Pt, deep blue and N of the 
NH3 groups, yellow. Colour code for DNA: N, blue; 0, red; P. orange and C, grey. 
Domain A of HMG1 is a purple ribbon with the intercalating phenylalanine 
23 highlighted in green (Coordinates are taken from the Protein Data Bank, ICKT).  
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1.5.1 Apoptosis 
On one hand an extensive occurrence of cell death results in serious consequences for 
the whole organism and on the other hand low induction of apoptosis is connected to 
an increased cancer risk. 2 Insufficient apoptosis is common in diseases such as 
mononucleosis, diabetes and cancer, while excessive apoptosis is common in diseases 
such as AIDS (Acquired immune deficiency syndrome), Alzheimer's disease, 
Parkinson's disease and in rejection of transplanted organs. 
1.6 Ruthenium chemistry 
Ruthenium is a group 8 transition metal and together with Os, Rh, Ir, Pd and Pt forms 
the platinum metals group. Ru has atomic number 44 (Kr5s'4d7) and the atomic 
weight 101.07. Ru has seven isotopes (96Ru, 98Ru, 99Ru, ' °°Ru, ' ° 'Ru, 102RU and 
104Ru), 102 R being the most abundant at 31.6%. The oxidation states of Ru range 
from 0 to VIII, and the most common oxidation states in bioinorganic chemistry are 
II, III and IV.25 Ru" and Ru" compounds usually have six-coordinated low-spin 
octahedral geometry. The three (t2 g)d orbitals are oriented towards the faces of the 
octahedron and are fully populated in Ru" while in Ru" (t2 g)d orbitals have a single 
electronic vacancy. 26, 27 The difference of one electron between the two oxidation 
states affects significantly their chemistry. Ru" behaves as a relatively "soft", 28  7E_ 
donor metal ion while Ru" behaves as borderline "hard" metal ion, which can 
function as a 1-acceptor. 29 
The reduction potential for the Ru ... /Ru" couple is a strong function of the ligand 
environment.'"' The effect of back donation of electron density from the metal 
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stabilizes Ru in lower oxidation state (Ru"). Therefore the coordination of it-acceptor 
ligands increases the reduction potential, while the electron donor ligands cause its 
decrease. 29,34 
1.7 Ruthenium antitumour agents 
Different types of ruthenium complexes have been tested with the aim of discovering 
a behaviour similar to that of cisplatin, but it has been found that just a few exhibit 
this. 35  Metal complexes are often prodrugs and they undergo transformations before 
reaching the target. The transformation of the complex can include oxidation or 
reduction of the metal ion, ligand substitution or modification of the ligands that are 
still bound to the metal. Therefore, in structure—activity relationships the nature of the 
active species, the role of the metal itself, and the role of the ligands are of the great 
importance. 
It has been found that Ru complexes are usually active against Pt-resistant tumours. 36 
Ru and its complexes have several features which make them very good for 
pharmacological use. Due to strong ligand field stabilization energy, ruthenium 
complexes of the most common oxidation states (Ru" and Ru' 11) are octahedral in 
geometry (vide infra) and fairly inert to ligand substitution, especially Ru" 
complexes. 37  This makes them attractive as drugs as they should ideally arrive at the 
target intact. 
Ru", due to its similarity with Fe", is thought to be transported into tumour cells via 
transferrin. Tumour cells should have a higher density of transferrin receptors due to 
the increased requirements for nutrients, which provides selectivity for targeting 
10 
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cancer cells over, those that are not. When transferrin is bound to the receptor it 
releases the drug. 
Fac-[Ru"C13(NH3)3] was found to induce filamentous growth of E. coli at 
concentrations comparable to cisplatin. 38 Both fac-[Ru ... C13(NH3)3] and cis-
[Ru"C12(NH3) 4] Ru-ammine complexes have low solubility which makes them 
unsuitable as drugs. 37 
Several other Ru" and Ru'11 complexes have been reported to exhibit anticancer 
activity, including mer-[Ru(terpy)C13] (terpy = 2,2':6',2 "-terpyridine), a-
[Ru(azpy)2C12] and a-[Ru(azpy)2-0,0'] (azpy = 2-(phenylazo)pyridine; 0,0' = 1,1-
cyclobutanedicarboxylate, oxalate, or malonate)39' 40  as well as Ru" complex 
[Ru(H2cdta)Cl2] (cdta = 1 ,2-cyclohexanediaminetetraacetate). 4 ' 
1. 7.1 Ru" complexes in clinical trials 
The most significant was the entry of two Ru" octahedral complexes into clinical 
trials for cancer treatment. One of them NAMI-A (imidazolium irans-
tetrachlorodimethylsulfoxideimidazoleruthenate(III); Figure 1.4), has relatively low 
toxicity towards cancer cells, but is particularly effective against solid tumour 
metastases and the drug has completed phase I clinical trials. 42  DNA has been 
proposed as one of the biological targets of KP 1019 (indazolium trans-
tetrachlorobis(lH-indazole)ruthenate(III); Figure 1.4), and it has also been reported 
that the drug triggers apoptosis. 43 However, the cellular mechanism of the activation 
of apoptosis is still not understood. 
11 
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Figure 1.4 Chemical structures of NAMI-A and KP1019, Ru" antimetastatic and 
cytotoxic potential anticancer agents, respectively. 
It has been suggested that Ru" complexes are "activated by reduction" in vivo to Ru" 
and so they should coordinate more rapidly to biomolecules 44,45  due to the increased 
lability of Ru"-CI bonds compared to that in Ru" complexes, which tend to be more 
inert toward ligand substitution (vide infra). The reduction of Ru" to Ru" could occur 
by single-electron transfer from proteins which exist in the mitochondrial electron-
transfer chain or proteins in microsomal electron-transfer systems. Microsomal 
proteins are believed to be more efficient. 37  Oxidation of Ru" back to Ru 111 could 
occur by reaction with molecular oxygen or cytochrome oxidaze, 46 as well as with 
other oxidants. 
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1.8 Ru" arene anticancer complexes 
Ru" arene complexes with phosphine ligands have been reported to possess 
antitumour and DNA binding properties. 4749 They include bifimctional Ru" arene 
complexes of the general formula [(176-arene)Ru"(pta)C1 2], where pta = 1,3,5-triaza-7-
phosphatricyclo[3 .3.1 .1 ]decane. These complexes showed pH dependent DNA 
damaging properties. 
Organoruthenium complexes of the type [(?I 6_arene)Ru, '(XY)Z] +, where arene is 
benzene (bz) or bz derivative, XY chelating ligand and Z halide (Figure 1.5) have 
been studied as potential anticancer agents. 10-12  The structure-activity relationships of 
these complexes have been discussed before. 50, 
5, 
Ru" arene complexes in which 
the chelating ligand is ethylenediamine (en) and the leaving group is chloride are 
cytotoxic to cancer cells, including cell lines that are resistant to cisplatin.50' ' It has 
been found for chlorido en complexes that cytotoxicity against A2780 human ovarian 
cancer cells increases with the increase of the size of the arene. 50' 56 
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Figure 1.5 General chemical structure of Ru" arene 'piano-stool' complexes 
containing i 6 bound arene, a chelating ligand XY and a monodentate ligand Z. 
In this type of complexes, the arene provides a hydrophobic face for the complex and 
stabilizes Ru in the +2 oxidation state so that oxidation to Ru 111 is difficult. The 
structural and electronic features of metal—arene bonding have been previously 
discussed .57  The arene is considered as a ic-acceptor ligand towards Ru and the 
evidence for this comes from the arene proton resonances in 'H NMR which, upon 
arene coordination to Ru" shift to a lower frequency due to the increase in electron 
density. 58 
The substitution of chloride by other halides has only a small effect on the 
cytotoxicity of en complexes. It is believed that bromido and iodido ligands are 
exchanged with chiorido ligands in an extracellular biological media as the 
concentration of chloride is 104 mM, so that the iodido and bromido complexes 
would act only as prodrugs. 59 
The chelating ligand provides additional stability. Complexes containing chelating 
ligands tend to be more active than those containing only mono-dentate ligands. 50 The 
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nature of the chelating ligand can play a crucial role in anticancer activity. 54  Changing 
the nature of the donor atoms in the chelating ligand (e.g. from N to 0) has also been 
investigated and in this case the structure-activity relationships become complicated. 
The structure-activity relationships reported for Ru" arene complexes containing 
N,N-chelating ligands show that although complexes containing en as chelating 
ligand were cytotoxic, complexes containing tetramethyl-en as chelating ligands 
showed no cytotoxicity. This suggests that NH groups on the chelating ligand play a 
role in the activity, possibly stabilizing G adducts on DNA via H-bonding (vide 
supra). 
1.8.1 Hydrolyses of Ru" arene complexes 
The mechanism of cytotoxic action of Ru" arene complexes is thought to involve 
hydrolysis of the Ru-Z bond generating reactive Ru-H20 species (Figure 1.6) that can 
further bind to DNA and form the adducts. In general, Ru" arene complexes that 
hydrolyse also exhibit cancer cell cytotoxicity, whereas those that do not hydrolyse 
exhibit usually no activity. Therefore the hydrolysis rates are of high importance in 
order to relate them to anti-cancer activity. The hydrolysis rates of en complexes [(,l 6 
bip)Ru(en)Cl] (3.95 x t12 = 2.92 min), [(116-tha)Ru(en)Clf (6.84 x 
t,,2 = 1.69 mm) and [( 6-dha)Ru(en)Clf (6.49 x s', t = 1.78 mm), where bip = 
biphenyl, tha = tetrahydroanthracene and dha = dihydroanthracene, are measured at 
37°C, and are found to be relatively fast and independent of ionic strength. 60 
15 








% 4/ \\ 
OH 2 
Figure 1.6 Hydrolysis of Ru" arene complexes in aqueous solution and formation of 
the aqua adduct. 
The presence of bipyridine (bipy) as a it-acceptor in [(,j 6-arene)Ru(bipy)Cl]Cl 
complexes, where arene = bz, p-cymene (p-cym) and hexamethylbenzene (hmb), has 
been reported to decrease the rate of hydrolysis by 2 orders of magnitude compared to 
analogues in which bipy is replaced with two aqua ligands. 6 ' The it-acceptor ligand 
bipy withdraws electron density from Ru and increases the positive charge on the 
metal, making it less favourable for Cl to leave, slowing down the hydrolysis. 
Density functional theory (DFT) calculations for aquation of complex [(q 6 
bz)Ru(en)Z}, where Z = Cl, Bf, F or N3 suggested that the aquation occurs via a 
concerted interchange pathway rather than a stepwise dissociacion/coordination 
process. The reaction barriers and overall reaction energies for aquation follow the 
order Br < Cl < I < N3. 55 The reactions were found to occur closer to the 'a 
(interchange-associative) mechanism than to the Id  (interchange-dissociative) 
mechanism. On the basis of electronegativity, the azido complex would be expected 
to hydrolyse at a rate between the chlorido and bromido complexes, but a slower rate 
was observed. The lower hydrolysis rate in the case of azido complex is ascribed to 
the increased steric bulk in the case of this pseudohalide. Further evidence for the 
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mechanism is that 'a  substitution is more influenced by steric factors than substitution 
via an Id  pathway. 55 The electron-accepting effect of the it-acid arenes is thought to be 
responsible for the shift of the pathway towards the more associative 'a  mechanism as 
the Ru metal has more characteristics of Ru" over those of Ru", and Ru" complexes 
are known to react via associative pathways. 62 
1.8.2 Interactions of Ru" arene complexes with 9-ethy1guanine (9-EIG) 
Intramolecular it-ic arene-9-EtG (model nucleobase) stacking has been observed in the 
crystal structure of [(i 6-bip)Ru"(en)(9-EtG-N7)] [PF 6]2 .63 This together with the 
strong H-bonding between an NH of en and C60 from 9-EtG, observed in the same 
crystal structure was found to contribute to the G-specificity when this type of 
complexes binds to DNA.M 
The x-ray crystal structures of [(,j 6 -dha)RuII  (en)(9-EtG-N7)] 2+  and [(, 6 -tha)RuII  (en)(9- 
EtG-N7)] 2 show again the presence of a strong intramolecular it—it arene-9-EtG 
stacking 65  (Figure 1.7). The outer ring of the arene (dha and tha, respectively) lies 
directly over the purine base. The outer arene ring is parallel to the purine ring and 
the centroid-centroid distance is 3.31 A in the structure of dha, and 3.45 A in the 
structure of tha 9-EtG adduct. Stereospecific H-bonding has also been observed 
between en NH C60 of 9-EtG in [(i 6-dha)Ru"(en)(9-EtG-N7)] 2 and [(,6 
tha)Ru"(en)(9-EtG-N7)] 2 , with distances of 2.1 A and 1.9 A, respectively. 65 
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Figure 1.7 Space filling representation of the x-ray crystal structure of the cation of 
(A) [(1 6-dha)Ru(en)(9-EtG-N7)] [PF 6]2 and (B) [(i 6-tha)Ru(en)(9-EtG-N7)] [PF 6] 2 . 
1.8.3 Interaction of Ru11 arene complexes with oligonucleotides 
The 	interaction 	of 	(-bip)Ru(en)} 2 	fragment 	with 	the 
d(ATACATGGTACATA)•d(TAT' 7G' 8TACCATGTAT) duplex has been studied by 
HPLC-ESI-MS as well as by 2D NOESY NMR. It has been found that ruthenation 
occurs at N7 of every G residue of the 14-mer. At one site (T"G") two different 
conformers were identified. In one conformer, intercalation of bip between G' 8 and 
adjacent thymine (T' 7) is observed and in the second conformer, the bip arene is non-
intercalated but it is stacked on the tilted i', lying on the surface of the major groove 
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Figure 	1.8 Molecular models of two conformers of 14-mer 
d(ATACATGGTACATA).d(TAT' 7G' 8TACCATGTAT) ruthenated at N7 of G' 8 with 
monofunctional {(i 6-bip)Ru(en)} 2 fragment (A) showing the intercalation of the 
arene between G' 8 and T' 7 and (B) bip is non-intercalated but stacked on a tilted T' 7 . 
Colour code: Ru shown in pink, en in deep blue and bip in green. 66 
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1.9 DNA binding of Ru" arene complexes 
1.9.1 DNA as a potential target site 
Platinum-based drugs that are in clinical use target DNA (vide infra), and these are 
believed to interact primarily with nucleic acid through coordination bond formation. 
As DNA is an important potential biological target for many metal-based anticancer 
agents,67 distortions of DNA structure often correlate with anticancer activity.68' 69 
Therefore, it is of a great importance to understand DNA binding properties of 
potential anti-cancer agents. 
Chiorido Ru" arene complexes are the dominant species in blood plasma (pH = 7.4), 
where the chloride concentration is ca. 104 mM (vide infra). In the cell nucleus where 
the chloride concentration is lower (ca. 4-20 mM) increased concentration of aqua 
species is more likely to occur. Once a Ru" arene complex is activated through 
hydrolysis and the aqua species is formed, Ru is a potential centre for nucleophilic 
attack by biomolecules. The binding of Ru" arene complexes to DNA is of special 
interest, as this may be the ultimate target for this type of agent. 
1.9.2 Interaction with CTDNA 
Ru" arene complexes of the type [( 6-arene)Ru(en)Cl], where arene = bip, dha, tha 
or p-cym have been found to interact with CT DNA in a cell-free medium and bind 
preferentially to N7 of G residues. In addition to coordination to G N7, hydrophobic 
20 
Chapter 1: Introduction 
(non-coordinative) interactions can occur between the arene and DNA .56  The non-
coordinative interactions relay on electrostatic interactions, shape and size molecular 
recognition, and hydrogen bonding. These interactions may include intercalation of 
the extended arene between DNA bases and minor groove binding. For more 
extended arenes the possibility of arene intercalation between the DNA bases arises. 70 
The extent of ruthenation of double helical CT DNA by Ru" arene complexes was 
followed, at an r, (molar ratio of free ruthenium complex to nucleotide phosphates at 
the onset of incubation with DNA) value of 0.1 in 10 mM NaC104 at 37°C. The 
amount of ruthenium bound per DNA nucleotide phosphate increased with time and 
ty2 (the time at which binding reaches 50%) was found to be dependent on the arene. 
The ty2 obtained for [(, 6-bip)Ru(en)Clf and [(ii6-tha)Ru(en)Cl]  complexes was 10 
and for [(116-dha)Ru(en)C111  15 mm, while ty2 for [(iî6-p-cym)Ru(en)Cl] was 3.5 h. 
Under the same conditions ty2 for cisplatin was ca. 2 h. Thus for bip, dha and tha Ru" 
complexes binding to CT DNA is for an order of magnitude faster compared to that 
of cisplatin. The binding of bip complex to DNA was nearly quantitative after Ca. 3 h 
(ca. 90%)56 
1.9.3 Unwinding ofplasmid DNA 
Ru'1 arene complexes of the type [(i 6-arene)Ru(en)Cl], where arene = bip, tha or dha 
were reported to unwind negatively-supercoiled pSP73KB plasmid DNA by 14 ± 1 0, 
while p-cym complex unwinds plasmid DNA by only 7± 0.5, .56  The result suggested 
that the higher unwinding for bip, tha and dha complexes, compare to that ofp-cym is 
a result of the intercalation of the extended arene (vide infra) into the DNA bases, 
upon mono-functional binding. 
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1. 9.4 Melting of CT DNA 
It has been found that at lower salt concentrations (0.01 M NaC1O4), Ru" arene 
complexes of the type [(i 6-arene)Ru(en)Clf', where arene = bip, tha and dha increase 
the melting temperature (tm) of CT DNA. The increase becomes more pronounced 
with increasing rb value (rb is a number of Ru atoms bound per nucleotide residue). 
When the ionic strength is increased (higher salt concentration), t m  was found to 
decrease. Lower electrostatic effects between the positively-charged complexes and 
CT DNA are expected with the increase of the concentration of Na ions from 
NaC104. This electrostatic effect stabilizes the DNA and should increase its melting 
temperature (tm) compared to the tm  of unmodified DNA. Hense at low ionic strengths 
the increase in tm  is due to the modification of DNA by bip, tha and dha complexes as 
the positive charges on Ru and the intercalation of the arenes increases the stability of 
DNA. 56 
The melting behavior of DNA modified by [( 6-p-cym)Ru(en)Cl] decreases tm even 
at low salt concentration indicating that the factors responsible for thermal 
stabilization of DNA are notably reduced. 56 The factor that can be involved in DNA 
stabilization is intercalation of the arene between the base residues (vide infra) and 
the separation of negative backbone charges caused by the intercalation (due to 
elongation and unwinding of DNA). 
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1.9.5 Fluorescence experiments 
Ethidium bromide (EtBr) is an intercalator and is fluorescent when bound to DNA. 
EtBr can be used to distinguish intercalating from nonintercalating ligands on DNA 
by competition. The possible intercalation of the arene into double helical DNA has 
been probed by EtBr fluorescence experiment, 56  and it has been found that complexes 
of the type [(116-arene)Ru(en)C1], when arene = bip, tha or dha are able to displace 
EtBr from DNA and quench its relative fluorescence more than the p-cym complex of 
the same type. 
1.9.6 Circular dichroism 
The binding of Ru" arene complexes of the type [( 6-arene)Ru(en)Cl], where arene = 
bip, tha, dha, p-cym or bz, to CT DNA has been studied by circular dichroism (CD). 56 
An induced CD band at 350-410 nm was observed for the interaction of bip, tha and 
dha complexes with CT-DNA. On the other hand no induced band in this region was 
observed for p-cym and bz complexes. This induced CD band appears to be related to 
intercalation of the extended arenes into DNA or to groove binding. Similar bands 
were previously observed for other metal complexes. 71,72 
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1.10 Aims 
The general aim of this thesis is to investigate the design, synthesis and anti-cancer 
activity of Ru" arene complexes containing different arenes and N,N-chelating 
ligands. The studies are focused on changes in anti-cancer activity influenced by 
changing the physical and chemical properties of complexes through the changes in 
the steric and electronic effects of the ligands. The main focus is on studies of 
aqueous solution chemistry, solid state structures, reactivity towards nucleobases and 
DNA (as potential cellular targets). The first aim was to investigate the effect of the 
size and the shape of the arene ligand on the binding mode of Ru" arene complexes to 
DNA and to relate this to the differences in anti-cancer activity. The second aim was 
to investigate the effects of It-acceptor and redox-active chelating ligands as well as 
the effects of their substituents on the chemical, physical and biological properties of 
Ru" arene complexes. The overall aim of this thesis is to create possible candidates 
for development as anticancer agents. 
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Chapter 2 
Experimental Section 
"We can't solve problems by using the same kind of 
thinking we used when we created them." 
Albert Einstein 
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In this Chapter the general techniques and instrumentation used are described. The 
methods related to particular experiments and details of these experiments are 
described in appropriate chapters. The focus of this Chapter is as well on synthesis 
and characterization of the starting materials, dienes used in a preparation of dimers, 
and dimers used in further syntheses of Ru" arene complexes. Syntheses of Ru" arene 
complexes are described in following chapters. 
2.1 Instrumentation and techniques 
2.1.1 Nuclear magnetic resonance (NMR) spectroscopy' 
2.1.1.1 Nuclear magnetism 
Nuclear magnetic resonance (NMR) spectroscopy relies on the magnetic properties of 
nuclei. In general, NMR makes use of 1 11, 13C, 15N nuclei, which all possess spin 1/2. 
Only the 'H (natural abundance 99.985) NMR was studied in this thesis and it was 
mainly used for characterization of synthesized complexes. When placed in a strong 
magnetic field (Bo; Figure 2.1) spins with a spin quantum number 1/2 will create a 
two-state distribution with different energies (a and 3 states) and precess at the 
Larmor frequency (vo) around B0 defined as: 
VO = 7B0/27t 
where ' is the gyromagnetic ratio of the nucleus. 
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a state 
P state 
Figure 2.1 Bulk magnetisation (Mt) resulting from population difference of spins in 
state a and 13  placed in a static magnetic field B0. 
At a macroscopic level, the population difference between a and 0 states results in a 
bulk magnetization (M') co-linear to B0. This magnetization is the source of the NMR 
signal and its size is related to the population difference between the two states. The 
manipulation of the M, using radiofrequency pulses, forms the basis of Fourier 
transform NMR spectroscopy. 
2.1.1.2 Chemical shift 
Each nucleus experiences a magnetic field that is a sum of external and local 
magnetic fields. Local magnetic field, resulting from shielding of nuclei, can be 
described as: 
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B1 	= B0( I -ci) 
where cy is the shielding constant. The shielding constant is affected by surrounding 
atoms whose contribution can be divided into diamagnetic and paramagnetic 
components: 
= diamagnetic + O paramagnetic 
For example, the magnetic field B0 induces a current in the phenyl ring which 
produces a field (B 1 ) which opposes the external magnetic field above and below the 
plane and is the same in direction to B0 in the plane of the ring (Figure 2.2). As a 
result, nuclei in the region above or below the plane are shielded and the protons in 
the plane of the ring are deshielded. The shielding effect leads to dispersion of signals 
of the same nucleus in NMR spectra, opening a possibility for assigning the observed 








Figure 2.2 Shielding (+) and deshielding (-) effect of a phenyl ring placed in a static 
magnetic field B 0 . The ring current effect (B1) in the plane and below and above the 
plane of the ring is shown by red and blue arrows, respectively. 
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In order to compare spectra acquired at different field strengths, the chemical shift () 
scale was introduced. This is a relative scale describing the position of a signal 
relative to the position of a reference compound, 
&jpm) = (( - ref)/ref)lO 
where E and 4rer. are the absolute frequencies. 
2.1.1.3 Pulsed-field gradients 
Pulsed-field gradients (PFG) are short, typically millisecond, pulses during which the 
static magnetic field B 0 is made inhomogeneous. This disturbance is not random. The 
strength of a PFG varies linearly along a certain axis, typically the z axis. During 
PFGs, spins experience different magnetic fields depending on their position in the 
NMR tube, resulting in a loss of coherence for any magnetization not aligned along 
the z axis. This magnetization, temporarily lost, can be recovered by applying an 
identical gradient with opposite sign, or as in polarization transfer experiments, with 
an appropriately scaled gradient. 
Gradients are also used for purging of unwanted magnetization, for example, after 
storing the useful magnetization along the z-axis or by manipulating selected signals 
by selective pulses. The latter principle is used for water suppression in the 
WATERGATE experiment2 and double-pulse field-gradient spin-echo (DPFGSE) 
experiment. 3 
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2.1.1.4 Experimental methods 
All NMR spectra were recorded on either Bruker DPX ('H 360 MHz) equipped with 
a QNP ['H, ' 3C, ' 5N] probe, DMX (500 MHz) equipped with a TBI ['H, 13C, 15N] z-
gradient probe or AVA (600 MHz) spectrometer equipped with a TXI ['H, 13C, 15N] 
x,y,z-gradient probe. 'H NMR signals were referenced to the residual solvent peak, 
2.52 (DMSO), 6 7.27 (chloroform) and 8 3.34 (methanol). Spectra for pH titrations 
were recorded on the Bruker DMX 500 spectrometer, with dioxan as an internal 
reference (8 3.75). All spectra were recorded at 25°C unless stated otherwise, using 5 
mm diameter tubes and standard pulse sequences modified by Dr Dusan Ubrin and 
Mr Juraj Bella (The University of Edinburgh). The data were processed using XWIN-
NMR (Version 3.6 Bruker UK Ltd). 
2.1.2 Ultraviolet-visible (UV- Vis) and fluorescence spectroscopy 4 
UV-Vis spectroscopy (wavelength of 200-800 nm) uses light in the visible 
(wavelength of 400-700 nm) and adjacent near ultraviolet (UV) and near infrared 
(NIR) ranges. The UV-Vis spectrum is a graph of light absorbance versus wavelength 
in a range of the UV-Vis regions of the electromagnetic spectrum, where molecules 
undergo electronic transitions between different energy levels. 
Absorption measures transitions from the ground state to the excited state, while 
fluorescence spectroscopy deals with transitions from the excited state to the ground 
state. Excitation is an elevation in energy level above ground energy state (Figure 
2.3). 
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Figure 2.3 Promotion of the electron from the HOMO (highest occupied molecular 
orbital) to the LUMO (lowest unoccupied molecular orbital), caused by absorption of 
the photon of the same energy as the gap between the orbitals. 
The transitions are classified as allowed and forbidden, dependent on their intensities. 
The probability of these transitions (intensities of transitions) is represented by E 
(molar extinction coefficient): 
= log (Io/I)/cl = A/cl 
where lo and I are intensities of incident and transmitted light, respectively, c 
concentration, I a path length in cm and A absorbance. 
Here some transitions that can occur in metal complexes are discussed. One of them, 
metal-to-ligand charge-transfer (MLCT) transition involves a MO with metal-like 
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character and those with ligand-like character. This is most commonly observed in 
complexes with ligands having low-lying ir orbitals (aromatic ligands). Ligand-to-
metal charge-transfer (LMCT) arises from transfer of electrons from an MO with 
ligand-like character to those with metal-like character. This type of transfer is 
predominant in metal complexes that have ligands with relatively high energy lone 
pairs or the metal with low-lying empty orbitals. These conditions imply that the 
acceptor level is available and low in energy. t - transitions are ascribed as a 
promotion of an electron from a 'bonding' 7E orbital of a ligand to an 'antibonding' it 
orbital, designated as lrK.  Many metal complexes are coloured due to d-d electronic 
transitions. Visible light of the correct wavelength is absorbed, promoting a lower 
energy d-electron to an higher excited state. This absorption of light causes colour. 
These colours are usually quite faint. This is because of the selection rules. 
The spin rule: t S = 0, the electron should not experience a change 
in spin. Electronic transitions which experience a change in spin are 
spin forbidden transitions. 
Laporte's rule: d-d transitions for complexes which have a center of 
symmetry are forbidden - symmetry forbidden or Laporte-forbidden 
transitions. 
Laporte-forbidden transitions tend to be more intense than spin forbidden transitions. 
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2.1.2.1 Experimental methods 
A Perkin-Elmer Lambda-16 UV-Vis spectrophotometer was used with quartz 
cuvettes (1 cm path length; 0.5 mL) and PTP1 Peltier temperature controller, unless 
otherwise stated. Experiments were carried out at 25°C unless otherwise stated, in the 
range of 200-800 nm and at the scan rate of 420 nmlmin (at 1 nm intervals). Spectra 
were processed using UV-Winlab software for Windows'95. 
Fluorescence measurements were performed on a Shimadzu RF 40 
spectrofluorophotometer using a 1 cm quartz cell. More details are described in 
Chapters 3 and 4. 
2.1.3 Electrospray ionization mass spectrometry (ESI-MS) 5 
ESI-MS was used in this work to characterize synthesized complexes. ESI-MS is a 
solution based technique and the sample must be present as an ion in solution. If 
species is not already charged the addition of a small amount of acid or base can 
protonate or deprotonate it (positive and negative ESI, respectively). 
The details vary with different commercial instruments, but the overall processes are 
similar. The sample, dissolved in the appropriate volatile solvent, is injected as a fine 
spray at a low flow rate (typical flow rates are 0.01 mL/min and concentrations 
required are in ppm) from a capillary held at a high voltage into a chamber at 
atmospheric pressure. The chamber into which the sample is sprayed is purged with a 
drying gas (usually nitrogen) which evaporates the solvent from the charged droplets. 
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As the droplets get smaller the charge density increases and ions are transferred to the 
gas phase once the charge density exceeds some critical value. The ions formed are 
then pumped through skimmer cones or similar, each at successively higher vacuum, 
before transferring to the mass analyzer. 
2.1.3.1 Experimental methods 
Positive-ion ESI (unless otherwise stated) mass spectra were obtained on a 
Micromass Platform II mass spectrometer and solutions were infused directly. The 
capillary voltage was 3.5 V and the cone voltage was either 15 or 25 V. The source 
temperature was dependent on the solvent used. Data were collected and analyzed on 
a MASS LYNX V3.5 Windows NT PC data system, unless otherwise stated. 
23.4 	Elemental analysis. 
By determining the percentage of C, N and H and comparing these to theoretical 
values, elemental analysis provides information about the purity of compounds. 
Elemental analysis was used to characterize complexes described in this work. 
2.1.4.1 Experimental methods 
Elemental analyses were carried out by the Warwick Analytical Service or the 
University of Edinburgh, using an Exeter analytical analyser CE 440, or by the 
University of St. Andrews using a Carlo Erba CHINS analyser. 
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23.5 X-ray crystallography 
X-ray crystallography determinates the arrangement of non-hydrogen atoms within a 
crystal. In this thesis, x-ray crystallography was used as a characterization method, 
together with other methods described in this Chapter. 
2.1.5.1 Experimental methods 
Diffraction data were collected and analyzed by Professor Simon Parsons and his 
research group at the University of Edinburgh. The instrument used, Bruker Smart 
Apex CCD diffractometer using Mo Ka radiation (k = 0.71073 A), is equipped with 
Oxford Cryo systems device that is operating at 150 K. Absorption corrections for all 
data sets were applied using the multi-scan procedure SADABS. 6 The details about 
the methods used are described in the following chapters. 
2.1.6 	Circular dichroism (CD) 7 
CD spectroscopy can be used to provide the information about molecular structure 
and about interactions between molecules. CD is used for studying chiral molecules 
(molecules that cannot be superimposed on their mirror images). All biological 
systems and many of non-living ones are chiral. A CD spectropolarimeter contains a 
source of monochromatic (more or less) left and right circularly polarized light and it 
detects the difference in absorbance of the two polarizations of light. Molecules 
40 
Chapter 2: Experimental Section 
absorb energy in units called photons. A chiral molecule has no reflection plane (or 
other symmetry element) and any rearrangement of its electrons will not have one 
either, and the electrons would move in some kind of helix. The interaction of chiral 
molecules in circularly polarized light, with left- and right-handed photons will be 
different. Every chiral molecule therefore, would have both positive and negative CD 
signal. 
2.1.61 CD of DNA 
The UV absorbance of nucleic acids from 200 to 300 nm is due to transitions of the 
planar purine and pyrimidine bases. This band is believed to be composed of more 
than one transition predominated by it-ir s transitions whose assignment is still a 
matter of debate. The backbone begins to contribute at about 190 nm. In the CD 
spectrum, the purine bases have a negative signal, while the pyrimidine bases have a 
positive signal. The sugar units (D-deoxyribose) and the helix of DNA provide the 
original chirality. The CD spectrum of DNA arises from the CD induced into the 
transitions of the bases as a result of their coupling with each other since the bases 
stack on top of each other in a chiral (helical) fashion. 
The signature of B-DNA in the CD spectrum (above 220 nm) is a positive band 
centered at 275 nm and a negative band at 240 run, with a zero at 258 nm (Chapter 3). 
These bands are superimpositions result of all the couplings of the transitions arising 
from all the DNA bases. A-DNA is characterized by a positive CD band centred at 
260 nm, which is larger than the corresponding B-DNA band, a fairly intense 
negative band at 210 nm, and a very intense positive band at 190 nm. Z-DNA does 
not readily form for all sequences. It is easily form for poly[d(G-C)]2 in the presence 
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of highly charged ions. In the CD spectrum (above 200 nm) characteristic is a 
negative band at 290 nm and a positive band at 260 nm. 
2.1.62 Experimental methods 
CD measurements were performed on a Jasco J-720 spectropolarimeter equipped with 
a thermoelectrically-controlled cell holder. The cell pathlength was 1 cm and spectra 
were recorded in the range of 230-500 nm in 0.5 nm increments, with an averaging 
time of 1 s. The details of the experiments are described in Chapter 3. 
2.1.7 Atomic absorption spectrometry (AAS) 8 
AAS is the measurement of the absorption of optical radiation by atoms in the 
gaseous state. In analytical chemistry, AAS is a technique for determining the 
concentration of a particular metal element in a sample. The electrons of the atoms in 
the atomizer of the instrument can be promoted to higher orbitals, by absorbing 
energy (light of a given wavelength). This amount of energy is specific to a particular 
electron transition for a particular element, and each wavelength usually corresponds 
to only one element, which gives selectivity to the technique. 
A sample has to be atomized in order to be analyzed and the flame is typically used 
for this purpose. As the quantity of energy put into the flame is known, and the 
quantity remaining at the detector is measured, it is possible to calculate how many of 
these transitions took place, and thus get a signal that is proportional to the 
concentration of the element. Apart from flame there are other common atomizers, 
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such as a graphite furnace or plasma (e.g. inductively coupled plasma). The 
instrument used for the experiments described in this thesis is the FAAS (Flameless 
Atomic Absorption Spectrometer) equipped with the graphite tube atomizer. 
2.1.7.1 Experimental methods 
The FAAS (Flameless Atomic Absorption Spectrometry) measurements were carried 
out on a Varian AA240Z Zeeman atomic absorption spectrometer equipped with a 
GTA 120 graphite tube atomizer. More details about measurements are reported in 
Chapters 3 and 4. The measurements were performed with assistance of Dr Olga 
Novakova in Bmo. 
2.1.8 Molecular modeling 9 
2.1.8.1 Density Functional Theory (DFT) 
Kohn-Sham DFT 10  is an important first-principle computational method for the 
accurate prediction of chemical and physical properties. The DFT approach provides, 
in most cases, a "chemical" accuracy of a few kcal/mol for binding energies; the 
computed orbitals are suitable for the typical MO-theoretical analyses and 
interpretations. 
The major problem with DFT is that the exact functional for exchange and correlation 
are not known except for the free electron gas. However, approximations exist which 
permit the calculation of certain physical quantities. In physics the most widely used 
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approximation is the local-density approximation (LDA), 9 where the functional 
depends only on the density at the coordinate where the functional is evaluated. 
Various approximations have been implemented in the Amsterdam Density 
Functional (ADF, described bellow) program at the level of the LDA, and with 
corrections of the generalized gradient approximation (GGA) included. At GGA level 
the first implemented options included the formulas of Becke (excange), Perdew 
(correlation), Perdew-Wang (both) and Lee-Yang-Parr (correlation).' 
1-14 
The self-consistent solution of the Kohn-Sham DFT equations is obtained in an 
interactive self-consistent field (SCF) procedure. From a trial density matrix 
P  the 
Fock matrix F' is computed and diagonalized to obtain the eigenvectors, i.e. the MOs. 
The occupied MOs then yield a new trial density matrix pk+l  etc. until 
pk  and pk+l  are 
identical, and we have reached self-consistency. The first derivatives of the energy 
with respect to nuclear displacements are calculated analytically for a particular 
geometry at the end of the SCF procedure. 
2.1.8.2 The Amsterdam Density Functional (ADF) program 
ADF is a program for electronic structure calculations that makes use of DFT. ADF 
was developed in the early seventies by the group of E. J. Baerends, working at the 
University of Amsterdam, and by the Ziegler group from Calgary. 15  At that time the 
program was named HFS, for Hartree-Fock-Slater. These two research groups with 
frequent additions and improvements of the program made ADF one of the widely 
used programs in quantum-chemical research. Recent developments enhance the 
efficiency and functionality of the program. 
DFT is implemented in ADF and all the DFT implementations employ some kind of 
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numerical integration scheme. ADF uses a Gaussian-type quadrature method, which 
is based on partitioning of space in atomic cells. ADF exploits Slater-type (ST) 
functions as basis set elements, in terms the molecular orbitals (MOs) are expanded. 
The Gaussian-type orbitals (GTOs), in comparison, typically would need a factor of 3 
more functions for the same level of basis set quality. The ADF package comprises a 
database with a large number of basis sets for all elements of the periodic table, 
ranging from minimum single-c (SZ) to doubly-polarised triple- (TZ2P) basis sets. 
An important aspect of ADF is the (optional) use of a frozen core 16  to trim down the 
computational time by reducing the size of the variational basis set. Because deep-
core atomic orbitals change very little upon bond formation, the frozen core 
approximation saves time without sacrificing much in quality. ADF supports the 
incorporation of relativistic effects (used for the heavy elements for which the frozen 
core approximation is applied), and a recently developed approximation is the zero-
order regular approximation (ZORA). 17  In ADF, bonding energies are calculated 
directly, with respect to the fragments, by one single numerical integral of the 
difference in energy density between the overall molecule and the constituting 
fragments. The conductor-like screening model (COSMO) 18 has been implemented in 
ADF to include solvent effects. 
The Veronoi Deformation Density (VDD) 19 method for computing atomic charges is 
based on the deformation density and a partitioning of space into non-overlapping 
atomic areas, the so-called Voronoi cells. The Voronoi cell of an atom is the region in 
space closer to the nucleus of that atom than to any other nucleus. The VDD charge 
of an atom monitors the flow of charge into, or out of the atomic Voronoi cell as a 
result of "turning on" the chemical interactions between the atoms. 
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2.1.8.3 Experimental methods 
The coordinates used were obtained directly from the crystal structures unless the 
modifications were performed using ChemCraft (Version 1 The calculations 
were carried out using DFT at the GGA as implemented in the ADF program (version 
2007.01). Geometries and energies were obtained by using the Becke Perdew 
gradient-corrected functional (BP86) with scalar ZORA relativistic correction, unless 
otherwise stated. The frozen core approximation was applied using TZP bases. The 
COSMO as implemented in ADF was used to simulate the aqueous environment, 
with £ = 78.4 and a probe radius = 1.9 A. The atomic radii used were Ru = 1.950, Cl 
= 1.725, 0 = 1.517, N= 1.608, C = 1.700 and H = 1.350. The VDD method for 
computing atomic charges was used. Default convergence criteria were applied for 
self-consistent field (SCF) and geometry optimisation. Further details are described in 
Chapters 4 and 5. The calculations were carried out with an assistance of Dr Robert J. 
Deeth. 
2.1.9 	Cancer cell growth inhibition 
Cytotoxicity tests were performed by Emily Jones and Daniel Simpson (Oncosense 
Ltd). Compounds were tested for inhibitory growth activity against A2780 human 
ovarian and A549 human lung cancer cell lines, using a previously described 
protocol . 2 ' For compounds described in Chapter 3, cytotoxicity tests were performed 
at the Institute of Biophysics (Academy of Sciences of the Czech Republic; Brno, 
CR), as described in the appropriate chapter. 
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2.2 Synthesis and characterization of starting materials 
2.2.1 Materials 
RuC13 3110 was purchased from Precious Metals Online and used as received. The 
arenes (m- and p-terphenyls, biphenyl, dihydroanthacene and hexamethylbenzene) 
and a-terpinene were purchased from Sigma-Aldrich. Ethanol was dried over Mg/12 
and THF over Na/benzophenone. 
2.2.2 	Birch reduction 22 
Birch reduction involves the reaction of benzene or a benzene derivative with an 
alkali metal in liquid ammonia containing an alcohol as a cosolvent. This is the 
classical Birch reduction pathway for monocyclic benzene derivatives with relatively 
low electron affinities, which do not readily form anions. The presence of alcohol is 
required to protonate the radical anion and shift the unfavorable equilibrium to the 
right leading to the completion of the reaction (formation of diene product). 
On the other hand, the polycyclic aromatic systems generally undergo a 
transformation to the dianion without the presence of the alcohol as a proton source, 
and in this case water or ammonium chloride is used as a protonating agent (added to 
the solution of the already dianionized hydrocarbon). This modified Birch reduction 
was used for reduction of biphenyl (bip), p-terphenyl (p-terp) and m-terphenyl (m-
terp) hydrocarbons. In the case of bip, rapid protonation is necessary to prevent its 
further reduction and isomerisation. Therefore in the reduction of bip ammonium 
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chloride is used as a source of protons. The details for individual reaction are 
described in the text bellow. Starting materials as well as the products from the 
reaction are listed in Table 2.1. 
Table 2.1 Arenes used in Birch reductions and dienes obtained as products 
Starting  
materials %/\j 	 )CO 
(arenes) 	 - 	 - 
\/ \/ 
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1,4-Dihydrobiphenyl (dhbip). 23 Biphenyl (bip; 17.5 g, 113.6 mmol) was dissolved 
in a dry, freshly-distilled THF (250 mL) and this was added to 1 L of liquid ammonia, 
which had been condensed under argon into a 2 L flask equipped with a Dewar 
condenser, cooling bath (dry ice / acetone) and mechanical stirrer. Li wire (1.99 g, 
286 mmol) was added in small pieces to the reaction mixture over -3 mm. The 
addition of Li was followed by a change of colour of the solution from white, via 
green to red. After 30 min of stirring and cooling, NH4C1 (22 g, 412 mmol) was 
added into the reaction mixture and the solution turned white immediately. The 
cooling bath was removed and the ammonia was allowed to evaporate overnight. 
Water was added (350 mL) into the mixture and the pH was adjusted to 3 using HC1. 
The mixture was extracted with ether (3 x  250 mL) and the combined ether layers 
were washed with saturated NaCl solution (200 mL), and dried over MgSO4. 
Removal of ether under reduced pressure afforded a yellowish oily product, which 
was distilled (58°C / 10 2  mbar) to give 14.40 g (81%, 15 mL, d = 0.96 g/cm 3) of pure 
product. 1 H NMR (CDC13): ö 7.28 (m, 5H), 5.85 (m, 411), 3.40 (broad t, 1H), 2.77 
(broad m, 211). 
1,4,5,8,9,10-Hexahydroanthracene (hha). A modification of the previously 
published procedure 24  for reducing anthracene to hha in liquid ammonia in the 
presence of Na, was applied here. 9,1 0-Dihydroanthracene (dha; 4.5 g, 24.99 mmol), 
used instead of anthracene, was dissolved in a dry and freshly-distilled mixture of 
THF (300 mL) and ethanol (130 mL). This was followed by addition of the solution 
to the refluxing ammonia (1 L), which had been condensed under argon into a 2 L 
flask equipped with a Dewar condenser, cooling bath (dry ice / acetone) and 
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mechanical stirrer. Li wire (12 g, 0.5 mols), used here instead of Na, was cut into 
small pieces and added to the reaction mixture over 3 mm. After 2 h of cooling and 
stirring, the cooling bath was removed and the ammonia was allowed to evaporate 
overnight. Water (200 mL) was added into the mixture. The mixture was extracted 
with ether (4 x  250 mL) and the combined ether layers were washed with saturated 
NaCl solution (200 mL) and dried over MgSO4. Removal of ether on a rotary 
evaporator afforded a white solid which was washed with warm petroleum ether (10 
x 250 mL) until all 1,4,9,10-tetrahydroanthracene (tha), present as a side product, was 
removed and only hha remained as white needles. Yield: 2.7 g (65%). 1 H NMR 
(CDC13): ö 5.68 (s, 4H), 2.51 (s, 8H), 2.37 (s, 411). 
1 ,4,9,1O-Tetrahydroanthracene (tha). A modification of the previously published 
procedure for the reduction of dha to tha, 25 was used here. Dha (6.5 g, 36.1 mmol) 
dissolved in 300 mL of dry and freshly-distilled THF was added to refluxing 
ammonia (1 L) which had been condensed under argon into a 2 L flask equipped with 
a Dewar condenser, cooling bath (dry ice / acetone) and mechanical stirrer. Li metal 
wire (0.66 g, 95.1 mmol) was added in small pieces. After refluxing and stirring for 2 
h, dry and freshly-distilled ethanol (60 mL) was added to the reaction mixture 
followed by 130 mL of water, and the ammonia was allowed to evaporate overnight. 
Additional water (50 mL) was added into the reaction mixture. This was extracted 
with diethyl ether (3 x  250 mL) and the combined ether layers were washed with 
saturated NaCl solution (200 mL) and dried over MgSO4. Removal of ether on a 
rotary evaporator afforded a light yellow solid which was recrystallised (10 x)  from 
petroleum ether to remove completely bha, formed as a side product as white needles. 
The residual yellowish solid (0.26 g) contained the starting material dha (40%) and 
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the product, tha (60%). 'H NMR (CDC13) of tha: 6 7.11 (m, 4H), 5.78 (s, 2H), 3.25 (s, 
4ff), 2.70 (s, 4H). 
Interaction of Li metal with p-terphenyl (p-terp) in liquid ammonia leads to formation 
of 3 different species: 1 ,4-dihydro-p-terphenyl (dh-p-terp) containing a reduced 
terminal ring of the tricyclic ring system, 1 ',4'-dihydro-p-terphenyl (dh'-p-terp) 
containing a reduced the middle ring of the tricyclic ring system, and 1',4',1",4"- 
tetrahydro-p-terphenyl  (th-p-terp) that contains both terminal rings reduced. The ratio 
of the mixture of dh-p-terp, dh'-p-terp and th-p-terp is dependent on the conditions 
used.26 When water is used as a source of protons, the inner ring product is 
repressed. 27 However this requires a small reaction scale, and in this work water 
could not be used as a quenching agent as 1 L of condensed cold ammonia was 
present (vide supra) and this would create extensive production of the gas, by 
warming up the solution. Therefore dh-p-terp was isolated as a side product from the 
Birch reduction for obtaining the dh'-p-terp. The slight difference in solubility of 
these two products, allowed the purification of dh-p-terp to be carried out (vide 
supra). 
1, 4-Dihydro-p-terphenyl (dh-p-terp). A solution of p-terp (25 g, 108.55 mmol) in 
THF (500 mL) was added to refluxing ammonia (1 L) which had been condensed 
under argon into a 2 L flask equipped with a Dewar condenser, cooling bath (dry ice / 
acetone) and mechanical stirrer. Li wire (1.74 g, 251.11 mmol) was added and upon 
the addition the solution turned deep blue. After 45 min of refluxing the reaction 
mixture was quenched by addition of NH4C1 (100 g, 1.87 mol), and the solution 
turned white. The ammonia was left to evaporate overnight. Products were isolated by 
/ThN ,. 
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partition between water (400 mL) and ether (4 x  200 mL), followed by separation of 
the ether layer which was washed with a saturated NaCl solution (200 mL), dried 
over MgSO4 and the solvent removed under reduced pressure. Fractional 
recrystallization from petroleum ether led to the purification of the products. The less 
soluble diene was dh'-p-terp and the diene remaining in the filtrate was dh-p-terp. 
This procedure was used to separate and purify the dienes. Yield of dh-p-terp: 0.35 g 
(1%). 'H NMR (CDC13) of dh-p-terp: 8 7.50 (m, 9H), 5.85 (d of d, 4H), 4.05 (broad t, 
1H), 2.80 (broad m, 2H) and 'H NMR (CDC13) of dh'-p-terp: ö 7.50 (m, 1OH), 5.90 
(s, 4H), 4.12 (s, 2H). 
The isolation and purification of th-p-terp (obtained as a side product) was carried out 
using fractional recrystallization from ethanol. 'H NMR (CDC13) of th-p-terp: 8 7.20 
(s, 4H), 5.80 (d of d, 8H), 4.0 (broad m, 211), 2.78 (broad m, 414). 
1,4-Dihydro-m-terphenyl (dh-m-terp). A solution of m-terphenyl (m-terp; 11.5 g, 
49.5 mmol) in THF (350 mL) was added to refluxing ammonia (1 L) which had been 
condensed under argon into a 2 L flask equipped with a Dewar condenser, cooling 
bath (dry ice / acetone) and mechanical stirrer. Li wire (0.77 g, 110.77 mmol) was 
added and upon the addition the solution turned deep blue. After 30 min of stirring 
and cooling, the reaction mixture was quenched by addition of NH4C1 (bOg, 1.87 
mol). The ammonia was left to evaporate overnight. The product was isolated by 
partition between water (400 mL) and ether (3 x  250 mL) and the separation of ether 
layer was followed by washing with 200 mL of a saturated NaCl solution, drying over 
MgSO4 and evaporation of the solvent under reduced pressure. Yield: 5.5 g (47%). 'H 
NMR (CDC13): ö 7.50 (m, 1011), 6.25 (m, 1H), 6.03 (m, 111), 5.90 (m, 111), 4.23 
(broad m, 111), 3.23 (broad m, 211). 
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2.2.3 Preparation of dimers 
All the dimers were prepared according to literature methods, 28  using a similar 
procedure. Typically a different excess of the reduced hydrocarbon (diene) was added 
to an ethanolic solution of RuC13 3H20. Details for individual reactions and 
characterization of dimers are described below. 
1(1
6-p-cym)RUC 12I2. RuC13 31­120 (3.50g. 16.8 mmol) was dissolved in dried and 
freshly-distilled ethanol (100 mL). Into this, a-terpinene (30 mL, 25.11 g, 202 mmol) 
was added drop-wise and the solution was heated to reflux for 24 h. During this time 
the solution changed color from originally dark brown to red. After the solution was 
allowed to cool down to room temperature, it was filtered to give a reddish-orange 
solid, which was washed with diethyl ether until the filtrate was clear and dried 
overnight in vacuum. Yield: 3.50 g (85%). 'H NMR (CDC13): ö 5.50 (d, 4H), 5.35 (d, 
4H), 2.95 (m, 2H), 2.15 (s, 6H), 1.30 (d, 12H). 
[(, 6-hmb)RuC12] 2. The dimer [(i 6-p-cym)RuCl2]2 (2.00 g, 3.26 mmol) and 
hexamethylbenzene (limb; 20 g, 123 mmol) were placed in a flask and heated up to 
Ca. 180°C for 3 h, and the mixture gradually turned from orange-red to orange-brown. 
During the heating of the mixture solidified limb around the top of the flask was 
continually scraped back down into the melting mixture. The reaction mixture was 
allowed to cool down, the orange-brown solid was washed with hexane (200 mL), 
followed by diethyl ether (200 mL) and the excess of limb was removed by 
sublimation. The brownish solid left was filtered through celite and washed with 
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chloroform (400 mL) until the filtrate turned colourless. Chloroform was removed on 
a rotary evaporator to leave a reddish-brown solid. Yield: 1.05 g (49%). 'H NMR 
(CDC13): ö 2.01 (s, 18H). 
1016-bip)RuC 12I2. 1,4-Dihydrobiphenyl (dhbip; 4.3 g, 27.5 mmol) was added to a 
solution of RuC13 3H0 (5 g, 19.12 mmol) in dry, freshly-distilled ethanol (60 mL). 
The reaction mixture was left refluxing under argon for 48 h. The warm reaction 
mixture was filtered and the brown solid was washed with fresh ethanol (3 mL) 
followed by ether (4 x  10 mL) and dried under vacuum. Yield: 5.06 g (81%). 'H 
NMR (DMSO-d6): 8 7.86 (d, 211), 7.54 (m, 311), 6.47 (d, 2H), 6.11 (m, 3H). 
I(,, 6-tha)RuC12I2. 1,4,5,8,9,10-Hexahydroanthracene (hha; 2.7 g, 14.6 mmol) was 
added to a solution of RuC13 3110 (1.42 g, 5.37 mmol) in dry, freshly-distilled 
ethanol (30 mL) and the reaction mixture refluxed under argon for 48 h. Immediately 
after the refluxing was stopped, the reaction mixture was filtered and yellowish-
brown solid washed with fresh ethanol (2 mL) followed by ether (4 x  10 mL) and 
dried tinder vacuum. Yield: 1.3 g (67%). 'H NMR (DMSO-d6): ö 5.83 (m, 211), 5.71 
(s, 2H), 5.61 (m, 211), 3.21 (m, 211), 3.05 (m, 211), 2.5 (m, 4H). 
1(q 6-dha)RuC12] 2. 1,4,9,10-Tetrahydroanthracene (tha; 0.26 g, 1.44 mmol) was added 
to a solution of RuC13 3H0 (1.28 g, 4.84 mmol) in dry, freshly-distilled ethanol (30 
mL). This mixture was left refluxing under argon for 48 h. The warm reaction 
mixture was filtered and dark brown solid was washed with fresh ethanol (2 mL) 
followed by ether (4 x  10 mL) and dried under vacuum. Yield: 0.29 g (18%). 'H 
NMR (DMSO-d6): 8 7.27 (m, 4H), 5.89 (m, 411), 3.92 (m, 4H). 
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[(j6-p-terp)RuC12] 2. 1 ,4-Dihydro-p-terphenyl (dh-p-terp; 0.35 g; 1.34 mmol) was 
added to a solution of RuC13 31420 (1.55 g, 6.68 mmol) in dry, freshly-distilled 
ethanol (60 mL). This mixture was left refluxing under argon for 48 h and was 
filtered while still warm. The dark brown solid was washed with fresh ethanol (5 mL) 
followed by ether (2 x  10 mL) and dried under vacuum. Soxhlet extraction was 
carried out using chloroform as a solvent in order to purify the dimer. The solvent 
was removed under reduced pressure and brownish solid dried in vacuum. Yield: 0.5 
g (20%). 'H NMR (CDC13): ö 7.95 (d, 2H), 7.80 (d of d, 4H), 7.52 (t, 2H), 7.43 (t, 
1H), 6.50 (d, 2H), 6.10 (m, 3H). 
1Qi6-m-terp)RuC12]2. 1,4-Dihydro-m-terphenyl (dh-m-terp; 5.5 g; 23.7 mmol) was 
added to a solution of RuC13 3H20 (1.60 g, 6.12 mmol) in dry, freshly-distilled 
ethanol (60 mL). This mixture was left refluxing under argon for 48 h. The reaction 
mixture was filtered while still warm and the dark brown solid was washed with fresh 
ethanol (5 mL) followed by ether (2 x  10 mL) and dried under vacuum. Soxhiet 
extraction was carried out using chloroform, in order to purify the dimer. The solvent 
was removed under reduced pressure and the bright orange solid dried in vacuum. 
Yield: 1 g (41%). 1 H NMR (CDC13): ö 7.80 (m, 8H), 7.45 (m, 12H), 6.23 (m, 4H), 
6.05 (d, 4H). 
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Chapter 3 
Terphenyl Ru" complexes 
"The joy of discovery is certainly the liveliest that the mind of man can ever feel." 
Claude Bernard 
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3.1 Introduction 
Organoruthenium complexes of the type [( q 6_arene)Rull(en)Cl] +, where arene = 
benzene (bz) or a benzene derivative, and en = ethylenediamine exhibit anticancer 
activity, including activity against cisplatin resistant cancer cells." 2  This class of 
complexes can form strong monofunctional adducts with DNA. 2 The selectivity of 
pseudo-octahedral Ru" arene en complexes for guanine (G) residues in DNA was 
found in the studies of reactions of DNA with Ru" arene complexes of the type [(i6 
arene)Ru(en)C1f, where the arene is biphenyl (bip), dihydroanthracene (dha), 
tetrahydroanthracene (tha), p-cymene (p-cym), or hz. 3 {(, 6-bip)Ru(en)Clf binds to 
DNA through coordination to G N7 as well as noncovalently, through hydrophobic 
interactions between the arene and DNA. These hydrophobic interactions may include 
intercalation of the non-coordinated phenyl ring between DNA bases and minor 
groove binding. Intramolecular it-it arene-nucleobase stacking has been observed in 
the crystal structure of [(i 6-bip)Ru(en)(9-EtG-N7)] [PF6]2,4 as well as a strong H-
bonding between an NH of en and C60 from G and both contribute to the G-
specificity. 5 
In this Chapter the synthesis and characterization of new complexes of the type [(p6.. 
arene)Ru(en)Cl], where the arene is ortho-, meta- orpara-terphenyl (o-, m- orp-terp) 
are reported. These complexes were synthesized in order to investigate the effect on 
cytotoxicity of an additional phenyl ring compared to hip as arene. Such complexes 
are expected to show enhanced arene intercalation compared to the bip analogue. In 
the case ofp-terp complex, Ru is bound to a terminal phenyl ring whereas in the cases 
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of o- and m-terp analogues, Ru is bound to the central phenyl ring. Aromatic 
hydrocarbons consisting of a chain of three benzene rings, terphenyls (terps), have 
three isomers in which the terminal rings are o-, m- or p-substituents of the central 
ring. Most of the natural terphenyls are p-terp derivatives. Very few m-terp 
derivatives occur naturally, and o-terps have not been found in nature. 6 In recent 
years, it has been reported that some terphenyls exhibit significant biological activity, 
such as neuroprotective, antithrombotic, anticoagulant, and cytotoxic activity. It has 
also been found that some popular edible mushrooms are rich in terphenyls, a sign 
that the toxicity of terphenyls is low. 
The potency of the p-terp complex (1) against A2780 human ovarian cancer cells 
(1050 = 4 p.M, IC50 = concentration inhibiting cell growth by 50%), reported in this 
Chapter, is higher than that of the bip analogue (10 50 = 6 j.tM),2 whereas, intriguingly, 
the o- and m-terp complexes (complexes 2 and 3) appeared to be much less active 
(with IC50 values of 30 iM for complex 2 and 42 p.M for complex 3). 
In this Chapter the relationship between cytotoxicity, cellular uptake and DNA 
binding of complexes consisting of p-, o- or m-terp arenes (complexes 1, 2, and 3, 
respectively) is investigated. Their activity towards human ovarian tumor cell lines 
A2780 (parent, cisplatin-sensitive) and A2780cisR (with acquired cisplatin 
resistance), human ovarian carcinoma CHI (cisplatin sensitive) and human mammary 
carcinoma SKBR3 (intrinsically cisplatin resistant) cell lines was also investigated. 
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3.2 Experimental section 
3.2.1 Materials 
The starting dimers [(,-arene)RuC12] 2, arene = p-terphenyl (p-terp, bound to the Ru 
through the terminal phenyl ring), o-terphenyl (o-terp, bound to the Ru through the 
central phenyl ring) and m-terphenyl (m-terp, bound to the Ru through the central 
phenyl ring), are prepared as described in Chapter 2. Ethylenediamine (en) and 1,3-
propylenediamine (pda) were purchased from Sigma-Aldrich. Methanol was dried 
over Mg/I2. Cisplatin and dimethylsulfoxide (DMSO) were obtained from Sigma-
Aldrich. [PtC1(dien)]Cl (dienPt) was a generous gift of Professor G. Natile from 
University of Ban. All other reagents were obtained from commercial suppliers. 
Stock solutions of complexes for the biophysical and biochemical studies were 
prepared at the concentration of 5 x  O' M in water, filtered and stored at room 
temperature in the dark. Stock solutions of metal complexes for the cytotoxicity and 
cellular uptake studies (performed by Anna Halamikova at University of Brno, Czech 
Republic) were prepared in DMSO and used immediately after dissolution. The 
concentrations of ruthenium or platinum in the stock solutions were determined by 
Flameless Atomic Absorption Spectrometry (FAAS), which is described in Chapter 2. 
CT DNA (42% G + C, mean molecular mass ca. 2 x  1 O) was prepared and 
characterized as described previously. 7, 8 pSP73KB (2455 bp) plasmid (superhelical 
density -0.036) was isolated according to standard procedures. EtBr was obtained 
from Merck KgaA and agarose purchased from FMC BioProducts. 
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3.2.2 Preparation of complexes 
All complexes were synthesized using a similar procedure. Typically the ligand (2 
mol equiv) was added to a methanolic solution of [(ij 6-arene)RuC12]2, where arene = 
p-terp, o-terp or m-terp. Details for individual reactions are described below. 
I(,, 6-p-terp)Ru(en)C1IIPF6I (1). To a suspension of [( 6-p-terp)RuC121 2 dimer (0.10 g, 
0.125 mmol) in dry, freshly-distilled methanol (50 mL) en (17 j.tL, 0.250 mmol) was 
added. The reaction mixture was stirred at ambient temperature under argon, 
overnight and the resulting clear yellow solution was filtered. NH4PF6 (0.061 g, 0.375 
mmol) was added and the flask shaken. A precipitate started to appear almost 
immediately. The flask was kept at -20°C overnight, and the product was collected by 
filtration, washed with cold methanol and ether, and dried in air to give an orange 
solid. Yield: 0.061 g (43%). 
Crystals suitable for x-ray analysis were obtained by slow evaporation of a methanolic 
solution at ambient temperature and the complex crystallized as [( 6-p-
terp)Ru(en)Cl][PF6]. ESI-MS: calcd for C20H22ClRuN 2 [M] m/z 426.9, found 427.0. 
1 H NMR in DMSO-d6: 8 7.87 (d, 211), 7.80 (d, 2H), 7.74 (d, 2H), 7.52 (t, 2H), 7.42 (t, 
1H), 6.50 (d, 2H; NH), 6.22 (d, 2H), 5.90 (t, 111), 5.82 (t, 2H), 4.20 (d, 211; NH), 2.31 
(m, 2H), 2.22 (m, 211). Anal. calcd for C20H22C1RuN 2PF6: C, 42.00; H, 3.88; N, 4.90. 
Found: C, 42.75; H, 3.97; N, 4.90. 
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1(116-0-terp)Ru(en)C 11 [PF6] (2). Complex 2 was prepared by Dr Abraha 
Habtemariam. To a suspension of [(? 7 6_o-terp)RuCI21 2  dimer (0.05 g, 0.06 mmol) in 
dry, freshly-distilled methanol (50 mL) en (8 p.L, 0.12 mmol) was added. The rest of 
the procedure was the same as described for complex 1. After addition of NI-L4PF 6 
(0.03 g, 0.18 mmol) the fine yellow solid was isolated as described for complex 1 and 
recrystallized from methanol/ether. Yield: 0.023 g (32%). 
ESI-MS: calcd for C20H22ClRuN2 [M] m/z 426.9, found 427.0. 'H NMR in DMSO-
d6: 6 7.43 (m, 4H), 7.31 (m, 2H), 7.26 (m, 4H), 6.49 (d, 2H; NH), 5.95 (m, 411), 4.31 
(d, 211; NH), 2.36 (m, 2H), 2.23 (m, 211). Anal. calcd for C20H22C1RuN 2PF6: C, 42.00; 
H, 3.88; N, 4.90. Found: C, 42.06; H, 3.75; N, 4.17. 
[(46-m-terp)Ru(en)C11[PF 6 1 (3). To a suspension of [(i 6-m-terp)RuCl2]2 dimer (0.053 
g, 0.065 mmol) in dry, freshly-distilled methanol (50 mL) en (8.7 p.L, 0.13 mmol) was 
added. The rest of the procedure was the same as described above. After addition of 
NH4PF6 (0.032 g, 0.19 mmol) brownish solid was isolated as described for complex 1 
and recrystallized from methanol. Yield: 0.024 g (32%). 
ESI-MS: calcd for C20H22ClRuN 2 [M] mlz 426.9, found 427.0. 'H NMR in DMSO-
d6: 8 7.92 (d of d, 414), 7.52 (m, 6H), 6.60 (s, 1H), 6.43 (d of d, 2H), 6.35 (d, 2H; NH), 
5.85 (t, 1H), 4.17 (d, 2H; NH), 2.30 (m, 2H), 2.15 (m, 211). Anal. calcd for 
C20H22C1RuN2PF6: C, 42.00; H, 3.88; N, 4.90. Found: C, 42.14; H, 4.11; N, 4.93. 
1Øj 6-m-terp)Ru(pda)C1] [PF61 (4). To a suspension of [(1 6-m-terp)RuCl2]2 dimer 
(0.050 g, 0.06 mmol) in dry, freshly-distilled methanol (50 mL) pda (10 .tL, 0.124 
mmol) was added. The rest of the procedure was the same as described above. After 
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addition of NH4PF6 (0.03 g, 0.18 mmol) fine orange solid was isolated as described 
for complex 1 and recrystallized from methanol/ether. Yield: 0.026 g (36%). 
Crystals suitable for x-ray analysis were obtained by slow evaporation of a 
methanolic/ether solution at ambient temperature and the complex crystallized as [( q 6 
m-terp)Ru(pda)Cl][PF6]. ESI-MS: calcd for C2 1 H24C1RuN2 [M] mlz 440.9, found 
441.1. 1 H NMR in DMSO-d6: ö 8.00 (d of d, 4H), 7.54 (m, 6H), 6.80 (s, 1H), 6.50 (d 
of d, 2H), 6.20 (d, 2H; NH), 6.05 (t, 1H), 3.10 (m, 2H), 2.70 (d, 2H; NH), 2.12 (m, 
2H), 1.4 (m, 2H). 
3.2.3 X-ray crystallography 
The details of the instrumentation used, are described in Chapter 2. The structure of 
complex 1 was solved by Professor Simon Parsons by Patterson method (DIRDIF) 9 , 
while the structure of 4 was solved by Stephen Moggach by direct method (S1R92)' ° . 
The structures were refined by full-matrix least squares against ITI2  using SHELXL" 
for the structure of 1 and CRYSTALS 12  for the structure of 4. Hydrogen atoms were 
placed in calculated positions, and all non-H atoms were modelled with anisotropic 
displacement parameters. The final conventional R factor (based on F and 3564 out of 
4590 with F> 4a(F)) was 0.0479 for the structure of 1, and the final conventional R 
factor (based on F and 4982 out of 6331 with F> 4cy(F)) was 0.0297 for the structure 
of 4. Other crystal and refinement data are summarized in Table 3.1. The crystal 
structure of 1 has been deposited in the Cambridge Crystallographic Data Centre 
under the accession number CCDC 681045. 
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3.2.4 Cytotoxicily 
The cytotoxicity tests were performed at the Institute of Biophysics in Brno (CR). The 
tumour cell lines A2780, A2780cisR, CHI and SKBR3 were cultured in RPM! 1640 
medium (Gibco) (A2780 and A2780cisR) and Dulbecco's Modified Eagle's Medium 
(DMEM) (CHI and SKBR3), supplemented with 10% FBS, 50 .tg/mL gentamycin at 
37°C in an atmosphere of 95% of air and 5% CO2. Cell death was evaluated by using 
a system based on the tetrazolium compound MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide] which is reduced by living cells to yield a soluble 
formazan product that can be detected colorimetrically.' 3 Cells were seeded in 96-well 
sterile plates at a density of 10 4 cells/well in 100 p.L of medium and were incubated 
16 h. The final concentration of DMSO in cell culture medium did not exceed 0.25%. 
Complexes 1, 2 and 3 were added to final concentrations from 0 to 256 .LM in a 
volume of 100 j.tL/well. Seventy-two hours later 10 L of a freshly diluted MTT 
solution (2.5 mg/mL) was pipetted into each well and the plate was incubated at 37°C 
in a humidified 5% CO2 atmosphere. After 5 h the medium was removed and the 
formazan product was dissolved in 100 j.tL of DMSO. The cell viability was evaluated 
by measurement of the absorbance at 570 run, using an Absorbance Reader Sunrice 
Tecan Schoeller. IC 50 values (complex concentration that produces 50% of cell 
growth inhibition) were calculated from curves constructed by plotting cell survival 
(%) versus drug concentration (l.tM).  All experiments were made in quadruplicate. 
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3.2.5 Cellular ruthenium complex uptake 
The cellular uptake experiments were performed at the Institute of Biophysics in Brno 
(CR). Cellular uptake of complexes 1-3, and cisplatin was measured in A2780 and 
A2780cisR cells (sensitive and resistant to cisplatin, respectively). The cells were 
seeded in 60 mm tissue culture dishes (30 000/cm 2). After overnight incubation, the 
cells were treated with the ruthenium complex for 72 h at the concentrations 
corresponding to the IC50 values (these concentrations were verified by the 
measurement of ruthenium in the growing medium by FAAS). The attached cells 
were washed twice with PBS (4°C), the pellet stored at -80°C and ruthenium content 
determined by FAAS. For other details, see the results section. All experiments were 
performed in quadruplicate. 
3.2.6 Metalation reactions in cell-free media 
Calf thymus (CT) and plasmid DNAs were incubated with ruthenium or platinum 
complexes in 10 mM NaC104 (pH = 6) at 37°C for 24 h in the dark, if not stated 
otherwise. The values of rb were determined by FAAS. 
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3.2.7 Fluorescence measurements 
The details of instrumentation are described in Chapter 2. Fluorescence measurements 
of CT DNA modified by Ru" arene complexes 1, 2 and 3, in the presence of EtBr 
were performed at an excitation wavelength of 546 nm, and the emitted fluorescence 
was analyzed at 590 nm. The fluorescence intensity was measured at 25°C in 0.4 M 
9 
NaCl to avoid secondary binding of EtBr to DNA. 14, 158 The concentrations were 0.01 
mg/mL for DNA and 0.04 mg/mL for EtBr, which corresponded to the saturation of 
all intercalation sites of EtBr in DNA. 14 
3.2.8 DNA melting 
The melting curves of CT DNA were recorded by measuring the absorbance at 260 
nni. The melting curves of unmodified or ruthenated DNA were recorded in a medium 
containing 10 mM NaC104 with 1 mM Tris-HC1/0. 1 mM EDTA, pH= 7.4. The value 
of tm (melting temperature) was determined as a temperature corresponding to a 
maximum on the first-derivative profile of the melting curves. The tm values could be 
thus determined with an accuracy of± 0.3°C. 
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3.2.9 Unwinding of negatively supercoiled DNA 
The unwinding experiments were performed by Dr Jana Kasparkova at the Institute of 
Biophysics in Brno (CR). Unwinding of closed circular supercoiled pSP73KB 
plasmid DNA was assayed by an agarose gel mobility shift assay. 16 The unwinding 
angle ci), induced per ruthenium-DNA adduct was calculated upon the determination 
of the rb value (rb values are defined as the number of atoms of the metal bound per 
nucleotide residue) at which the complete transformation of the supercoiled to relaxed 
form of the plasmid was attained. Samples of plasmid DNA were incubated with 
complexes 1, 2 or 3 at 37°C in the dark for 24 h. All samples were precipitated by 
ethanol and redissolved in the TAE (Tris-acetate/EDTA) buffer. One aliquot of the 
precipitated sample was subjected to electrophoresis on 1% agarose gels running at 
25°C in the dark with TAE buffer and the voltage set at 25 V. The gels were then 
stained with EtBr, followed by photography with a transilluminator. The other aliquot 
was used for the determination of rb values by FAAS. 
3.2.10 Other Physical Methods 
Absorption spectra were measured with a Beckman DU 7 4000 spectrophotometer 
equipped with a thermoelectrically controlled cell holder and quartz cells with the 
path length of 1 cm. For FAAS analysis, DNA was precipitated with ethanol and 
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dissolved in 0.1 M HC1. The gels were visualized by using a BAS 2500 FUJIFILM 
bioimaging analyzer. 
3.3 Results 
3.3.1 Synthesis and characterization 
Complexes reported in this Chapter are shown in Figure 3.1. 
Figure 3.1 Chemical structures of Ru" arene complexes 1, [(i7 6-p-terp)Ru(en)Clf ; 2, 
	
6 	 + 	6 	 + 	6 	 + [(q ; 3 [('i  -m-terp)Ru(en)C1] and 4 [(,j  -m-terp)Ru(pda)Cl] 
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Synthesis and characterization of these complexes are reported in the experimental 
section. UV-Vis spectra of complexes 1, 2 and 3 are shown in Figure 3.2A. The UV-
Vis spectrum of complex 1 in water shows a shoulder at 260 rim (c = 13497 M 1cm) 
and a band at 285 rim (c = 19263 M 1 cm 1 ), complex 2 has bands at 233 rim (E = 
14595 M'cm') and 260 rim (c = 6761 M 1 cn1 1 ), and complex 3 at 260 rim (E = 11100 
M 1 cm) and 447 nm (c = 1350 M 1 cm). The lower energy bands (at 285, 260 and 
447 nm for 1, 2 and 3, respectively) correspond to MLCT, 17 assigned to Ru (4d6) -* 
* (arene) transitions. The difference in the energy of these bands is not surprising as 
the free arenes (o-, m- and p-terp) exhibit different absorption spectra as well, due to 
the different electronic interactions between the first and the third phenyl ring of o-, 
m- and p-terp. 18 The higher energy bands (at 260, 233 and again 260 rim for 1, 2 and 
3, respectively) are assigned to the arene it -+ it transitions. 17  Figure 3.2B shows the 
difference in absorbance (at 260 rim) of DNA modified by complexes 1, 2 and 3 (24 h 
incubation) and the absorbance of unmodified DNA. The table in Figure 3.2 shows 
the dependence of these differences in absorbance (AA 260)on  the concentration of 1, 2 
and 3 (determined by FAAS). 
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Figure 3.2 (A) UV-Vis spectra of complexes 1, 2 and 3 in water at concentrations of 
3.5, 4.1 and 3.8 x 10-5 M, respectively. (B) The difference in absorbance (at 260 nm) 
of DNA modified by complexes 1, 2 and 3 (24 h incubation) and the absorbance of 
unmodified DNA; concentrations of 1, 2 and 3 are determined by FAAS. 
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3.3.2 Crystal structures 
The x-ray crystal structures of the cations of complexes [( 6-p-terp)Ru(en)Cl] [PF6] (1) 
and [(, 6-m-terp)Ru(pda)Cl][PF6] (4) are shown in Figure 3.3. Both complexes 
crystallized as PF6 salts. The crystallographic data are listed in Table 3. 1, and selected 
bond lengths and angles in Table 3.2. In both complexes, Ru" adopts the familiar 
'three-legged piano-stool' geometry with an q 6  7t-bonded arene, forming the seat of 
the stool. The legs of the stool form a-bonded Cl and N atoms of the en or pda 
chelating ligands, respectively. 
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Figure 3.3 ORTEP diagrams for cations of (A) [(, 6-p-terp)Ru(en)C1][PF6] (1) and (B) 
[(,7 6-m-terp)Ru(pda)C1][PF6] (4), with 50% probability thermal ellipsoids. All 
hydrogen atoms have been omitted for clarity. 
73 
Chapter 3: Terphenyl Ru' complexes 
Table 3.1 X-ray crystal structure data for complexes 1 and 4 
Complex 	 1 	 4 
Formula C20H22CIF6N2PRu C21 H24CIF6N2PRu 
Molar mass 571.89 585.92 
Crystal system monoclinic monoclinic 
Crystal size /mm 0.27 x  0.21 x 0.21 0.56 x  0.22 x 0.16 
Space group P211c P1211cl 
Crystal yellow / block yellow / rod 
a/A 19.0359(10) 11.0450(3) 
b / A 10.1405(5) 10.6507(3) 
c/A 11.2966(5) 19.2317(5) 
a/ deg 90 90 
fl/deg 105.218(3) 98.737(2) 
r/ deg 90 90 
TIK 150(2) 150 
Z 
R [F > 4c (F)]a 0.0479 0.0297 
R  0.1256 0.0778 
GOFC 1.041 0.9572 
ip max and mm, /eA3 1.557,-0.814 0.80,-0.92 
aR = IIFOI - IFII/IF0I. bR = [w(F 02 - F2)2/wF02)]'. CGOF = [w(F 02 - F2)2/(n-
p)] 112. where n = number of reflections and p = number of parameters. 
74 
Chapter 3: Terphenyl Ru" complexes 
Table 3.2 Selected bond lengths (A) and angles (°) for complexes 1 and 4 
Bond/Angle 1 4 
Ru-CI 2.3929(11) 2.3894(5) 
Ru-N12/N19 2.125(4) 2.1370(18) 
Ru-N42/N23 2.126(4) 2.1231(16) 
Ru-CI1/C7 2.174(4) 2.210(2) 
Ru-C21/C8 2.152(5) 2.1669(19) 
Ru-C31/C9 2.190(4) 2.1817(19) 
Ru-C41/C15 2.225(4) 2.2067(18) 
Ru-051/C16 2.191(4) 2.2237(19) 
Ru-C61/C18 2.157(5) 2.2182(18) 
N 12/ Ni 9-Ru-N42/ N23 78.76(14) 83.14(7) 
N12/N19-Ru-C1 83.65(10) 83.29(5) 
N42/ N23-Ru-C1 84.57(11) 83 .66(5) 
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Twisting of the phenyl rings is present in the crystal structure of 1. The twist angle 
between the bound and the middle ring is 43.21°, and between the middle and the 
terminal ring 38.47°. The planes, in which the terminal and bound rings lay, are 
twisted by 5.62°. The twisting between the phenyl rings has been previously observed 
for {(, 6-bip)Ru(en)C1] [PF6] (twist angle 24.6 *).2  CHI 7t interaction is present between 
the C6 1 H proton of the bound ring of p-terp from one molecule and the centre of the 
ic-system of the middle ring of p-terp from another molecule (2.6 A; Figure 3.4). The 
distances between carbons of the bound arene ring and the metal centre range from 
2.152(5) to 2.225(4) A. The bond between Ru and the substituted carbon (Ru-C41 
with the value of 2.225(4) A; Table 3.2) is 0.034 A longer than any other Ru-C bond 
in the molecule. This pattern has been reported previously for the bip analogue [(?7 6 
bip)Ru(en)Cl][PF6], where the bond between Ru and the substituted carbon, of 
2.244(6) A, is 0.054 A longer than any other Ru-C bond in that molecule. 2 
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Figure 3.4 Capped-stick model of the crystal structure of complex 1, showing 
interactions between C61 H proton of the bound ring of p-terp from one molecule and 
the centre of the 7r-system of the middle ring ofp-terp from another molecule. 
In the crystal structure of 4 the common chair conformation is adopted by the six-
membered ring formed between pda chelating ligand and Ru. The twisting of the 
phenyl rings of m-terp is present. The twist angles between middle (bound) phenyl 
ring and terminal rings are 32.07° and 36.84°. The twist angle between the two 
terminal phenyl rings of m-terp is 58.24°. The Ru carbon (of the bound phenyl ring) 
distances range from 2.1669(19) to 2.2237(19) A. The bond length between Ru and 
the substituted carbons (Ru-C16/C18 with the values of 2.2237(19) and 2.2182(18) A; 
Table 3.2) are 0.014 and 0.008 A (for C16 and C18, respectively) longer than any 
other Ru-C bond in the molecule. 
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3.3.3 Cytotoxicity 
The cytotoxicity of m-terp pda complex 4 was determined against A2780 ovarian 
(1050 = 12 pM) and A549 lung (1050 = 18 pM) cancer cell lines, by Oncosence Ltd 
using the procedure from Chapter 2 (24 h exposure). The cytotoxic activity of Ru" 
arene complexes 1-3 was determined against four different cisplatin-sensitive and 
cisplatin-resistant cancer cell lines. The human ovarian carcinoma cell lines A2780, 
CH 1 (both cisplatin sensitive), A2780cisR (with acquired cisplatin resistance) and 
human mammary carcinoma cell line SKBR3 (intrinsically cisplatin resistant) were 
employed. A2780cisR cells are resistant to cisplatin through a combination of 
decreased uptake, enhanced DNA repair/tolerance, and elevated glutathione (GSH) 
levels. 19 The tumor cell lines were incubated for 72 h with complexes 1, 2 and 3 or 
cisplatin and the cell survival in the culture was evaluated as described in the 
experimental section. All complexes show activity and their corresponding IC50 
values (10 50 = concentration inhibiting cell growth by 50%) are reported in Table 3.3. 
In general activity follows the order 1, cisplatin>> 2 > 3, with all Ru complexes 
lacking cross-resistance with cisplatin. 
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Table 3.3 IC50 values (tM) for Ru" en complexes described in this Chapter'" 
Complex CHI SKBR3 A2780 A2780cisR (RF)c 
cisplatin 0.9±0.1 8±2 2.8±0.7 18.6±0.4 (6.7) 
1 2.2±0.3 8±1 4±1 1.4±0.6 (0.4) 
2 23±1 13±3 30±4 18.3±0.8 (0.6) 
3 51±9 80±5 42±4 31±4 (0.7) 
a Drug-treatment period was 72 h. 
b The experiments were performed in quadruplicate. 
C  Resistance factor (RF), defined as IC50 (resistant) / IC50 (sensitive), is given in 
parentheses. 
3.3.4 Cellular ruthenium complex uptake 
An important factor that usually contributes to transition metal-based drug 
cytotoxicity is cellular uptake. To examine accumulation of complexes 1-3, the 
cellular levels of these complexes were measured after a 72 h exposure of the A2780 
and A2780cisR cells to 1, 2 and 3 at equitoxic concentrations (i.e. at the 
concentrations corresponding to the IC 50 values shown in Table 3.3). The amount of 
ruthenium found in cells (in pmolI10 6 cells, Table 3.4): 2 >> 3> 1, does not correlate 
with their cytotoxicity (IC 50 value). Since complexes 1-3 were tested at their equitoxic 
doses, the results shown in Table 3.4 imply that notably less molecules of complex 1 
inside the cells, in comparison with complexes 2 and 3, are necessary to induce the 
same cytotoxic effect. 
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Table 3.4 Uptake of Ru" arene en complexes and cisplatin into cells 
Cell line 	 Uptake (pmol/10 6 cells) 
cisplatin 	complex 1 complex 2 	complex 3 
A2780 	30±2 	350±20 
A2780cisR 	47±3 	150±10 
2130±130 	630±50 
1010±90 	490±80 
a Table shows the uptake of cisplatin and complexes 1-3 at their equitoxic 
concentrations (corresponding to the IC50 values shown in Table 3.3) into A2780 or 
A2780cisR cells after 72 h. Each value shown in the Table 3.4 is in pmol of Ru or 
pt/106 cells. 
b The experiments were performed in triplicate. 
3.3.5 DNA binding in cell-free media 
DNA is an important potential biological target for many metal-based anticancer 
agents. 20 Distortions of DNA structure often correlate with anticancer activity. 21, 22 
Hence, it is of great importance to understand in detail DNA binding properties of 
complexes 1, 2 and 3 and their possible relationship to cytotoxicity in tumor cell lines. 
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3.3.5.1 Kinetics of binding to calf thymus (CT) DNA 
The rate of binding of Ru" arene complexes 1, 2 and 3 to CT DNA was determined at 
an r1 (molar ratio of free Ru" arene complex to nucleotide phosphate) ratio of 0.08 in 
10 mM NaC104. Ru" arene complexes were incubated with CT DNA (at 37°C in the 
dark) and aliquots removed at various time intervals, and rapidly cooled. DNA with a 
bound complex was precipitated out by addition of ethanol, and the concentration of 
free complex in the supernatant determined by flameless atomic absorption 
spectrometry (FAAS; Figure 3.5). Complexes 1 and 3 bind rapidly to DNA (t,,2 ca. 5 
and 9 min for 1 and 3, respectively), while ti/2 for complex 2 is ca. 31 mm. Complex 1 
binds to CT DNA almost quantitatively, whereas only Ca. 90% of complex 2 and 80% 
of complex 3 are bound after 48 h. 
The binding experiments carried out in this Chapter indicated that modification 
reactions resulted in the irreversible coordination of complexes 1, 2 and 3 to CT 
DNA, which thus facilitated sample analysis. Hence, it was possible to prepare 
samples of DNA modified by Ru" complexes at a preselected value of rb.  Thus, 
except where stated, samples of DNA modified by Ru" arene complexes 1, 2 and 3 
and analyzed further by biophysical or biochemical methods were prepared in 10 mM 
NaC104 at 37 °C. After 24 h of the reaction of DNA with a complex, the samples 
were precipitated in ethanol and dissolved in the medium necessary for a particular 
analysis, and the rb value in an aliquot of this sample was checked by FAAS. In this 
way, all analyses described in this Chapter were performed in the absence of unbound 
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time /h 
Figure 3.5 Kinetics of the binding (studied by ethanol precipitation method) of 
complexes 1 (.), 2 (Y) and 3 (,) to calf-thymus (CT) DNA in the medium of 10 
mM NaC104, at 37 °C and pH = 6. The concentration of DNA was 3x 104  M and r1 
was 0.08 (concentration of complexes was 2.4x 10 -5 M). 
3.3.5.2 Circular Dichroism (CD) 
To gain further information, CD spectra of DNA modified by complexes 1, 2 and 3 
(at 25 °C in 10 mM NaC104, for more details see Chapter 2) were also recorded. 
These complexes have no intrinsic CD signals as they are achiral and any CD signal 
above 300 nm is, therefore, attributed to the interaction of complexes with DNA. 
Below 300 nm any change in the spectrum of B-DNA (see Chapter 2) is due either to 
the DNA induced CD (lCD) of the metal complex or the metal-complex-induced 
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perturbation of the DNA spectrum. The signature of complex 1 bound to CT DNA is a 
strong negative lCD at around 308 nm and a strong positive lCD centered at 376 nm 
with the crossover at 351 nm (Figure 3.6). On the other hand, the signature of 
complex 3 bound to CT DNA is only very weak and broad positive lCD centered at 
376 nm. Complex 2 bound to CT DNA does not have any signature in the region 
above 300 nm. These results reflect different binding modes of complexes 2 and 3 to 
DNA, compare to that of complex 1. Unfortunately these complexes also absorb in 
the DNA region (Chapter 2 and Figure 3.2B), leading to the interpretation of the CD 
spectra (below 300 nm) in terms of alterations of DNA conformation or the DNA 
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Figure 3.6 Circular dichroism (CD) spectrum of CT DNA (1 x  10 M) modified by 
complex 1; the medium was 10 mM NaC104, pH = 6. DNA was modified by complex 
1 at r 1 = 0, 0.01, 0.02, 0.04, 0.08 and 0.12 (r 1 = molar ratio of free Ru complex to 
nucleotide phosphates at the onset of incubation with DNA). The arrows show 
changes in CD spectrum with increasing the r 1 value. 
The changes in CD spectra of CT DNA modified by Ru 1 ' terphenyl complexes (at 
different rb values) are shown in Figure 3.7. The changes in the CD spectrum of CT 
DNA modified by complex 1 were monitored at 244, 278, 308 and 378 nm, and for 
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Figure 3.7 The changes induced in CD spectra of CT DNA modified by Ru" 
complexes 1, 2 and 3 at different rb values. 
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3.3.5.3 Ethidium bromide (EtBr) fluorescence 
The ability of complexes to displace the DNA intercalator EtBr from CT DNA was 
probed by monitoring the relative fluorescence of the EtBr-DNA adduct after treating 
the DNA with varying concentrations of!, 2 and 3. Figure 3.8 shows a plot of relative 
fluorescence vs rb for complexes 1, 2 and 3, cisplatin and monofunctional dienPt. The 
adducts of Ru 11 arene complexes 1 and 3 competitively replaced intercalated EtBr 
markedly more effectively than the adducts of monofunctional dienPt and even 
slightly more than the adducts of bifunctional cisplatin. The replacement of EtBr by 
the adducts of complex 2 was closer to that observed for monofunctional dienPt, than 
observed for the other two complexes. Notably, the ability of complex 1 to displace 
DNA intercalator EtBr from CT DNA was considerably greater than that of 
complexes 2 and 3 (Figure 3.8). 
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0.050 61.0 73.2 68.7 - - 
0.100 34.0 52.5 49.6 50.0 82.50 
Figure 3.8 Plots of the EtBr fluorescence versus rb for DNA modified by cisplatin, 
dienPt and Ru" arene complexes 1, 2 and 3 in 10 mM NaC104 at 37°C (incubation for 
24 h): (x), dienPt; (a), cisplatin; (U), complex 1; (.), complex 2 and (o), complex 3. 
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3.3.5.4 DNA melting 
CT DNA was modified by Ru" arene complexes 1, 2 and 3 at various rb values 
(Figure 3.9) in 10 mM NaC104 at 37°C for 24 h. The salt concentration was then 
further adjusted by addition of NaC104 to values in the range 0.01-0.205 M (Figure 
3.9). The DNA melting temperature (tm) is dependent both on the amount of 
ruthenium bound and on the salt concentration. At low concentrations of NaC104 
(0.01 M) an increase in tm  was observed for DNA modified by complex 1 compared 
to that of unmodified DNA, and this became more pronounced with increasing rb 
values (Figure 3.9). With increasing ionic strength, the enhancement of tm (At., 
defined as the difference between the values of ruthenated and nonmodified DNA5) 
due to the presence of the complex decreased. CT DNA modified by complexes 2 and 
3 exhibited a different melting behavior. At higher concentrations of NaC104 (0.055-
0.205 M) a decrease in tm  was observed for modification by complexes 2 and 3, and 
this became more pronounced with increasing rb values (Figure 3.9). With increasing 
ionic strength, the Atm due to the modification by 2 and 3 decreased. At a 
concentration of NaC104 as low as 0.01 M for DNA modified by complex 2 an 
increase in tm was observed with increasing rb value, while for the modification by 
complex 3, a slight increase in tm was first observed with increasing rb (rb <0.078), 
but at higher rb values At,,, decreased with increasing rb. 
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Figure 3.9 Plots showing the dependence of Atm values on r, for calf thymus (CT) 
DNA modified by Ru" arene complexes 1, 2 and 3. The melting curves were 
measured in of 1 mlvi Tris-HC1 with 0.1 mM EDTA, at pH = 7.4 and varying 
concentrations of NaC104 : 0.01 M, 0.055 M, 0.105 M and 0.205 M. Atm is defined as 
the difference between the tm values of ruthenated and nonmodified DNAs. 
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3.3.5.5 Unwinding of supercoiled DNA 
As being the most and the least cytotoxic of the terphenyl complexes, 1 and 3, 
respectively, were chosen for studies of the unwinding of supercoiled DNA. The 
unwinding of supercoiled plasmid pSP73KB DNA induced on binding complexes 1 
and 3 was determined by incubating the plasmid with 1 or 3 for 24 h at 37°C at 
various rb values (different lanes in the gel). The native agarose gels, resulting from 
DNA modified by Ru" terphenyl complexes 1 and 3, are shown in Figure 3.10 (top 
and bottom panels, respectively). A decrease in the rate of migration is the result of 
unwinding the DNA as this reduces the number of supercoils. The mean unwinding 
angle can be calculated from the equation = -1 8a/rb(c), where a is the superhelical 
density (represents the number of turns added or removed relative to the total number 
of turns in the relaxed plasmid, indicating the level of supercoiling) and rb(c) is the rb 
at which the supercoiled and nicked forms comigrate. 16 It can be seen in Figure 3.10 
(top) that complex 1 causes a significant unwinding of DNA (b = 14±1°, the 
comigration point of the modified supercoiled and nicked DNA, rb(c),  was reached at 
rb = 0.047). In contrast, complex 3 unwinds the DNA significantly less (b = 8±1°, the 
comigration point of the modified supercoiled and nicked DNA, rb(c),  was reached at 
rb 0.083). The high level of unwinding induced by complex 1 is similar to that 
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Figure 310 The unwinding of supercoiled pSP73KB plasmid DNA by complexes 1 
(top) and 3 (bottom). The plasmid was incubated with Ru" arene complexes in 10 mM 
NaC104, at pH = 6 for 24 h at 37 °C. Lanes in the top panel: I and 12, control, 
unmodified DNA; 2, r, = 0.008; 3, rb = 0.016; 4, r, = 0.024; 5, rb = 0.031; 6, rb = 
0.039; 7, rb = 0.047; 8, rb = 0.055; 9, rb = 0.063; 10, r, = 0.071; 11, rb = 0.079. Lanes 
in the bottom panel: 1 and 12, control, unmodified DNA; 2, rb = 0.017; 3, rb = 0.033; 
4, rb = 0.050; 5, rb = 0.058; 6, rb = 0.066; 7, rb = 0.074; 8, rb = 0.083; 9, r, = 0.091; 10, 
rb = 0.099; 11, rb = 0.108. The top bands in each panel correspond to the form of 
nicked plasmid, and the bottom bands, to the closed, negatively supercoiled plasmid. 
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3.4 Discussion 
New complexes of the type [(I 6_arene)Ru(N,N)Cl] +, where arene = ortho-, meta- or 
para-terphenyl (o-, m- or p-terp) and N,N = ethylenediamine (en) or 1,3-
propylenediamine (pda), reported in this Chapter are shown in Figure 3.1. 
In the reported crystal structure of the p-terp complex 1 the twisting of the phenyl 
rings is shown to be caused by the presence of inter-molecular CHI it interaction 
between the C61  proton of the bound ring of p-terp (Figure 3.4) from one molecule 
and the center of the it-system of the central ring of p-terp from another molecule. 
With a value of 2.6 A this interaction is classified as weak. 23 This suggests that in the 
solution the CW it interaction could be absent and the p-terp arene of 1 could possibly 
become well positioned for the intercalation into DNA (vide supra). 
DNA binding mode, the effect on cytotoxicity and cellular Ru" complex uptake were 
investigated for terphenyl complexes that contain en as the chelating ligand 
(complexes 1, 2 and 3). The cytotoxic activity of Ru" arene complexes 1-3 was 
determined against different cisplatin-sensitive and cisplatin-resistant cancer cell lines 
(Table 3.3). The highest activity in all cell lines is exhibited by the p-terp complex 1. 
Interestingly, in A2780, CHI and SKBR3 cells, complex 1 shows potency comparable 
with that of conventional cisplatin. Importantly, the cytotoxicity of all Ru" arene en 
complexes, tested in this Chapter in the cisplatin-resistant line A2780cisR, is 
characterized by remarkably low resistance factors, less than 1 (Table 3.3); complex 1 
shows the best circumvention of cisplatin resistance (lowest value of resistance 
factor). On the other hand, complex 3 is the least potent in all cell lines with IC50 
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values in the range of 31 - 75 IM Notably all Ru" arene en complexes 1-3 show 
higher potency towards cisplatin-resistant compared to cisplatin-sensitive A2780 
cells, indicating a mechanism of cytotoxicity of this class of Ru" complexes different 
from that of cisplatin. 
The ruthenium complexes uptake does not correlate with their cytotoxicity (10 50 
value). Since complexes 1-3 were tested at their equitoxic doses, the results imply that 
notably less molecules of complex 1 inside the cells are needed, in comparison with 
complexes 2 and 3, to induce the same cytotoxic effect. This means that intracellular 
damage induced by complex 1 and responsible for cytotoxic effects is more efficient 
than those induced by complexes 2 and 3. 
The results of studies of the binding of 1, 2 and 3 to natural double-helical CT DNA 
(in a cell-free medium) are summarized in Table 3.5. 
OXI 
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Table 3.5 Summary of DNA binding studies for complexes 1, 2 and 3 
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-11.6°C  
rapid (t119 mm)! 
80% (48 h) 





less replacement 	less replacement 
The results show (Table 3.5) that the reactions with CT DNA of complexes 1 and 3 
are significantly faster than that of complex 2. The rate of binding is dependent on the 
type of arene ligand: complex 2 containing o-terp shows the slowest binding to CT 
DNA, while complex 3 containing m-terp binds to CT DNA faster than 2, but still 
slower than 1 (a complex with p-terp arene). The binding is quantitative in the case of 
complex 1, but not quantitative in the case of complexes 2 and 3 (90 and 80% for 2 
and 3, respectively after 48 h). Different rates of reactions between CT DNA and Ru" 
arene complexes were also observed in the case of analog Ru 11 complexes of the type 
[(16-arene)Ru(en)Clf, where the arene is biphenyl, dihydroanthracene, 
tetrahydroanthracene, p-cymene, or benzene. 3 It has been deduced that hydrophobic 
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interactions contribute to the driving force for the binding of chlorido Ru" arene 
complexes to double-helical DNA. Hence, a faster reaction between CT DNA and 
complex 1 suggests that DNA binding mode of complex 1 involves not only its 
coordination to the base residues in DNA, but also hydrophobic interactions, such as 
intercalation of the p-terp arene. This interpretation also implies that the significance 
of these hydrophobic interactions in DNA binding mode of complex 3 is diminished, 
and for complex 2 these interactions might be completely absent, due to the most 
compact, bulky arene (o-terp). 
The CD measurements are consistent with different binding modes of complexes 1, 2 
and 3 to DNA and support the hypothesis that the DNA binding mode, particularly of 
complex 1, may involve its interaction in specific orientations. The CD spectra of 
DNA modified by complexes 1, 2 or 3 (the changes in spectra are shown in Figure 
3.7) indicate that the binding of these complexes results in conformational alterations 
in double-helical DNA. Complex 1 bound to CT DNA yields a strong negative lCD at 
around 308 nm and a strong positive lCD centered at 376 nm (Figure 3.6). On the 
other hand, complex 3 bound to CT DNA yields only a very weak and broad positive 
lCD centered at 376 run, while the CD spectrum of CT DNA modified by complex 2 
shows no band in the region above 300 run. 
The CD changes observed for double-helical DNA modified by complexes 1, 2 and 3 
also correlate with the results of competitive EtBr displacement (Figure 3.8) and DNA 
unwinding (Figure 3.10) experiments. The adducts of p-terp complex 1 are 
considerably more efficient in DNA-EtBr fluorescence quenching than those of o-terp 
complex 2 and m-terp complex 3. A greater efficiency of DNA unwinding for 
complex 1 compared to 3 is also observed. The large unwinding angle of 14° was 
produced by complex 1 while complex 3 unwinds DNA only by 8° (Figure 3.10), a 
0-11 
Chapter 3: Terphenyl Ru" complexes 
similar behavior to that of the monofunctional adducts of dienPt (unwinding angle 
6') 16  or of [(16-arene)Ru(en)Cl], where the arene is non-intercalating p-cymene 
(unwinding angle 70)3.  This observations may be explained by additional contribution 
to fluorescence quenching and unwinding from intercalation of the extended arene 
ligand of 1 into the duplex upon its monofunctional binding. It seems reasonable to 
suggest that o-terp and m-terp arenes in complexes 2 and 3 do not interact with the 
double helix in a similar way to that of p-terp arene of complex 1. Hence, the results 
of DNA-EtBr fluorescence quenching and unwinding experiments strengthen the 
theory based on combined intercalative and monofunctional binding mode of complex 
1. 
Melting of DNA modified by complex 1, 2 or 3 (Figure 3.9) also deserves discussion. 
The following factors can be invoked to account for the thermal stability of DNA 
modified by Ru" arene complexes: 3 
Stabilizing effects of the positive charge on ruthenium, favorable stacking 
interactions between the base residues and the arene, and the separation of 
negative backbone charges inherent to intercalating arene residue (due to 
elongation and unwinding of DNA). The changes in solvent structure and 
the counterion distribution around the phosphate groups may help to 
overcome electrostatics unfavorable for the hybridization of the strands of 
the duplex. 24,25 
A destabilizing effect of conformational distortions induced in DNA by 
ruthenium coordination. The dependence of the tm value of DNA modified 
by non-intercalating ruthenium drugs on ionic strength can be explained 
by competing electrostatic effects as the salt concentration is varied. 26 
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Thus, the observed change in t m  will reflect the relative proportion and 
contribution of all limiting binding modes. 
At low ionic strength (0.01 M), it is reasonable to conclude that the increase in t m due 
to the modification of DNA by complex 1 (Figure 3.9) is caused by positive charges 
on ruthenium [(q 6_arene)Ru(en)Clj complex and by the intercalation. The smaller 
increase in tm  due to the modification by complex 1 observed at high ionic strength is 
a consequence of reduced stabilizing effects, since the electrostatic stabilizing effects 
of this complex are apparently lowered with increasing concentration of Na 
counterions from NaC104. 
The melting behavior of DNA modified by complexes 2 and 3 is different (Figure 
3.9). Modification by these complexes already decreases t m at concentrations of Na 
as low as 0.055 M. This indicates that the effects of the factors responsible for the 
thermal stabilization of DNA (the positive charge on ruthenium and intercalation of 
the arene into the duplex) are noticeably reduced (in general more for complex 2 
compare to 3) so that the destabilization effect of conformational alterations induced 
by these complexes predominates already at low salt concentrations. Thus, the results 
of DNA melting experiments are consistent with the formation of a monofunctional 
adducts of o- and m-terp complexes 2 and 3 with DNA (coordination to G N7) and the 
absent or reduced intercalation. 
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3.5 Summary 
In summary, complex 1 containing p-terp arene exhibits promising cytotoxic activity 
in several human tumor cell lines including those resistant to conventional cisplatin 
and its DNA binding mode involves combined intercalative and monofunctional 
(coordination) binding modes. In contrast, complexes 2 and 3 containing o- and m-
terp arenes are much less cytotoxic and bind to DNA via preferentially 
monofunctional coordination to DNA bases. In the case of complex 1, ruthenium is 
bound to a terminal phenyl ring whereas in the case of complexes 2 and 3, ruthenium 
is bound to the central phenyl ring. It is therefore possible that the distances between 
marginal phenyl rings in complexes 2 and 3 and Ru coordinated to DNA bases is too 
short to allow these marginal phenyl rings to adopt configurations which allow 
intercalation into DNA. In complex 1, the distance between distant marginal phenyl 
ring and Ru coordinated to DNA bases is greater allowing this phenyl ring to adopt a 
configuration appropriate for intercalation. In any case, the results of this Chapter 
further support the view that the presence of the arene ligand in [(q 6_arene)Ru(en)Cl] 
complexes capable of noncovalent, hydrophobic interaction with DNA considerably 
enhances cytotoxicity in tumor cell lines. Thus, these results represent a further 
improvement in the structure-activity relationship needed for the design of new 
antitumour ruthenium drugs. 
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Chapter 4 
. Bipyridme RuII arene complexes 
"Happy is he who gets to know the reasons for things." 
Virgil 
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4.1 Introduction 
Structure-activity relationships for Ru" arene complexes containing N,N-chelating 
ligands have been reported previously.' It was notable that although complexes 
containing ethylenediamine (en) as chelating ligand were active (cytotoxic to cancer 
cells), complexes containing tetramethyl-en or bipyridine as chelating ligands were 
inactive. This suggests that NH groups on the chelating ligand (en) play a role in the 
activity, perhaps stabilizing guanine (G) adducts on DNA via H-bonding. Indeed 
stereospecific H-bonding has been observed between en NH £60 of 9-ethylguanine 
(9-EtG) in the crystal structures of [( 6-tha)Ru"(en)(9-EtG)] 2 and [(6 
dha)Ru"(en)(9-EtG)] 2 (distances of 1.9 A and 2.1 A, respectively) . 2 
In the work reported in this Chapter, the presence of hydroxyl groups at the 3,3'-
positions of 2,2'-bipyridine (2,2'-bipyridine-3,3'-diol) is found to dramatically alter 
the activity profile of these Ru" arene complexes. Unlike en, which is purely a a-
donor, the bipyridine derivatives are a-donors and it-acceptors, and as it-acceptors 
make the metal center more acidic. The 3,3'-positions in 2,2'-bipyridine are different 
from the other positions on the ligand; for example, they have been reported to 
introduce steric strain upon the 3,3'-protons in [Ru(bipy)3] 2 . 3 When 2,2'-bipyridine-
3,3'-diol chelates to a metal, steric constraint is introduced 4 by the proximity of the 
two hydroxyl substituents and the strain is released upon the formation of 0—H 0 H-
bond and a deprotonation of one of the OH groups. 
It was of interest here to compare the aqueous solution chemistry, solid-state 
structures and cytotoxicity of Ru" arene complexes containing bipyridine (bipy), 
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bipyridinediol (bipy(OH)2) or deprotonated bipyridinediol (bipy(OH)O) as N,N -
chelating ligands. Eight chiorido Ru" arene complexes containing bipy, bipy(OH)2 or 
bipy(OH)O with a variety of arenes were synthesized and the structures of complexes 
[( 6-tha)Ru(bipy)Cl] [PF6] (1), [(176-tha)Ru(bipy(OH)O)C1] (2) and [(1-
ind)Ru(bipy(OH)2)Cl] [PF6] (8) were determined by x-ray crystallography. The effects 
of hydroxylation and methylation of the bipy ligand on the electron distribution were 
studied using DFT calculations. The aqueous solution chemistry of these complexes 
(hydrolysis, arene loss, and acidity of OH protons of bound bipy(OH)2 and 
bipy(OH)O) has been investigated, as well as interactions with the DNA model 
nucleobase 9-EtG both in solution and by x-ray crystallography, and cytotoxicity 
towards human ovarian (A2780) and human lung (A549) cancer cells. In addition 
DNA binding studies were performed with complexes [(6 
ind)Ru(bipy(OH)2)Cl] [PF6] (8) and [(, 6-ind)Ru(bipy)Cl] [PF6] (16). 
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4.2 Experimental section 
4.2.1 Materials 
The starting materials [(,1 6-arene)RuC12}2, arene = biphenyl (bip), p-terphenyl (p-terp, 
bound to Ru through the terminal phenyl ring), tetrahydroanthracene (tha), or 
dihydroanthracene (dha), were prepared as described in Chapter 2. [(i 6-bz)RuC12]2, 
[(,16-ind)RuC12]2 and [(, 6-thn)RuC12]2, where bz = benzene, md = indan and tim = 
tetrahydronaphthalene were donated from Dr Abraha Habtemariam. 2,2'-Bipyridine-
3,3 '-diol, 2,2 '-bipyridine, N-methylimidazole (N-MeIm) and 9-ethylguanine (9-EtG) 
were purchased from Sigma-Aldrich. Methanol was dried over Mg/I 2. Complexes 
[(1 6-ind)Ru(4,4'-Me 2-bipy)Cl] [PF6] (13), [(176-ind)Ru(hen)Cl] [PF6] (14), [(,(.. 
bip)Ru(bipy)Cl][PF6] (15) and [(1 6-ind)Ru(bipy)C1][PF 6] (16) were prepared as 
previously described,' by Dr Abraha Habtemariam. Cisplatin was obtained from 
Sigma-Aldrich and [PtC1(dien)]Cl (dienPt) was a generous gift of Professor G. Natile 
from University of Ban. Ethidium bromide (EtBr) was obtained from Merck KgaA. 
All other reagents were obtained from commercial suppliers. 
Stock aqueous solutions of metal complexes (5 x  10-4 M) for the biophysical and 
biochemical studies were filtered and stored at room temperature in the dark. The 
concentrations of ruthenium or platinum in stock solutions were determined by 
flameless atomic absorption spectrometry (FAAS). Calf thymus (CT) DNA (42 % G 
+ C, mean molecular mass Ca. 2 x  1 07)  was also prepared and characterized as 
described previously. 5,6 
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4.2.2 Synthesis of ruthenium complexes 
All chiorido complexes were synthesized in methanol using a similar procedure. 
Typically the ligand (2 mol equiv) was added to a methanolic solution of the 
ruthenium dimer [(,j 6-arene)RuC12]2. Details for individual reactions are described 
below. 
[(16-tha)Ru(bipy)C1] IIPF6I  (1). To a suspension of [( q 
6_tha)RUC1212 (0.053 g, 0.075 
mmol) in dry, freshly-distilled methanol (25 mL) bipyridine (0.023 g, 0.150 mniol) 
was added. The reaction mixture was stirred at ambient temperature under argon, 
overnight. The resulting clear yellow solution was filtered, NH 4PF6 (0.060 g, 0.374 
mmol) was added and the flask was shaken. A precipitate started to appear almost 
immediately. The flask was kept at -20°C overnight, and the product was collected by 
filtration, washed with cold methanol and ether, and dried in air to give a brownish 
solid. Yield: 0.036 g (39%). 
Crystals suitable for x-ray analysis were obtained by slow evaporation of a methanolic 
solution at ambient temperature and the complex crystallized as 
tha)Ru(bipy)C1][PF6] HO. 'H NMR in DMSO-d6: 8 9.55 (d, 211), 8.6 (d, 2H), 8.3 (d 
of d, 211), 7.85 (m, 211), 6.4 (d of d, 214), 6.1 (d of d, 2H), 5.45 (s, 211), 3.12 (m, 211), 
2.43 (m, 4H), 1.5 (m, 211). Anal. Calcd for C24H24C1F6N2PORu (1 H20): C, 45.33; 
H, 3.80; N, 4.41. Found: C, 45.43; H, 3.40; N, 4.55. 
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[(,6-tha)Ru(bipy(OH)O)C11 (2). To a suspension of [(, 64ha)RuC12]2 (0.050 g, 0.070 
mmol) in dry, freshly-distilled methanol (25 mL), 2,2'- bipyridine- 3,3'-diol (0.026 g, 
0.140 mmol) was added. The reaction mixture was stirred at ambient temperature 
under argon overnight, filtered and the volume was reduced until the onset of 
precipitation. It was kept at -4°C for 24 h to allow further precipitation to occur. The 
fine yellow solid was collected by filtration, washed with methanol followed by ether, 
and dried in vacuum. It was recrystallized from methanol/ether. Yield: 0.036 g (5 1%). 
A portion of the complex (1 mg) was dissolved in methanol (1 mL) and filtered to 
yield a clear yellow solution. Slow diffusion of diethyl ether into this solution resulted 
in the formation of yellow crystals suitable for x-ray diffraction. ESI-MS: calcd for 
RuClN202C24H22 [M+H]+ m/z 507.0, found 507.3. 'H NMR in DMSO-d6: 8  17.92 (s, 
1H, OH), 8.62 (d, 2H), 7.22 (d of d, 2H), 7.06 (d, 2H), 6.08 (d of d, 2H), 5.91 (d of d, 
2H), 5.56 (s, 2H), 3.12 (m, 2H), 2.43 (m, 4H), 1.92 (m, 2H). 
[(q6-dha)Ru(bipy(OH)O)C1] (3). To a suspension of [(,16-dha)RuC12]2 (0.028 g, 
0.040 mmol) in dry, freshly-distilled methanol (30 mL), 2,2'- bipyridine- 3,3'-diol 
(0.015 g, 0.080 mmol) was added. The rest of the procedure was the same as 
described for 2. The fine yellow solid was recrystallized from methanol/ether. Yield: 
0.016 g (41%). 
ESI-MS: calcd for RuClN202C24H20 [M+H] m/z 504.9, found 504.8. 'H NMR in 
MeOD-d4: 8 17.69 (s, 1H, OH), 8.62 (d, 2H), 7.14 (d of d, 2H), 6.95 (d, 2H), 6.89 (d, 
2H), 6.63 (t, 2H), 6.30 (d, 2H), 5.96 (t, 2H), 4.17 (d, 2H), 3.77 (d, 2 H). 
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((1 6-thn)Ru(bipy(OH)O)C1] (4). To a suspension of [(, 6-tbn)RuC12]2 (0.030 g, 0.050 
mmol) in dry, freshly-distilled methanol (30 mL), 2,2'- bipyridine- 3,3'-diol (0.018 g, 
0.100 mmol) was added. The rest of the procedure was the same as described for 2, 
the only difference was that the reaction mixture was stirred for 4 h instead of 
overnight. The fine yellow solid was recrystallized from methanol/ether. Yield: 0.030 
g (68%). 
ESI-MS: calcd for RuC1N202C20H26' [M+H] 1 m/z 456.9, found 457.3. 'H NMR in 
DMSO-d6: 8 17.92 (s, 1H, OH), 8.66 (d, 2H), 7.27 (d of d, 2H), 7.10 (d, 2H), 5.96 (t, 
2H), 5.84 (d, 2H), 2.54 (m, 211), 2.20 (m, 211), 1.52 (m, 2H), 1.20 (m, 211). 
I(17 6-bz)Ru(bipy(OH)0)C11 (5). To a suspension of [(1 6-bz)RuC12]2 (0.052 g, 0.106 
mmol) in dry, freshly-distilled methanol (30 mL), 2,2'-bipyridine- 3,3'-diol (0.040 g, 
0.213 mmol) was added. The rest of the procedure was the same as described for 2, 
the only difference was that the reaction mixture was stirred for 3 h instead of 
overnight. The fine yellow solid was recrystallized from methanol/ether. Yield: 0.060 
g (72%). 
'H NMR in DMSO-d6: 6 17.89 (s, 1H, OH), 8.78 (d, 2H), 7.21 (d of d, 2H), 7.09 (d, 
2H), 6.05 (s, 6H). Anal. Calculated for C 16H,3C1N202Ru 0.5 H2O (5 .  0.5 H2O): C, 
46.77; H, 3.43; N, 6.82. Found: C, 46.72; H, 2.83; N, 6.68. 
1(i6-p-terp)Ru(bipy(OH)O)C11 (6). To a suspension of [(1 6-p-terp)RuC12]2 (0.050 g, 
0.062 mmol) in dry, freshly-distilled methanol (50 mL), 2,2'- bipyridine- 3,3'-diol 
(0.023 g, 0.124 mmol) was added. The rest of the procedure was the same as 
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described for 2. The fine yellow solid was recrystallized from acetone/ether. Yield: 
0.05 1 g (75%). 
'H NMR in DMSO-d6: ö 17.91 (s, 1H, OH), 8.5 (d, 2H), 7.75 (m, 6H), 7.5 (t, 2H), 7.4 
(t, 1H), 7.1 (m, 4H), 6.5 (d, 2H), 6.2 (t, 2H), 6.1 (t, 1H). Anal. Calculated for 
C28H23C1N203Ru (6 H20): C, 58.79; H, 4.05; N, 4.89. Found: C, 59.22; H, 3.41; N, 
I(,16-bip)Ru(bipy(OH)O)C1] (7). To a suspension of [(1 6-bip)RuC12]2 (0.053 g, 0.08 
mmol) in dry, freshly-distilled methanol (30 mL), 2,2'- bipyridine-3,3'-diol (0.030 g, 
0.16 mmol) was added. The rest of the procedure was the same as described for 2. 
The fine yellow solid was recrystallized from acetone/ether. Yield: 0.049 g (63%). 
'H NMR in DMSO-d6: 6  17.85 (s, 1H, OH), 8.5 (d, 2H), 7.7 (t, 1H), 7.6 (d, 2H), 7.4 
(t, 2H), 7.00 (m, 411), 6.5 (d, 211), 6.2 (t, 2H), 6.1 (t, 1H). Anal. Calculated for 
C22H 1 7C1N202Ru: C, 55.29; H, 3.58; N, 5.86. Found: C, 55.36; H, 3.27; N, 5.88. 
1(,,64nd)Ru(bipy(OH)2)C1] [PF6I (8). Complex 8 was prepared by Dr Abraha 
Habtemariam. To a suspension of [(, 6-ind)RuCl2]2 (0.075g, 0.13 mmol) in dry, 
freshly-distilled methanol (10 mL), 2,2'- bipyridine-3,3'-diol (0.050g, 0.26 mmol) 
dissolved in methanol (3 mL) was added dropwise. The reaction mixture was left 
stirring at ambient temperature for 1 h. It was then filtered and to the filtrate NH 4PF6 
(0.128 g, 0.80 mmol) was added and the flask shaken. A precipitate started to appear 
almost immediately. The flask was kept at -20°C overnight. The solid obtained was 
collected by filtration, washed with cold methanol and ether and dried in air to give an 
intense bright yellow solid. Yield: 0.079 g (52%). 
109 
Chapter 4: Bipyridine Ru" arene complexes 
Crystals suitable for x-ray analysis were obtained by slow evaporation of a methanolic 
solution at ambient temperature and complex crystallized as [(j7 6 
ind)Ru(bipy(OH)2)Cl][PF6] CH30H. 'H NMR in DMSO-d6: ö 8.60 (d, 2H), 7.27 (d 
of d, 211), 7.05 (d, 211), 6.10 (m, 211), 5.82 (m, 2H), 2.67-2.50, 2.05-1.85 (m, 6H), 
Anal. Calcd for C,9H18C1F6N202PRu: C, 39.73; H, 3.67; N, 4.63. Found: C, 39.03; H, 
3.66; N, 4.66. 
[(,,6-tha)Ru(bipy)(9-EtG-N7)11PF 61 2 	(9). 	To 	a 	suspension 	of [(p6.. 
tha)Ru(bipy)Cl][PF 6] (0.020 g, 0.030 mmol) in water (30 mL), 9-ethylguanine (0.006 
g, 0.030 mmol) was added. The reaction mixture was left stirring for 2 h at 37°C. The 
clear yellow solution was then filtered and to the filtrate NH 4PF6 (0.026 g, 0.160 
mmol) was added. The volume was reduced until the onset of precipitation. The flask 
was sealed and placed on ice for 2 h for further precipitation to occur. The precipitate 
was filtered off, washed with water followed by ethanol and ether, and dried in 
vacuum to give a brown solid. 
ESI-MS: calcd for RuN70C31H31 [M-H] m/z 618.7, found 619.0. 'H NMR in 
DMSO-d6(90 % of complex 9): 8 11.1 (broad, 1H, NH), 10.0 (d, 2H), 8.6 (d, 2H), 8.3 
(d of d, 211), 7.9 (m, 2H), 7.4 (s, 1H), 7.0 (broad, 2H, NH), 6.65 (d of d, 211), 6.10 (d 
of d, 2H), 5.4 (s, 211), 3.8 (q, 2H), 3.18 (d, 211), 2.30 (m, 4H), 1.3 (d, 2H), 1.15 (t, 
3H). 
I(ii6-tha)Ru(bipy(OH)O)(9-EtG-N7)] LPF6I (10). To a suspension of [(,- 
tha)Ru(bipy(OH)O)Cl} (0.020 g, 0.030 mmol) in water (30 mL), 9-ethylguanine 
(0.006 g, 0.030 mmol) was added. The reaction mixture was left stirring for 2 h at 
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37°C. The clear yellow solution was filtered and to the filtrate NH4PF6 (0.020 g, 0.150 
mmol) was added. The rest of the procedure was the same as for 9. The complex (1 
mg) was dissolved in methanol (1 mL) and filtered to yield a clear yellow solution. 
Slow diffusion of diethyl ether into this solution resulted in the formation of brown 
crystals suitable for x-ray diffraction. The complex crystallized as [(,6 
tha)Ru(bipy(OH)O)(9-EtG-N7)][PF6] CH 30H (10 CH30H). 
ESI-MS: calcd for RuN 703C31H30 [M] m/z 649.7, found 650.0. 'H NMR in MeOD-
d4(98 % of complex 10): 8 17.88 (s, 1H, OH), 9.14 (d, 2H), 7.39 (d of d, 2H), 7.26 (d, 
2H), 7.12 (s, 1H), 6.25 (d of d, 2H), 6.00 (d of d, 2H), 5.53 (s, 211), 3.95 (q, 2H), 3.18 
(d, 2H), 2.45 (m, 411), 1.79 (d, 2H), 1.25 (t, 311). 
1(16-thn)Ru(bipy(OH)O)(N-MeIm)1 IPF6] (11). To a suspension of 
[(p6.. 
thn)Ru(bipy(OH)O)Cl] (0.014 g, 0.023 mmol) in water (30 mL), AgNO3 (0.0039 g, 
0.023 mmol) was added. The reaction mixture was left stirring overnight at ambient 
temperature covered with aluminium foil. It was then filtered to remove AgCl, and to 
the filtrate N-methylimidazole (1.85 j.tL, 0.023 mmol) dissolved in methanol (5 mL) 
was added. The reaction mixture was left stirring for 3 h at 37°C. The clear yellow 
solution was then filtered and the volume reduced to 5 mL. NH4PF6 was added 
(0.058 g, 0.35 mmol) and the flask sealed and placed on ice for 2 h for further 
precipitation to occur. The yellow precipitate was filtered off, washed with a little 
water followed by ethanol and ether, and dried in vacuum. It was recrystallized from 
methanol. Yield: 0.013 g (67%). 
The complex (1 mg) was dissolved in methanol (1 mL) and filtered to yield a clear 
yellow solution. Slow evaporation of this solution resulted in the formation of yellow 
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crystals suitable for x-ray diffraction. 'H NMR in DMSO: ö 17.88 (s, 1H, OH), 8.82 
(d, 2H), 7.70 (s, 1H), 7.39 (t, 2H), 7.21 (d, 2H), 6.65 (d of d, 2H), 6.19 (t, 2H), 6.00 
(d, 2H), 3.65 (s, 311), 2.67 (m, 2ff), 2.06 (m, 2H), 1.60 (m, 2H), 1.16 (m, 2H). 
I(,,6-bz)Ru(bipy(OH)O)(9-EtG-N7)1 [PF6] (12). To a suspension of [( 6-
bz)Ru(bipy(OH)O)Cl] (0.030 g, 0.060 mmol) in water (30 mL), 9-ethylguanine (0.011 
g, 0.06 mmol) was added. The reaction mixture was left stirring for 2 h at 37°C. The 
clear yellow solution was filtered and to the filtrate NH4PF6 (0.029 g, 0.180 mmol) 
was added. The rest of the procedure was the same as for 9. It was recrystallized from 
methanol to give a bright yellow solid. 
ESI-MS: calcd for RuN703C23H22 [M] mlz 545.6, found 545.9. 'H NMR in DMSO-
d6(100 % of complex 12): 6 17.6 (s, 1H, OH), 11.0 (broad, 111, NH), 9.1 (d, 211), 7.35 
(d of d, 2H), 7.15 (d, 2H), 7.05 (s, 1H), 6.9 (broad, 2H, NH), 6.2 (s, 6H), 4.0 (d of d, 
211), 1.2 (t, 3H). 
4.2.3 X-ray crystallography 
The details of the instrumentation are described in Chapter 2. x-ray crystal structures 
of complexes 1, 2 and 11 are solved by Professor Simon Parsons, 8 by Mr Andrew 
Parkin and 10 by Mr Alessandro Prescimone. Structures 1 and 10 were solved by 
direct methods (S1R92) 7 and refined using CRYSTALS,' while 2, 8 and 11 were 
solved using Patterson methods (SHELXS-97 9 or DIRDIF)' ° and refined with 
SHELXL-97." In most cases H atoms were placed in idealised positions. In complex 
1, H-atoms belonging to the water of crystallisation were located in a difference map 
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and the positions refined subject to the restraint that the OH distance was equal to 
0.85(1) A. In complex 2, H52 was located in a difference map in a bridging position 
between 052 and 082; it was refined freely with an isotropic displacement parameter. 
H-atoms in complex 8 attached to methyl and hydroxyl groups were located in a 
difference synthesis and refined using the Sheldrick rigid rotating group model. In 
complex 10, the H-atoms were located in a difference map, idealised, and then 
allowed to ride on their parent atoms; H231 is involved in a hydrogen bond, and its 
position was refined freely. In complex 11, the thn ligand is disordered at C81 over 
two positions in the ratio 0.85 : 0.15. Similarity restraints were applied to the 
geometry about the part-weight atoms. Only the major component (C81) was refined 
with anisotropic displacement parameters. The expected formula for a protonated 
bipy(OH)2 chelating ligand had 2 PF6 per formula unit, but only one was located in 
the crystal structure. A difference map in the region of the two 0-atoms attached to 
the bipy showed one peak in a bridging position between the two 0-atoms, bonded 
predominantly to 052. This was interpreted as a bridging & ...O H-bond, with the 
overall charge on the ligand being -1, thus ensuring change balance. The hydroxyl 
group 052-H52 was treated as a variable metric rigid group. The crystal structures of 
1, 2, 8, 10 and 11 have been deposited in the Cambridge Crystallographic Data Center 
under the accession numbers CCDC 676256, 676253, 611053, 676255 and 676254, 
respectively. 
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4.2.4 pH measurement 
The pH values of NMR samples in D20 were measured at 25°C directly in the NMR 
tube before and after recording NMR spectra using a Corning pH meter 145 calibrated 
with pH 4, pH 7 and pH 10 buffer solutions (Sigma Aldrich) and equipped with 
Aldrich microcombination electrode. No corrections have been made for the effect of 
deuterium on the glass electrode and these are termed as pH*  values. The pH*  values 
were adjusted with NaOD and DC1 of varying concentrations. 
4.2.5 Hydrolysis 
Hydrolysis of the chlorido complexes was monitored by UV/Vis spectroscopy or by 
'H NMR spectroscopy, without explicit control of pH or chloride concentrations. For 
UVIVis spectroscopy: complexes were dissolved in methanol and diluted with H20 to 
give Ca. 50 pM solutions (95% H20, 5% MeOH). The absorbance was recorded at 30 
or 60 s intervals at the selected wavelength over Ca. 4 h at 37'C. Plots of the change in 
absorbance with time were computer-fitted to the first-order rate equation: A = Co + 
C,e (Co and C, are computer-fitted constants and A is the absorbance corresponding 
to time t) using Origin version 7.5 (Microcal Software Ltd) to give the half-lives (t,,2) 
and rate constant values (k). For 'H NMR spectroscopy: complexes were dissolved in 
MeOD-d4 and diluted in D20 to give Ca. 100 [LM solutions (95% D20, 5% MeOD-d4). 
The 1 H NMR spectra were recorded at various time intervals at 37°C. The relative 
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amounts of chiorido species or aqua adducts (determined by integration of peaks in 
NMR spectra) versus time were fitted to appropriate equations for pseudo-first-order 
kinetics using Origin version 7.5 (Microcal Software Ltd) to give the half-lives and 
rate constants. 
4.2.6 Rate of arene loss 
The complexes were dissolved in MeOD-d4 and diluted with D20 to give ca. 100 j.tM 
solutions (95% D20, 5% MeOD-d4). Arene loss with time was followed by 1 H NMR. 
4.2.7 Computation 
The details are described in Chapter 2. Single point calculations were carried out for 
the tha fragment of the cation of complex 10 [( 6-tha)Ru(bipy(OH)O)(9-EtG-N7)] 
and the fragment of the cation without tha. The energies of these two separate 
fragments were subtracted from the energy of the entire 1+ cation of complex 10, in 
the single point calculation of cation of 10 [(, 6-tha)Ru(bipy(OH)O)(9-EtG-N7)], to 
obtain the total bonding energy of tha. The total bonding energy of tha is a sum of the 
bonding energy of the arene and Ru and the energy of the CH/7r interaction between 
the arene and the chelating ligand (bipy(OH)O). The tha ligand in the crystal structure 
of 10 was rotated so as to allow IL-it interaction with the purine ring of 9-EtG fragment 
and the geometry was optimized to give the minimum energy structure. After 
geometry optimization a single point calculation was carried out again on the tha 
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fragment of the modified cation of 10 and the fragment of the cation without tha. The 
energies of these two separate fragments were subtracted, in the single point 
calculation of the 1+ cation of modified 10, from the energy of the entire cation of 
modified 10 [(q 6_tha)Ru(bipy(OH)O)(9-EtG-N7)] +. The total bonding energy of tha 
obtained is in this case a sum of the bonding energy of the arene and Ru and the 
energy of the 7t-it interaction. Upon geometry optimization, the atomic coordinates of 
the minimum energy structures were used in single point calculations. 
4.2.8 Metallation reactions 
CT DNA was incubated with ruthenium or platinum complex in 10 mM NaC104 (pH 
= 6) at 37°C for 48 h in the dark, if not stated otherwise. The values of rb (defined as 
the number of atoms of the metal bound per nucleotide residue) were determined by 
FAAS. 
4.2.9 Circular dichroism (CD) 
Isothermal CD spectra of CT DNA modified by ruthenium complexes were recorded 
at 25°C in 10 mM NaC104. 
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4.2.10 DNA melting 
The melting curves of CT DNA were recorded by measuring the absorbance at 260 
nm. The melting curves of unmodified or ruthenated DNA were recorded in the 
medium containing 10 mM NaC104 with 1 mM Tris-HC1/0.1 mM EDTA, pH = 7.4 
and 0.01 M or 0.1 M NaC104. The value of melting temperature (t m) was determined 
as the temperature corresponding to a maximum on the first-derivative profile of the 
melting curves. The tm values could be thus determined with an accuracy of± 0.3°C. 
4.2.11 Fluorescence measurements 
The details of the instrumentation are described in Chapter 2. Fluorescence 
measurements of CT DNA modified by Ru" arene complexes, in the presence of EtBr 
were performed at an excitation wavelength of 546 nm, and the emitted fluorescence 
was analyzed at 590 nm. The fluorescence intensity was measured at 25°C in 0.4 M 
NaCl to avoid secondary binding of EtBr to DNA. '2' 13  The concentrations were 0.01 
mg/mL for DNA and 0.04 mg/mL for EtBr, which corresponded to the saturation of 
all intercalation sites for EtBr in DNA. 12 
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4.3 Results 
4.33 Synthesis and characterization 
The ligands used in this work are shown in Figure 4.1. The chlorido Ru" arene 
complexes 1-8 (Figure 4.1) were synthesized as P176 salts or as neutral complexes in 
good yields (39.0-74.6%) by the reaction of [(,j 6-arene)RuC12]2 dimers and the 
appropriate chelating ligand in methanol. All the synthesized complexes were fully 
characterized by 'H NMR and the OH proton resonance from bipy(OH)O was shifted 
to very low field, at 18 ppm. The 'H NMR resonances of the coordinated ?7 6-arenes 
are shifted upfield compared to the uncoordinated arenes. 
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_j=\ 
U-V U-V 
4,4-Mebipy 	 phen 
H CH2C—N'N 
NO 	 rN 
>—HH CH3 
H2N 
9-EtG 	 N-MeIm 
Complex 	Arene N-N 	 X 
I 	tha 	bipy 	 CI 
2 	tha 	bipy(OH)0 	CI 
3 	dha 	bipy(OH)O 	CI 
4 thn bipy(OH)O CI 
5 bz bipy(Ol-4)O CI 
6 p-terp bipy(OH)O CI 
7 bip bipy(OH)O CI 
8 md bipy(OH)2 CI 
the 9 bipy 9-EtG 
10 tha bipy(OH)O 9-EtG 
11 thn bipy(OH)O N-MeIm 
12 bz bipy(OH)O 9-EtG 
13 md 4,4'-Me2-bipy CI 
14 ind phen CI 
15 bip bipy CI 
16 md bipy CI 
Figure 4.1 General structures of complexes studied in this Chapter, as neutral or PF 6 
salts. 
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4.3.2 Crystal structures 
The crystal structures of [(, 6-tha)Ru(bipy)Cl] [PF6] (1), [(,1 6-tha)Ru(bipy(OH)0)Cl] 
(2) and [(i76-ind)Ru(bipy(OH)2)Cl][PF6] (8) are shown in Figure 4.2. The crystal 
structures of N-MeIm and 9-EtG adducts [(776-thn)Ru(bipy(OH)O)(N-MeIm)][PF6] 
(11) and [( 6-tha)Ru(bipy(OH)O)(9-EtG-N7)][PF6] (10) are shown in Figure 4.3. The 
crystallographic data are listed in Table 4.1 and Table 4.2, and selected bond lengths 
and angles in . In all the complexes, Ru" adopts the familiar 'three-legged piano-
stool' geometry. It is it-bonded to the appropriate arene ligand and a-bonded to the N 
atoms of the chelating ligand and Cl, or N-MeIm, or N7 of 9-EtG.. The Ru-Cl bond 
lengths in all the chiorido Ru" complexes are almost the same (-j 2.4 A). In the crystal 
structure of [(i7 6-tha)Ru(bipy)Cl}[PF6] 1120 0 . H20), the Ru-N (bipy) distances 
(2.085(2) and 2.0796(19) A; Table 4.3) are significantly longer than Ru-N 
(bipy(OH)0) distances in [(7 6-tha)Ru(bipy(OH)0)Cl] (complex 2; 2.0701(14) and 
2.0659(13) A; Table 4.3). In all the crystal structures, the Ru - arene centroid 
distances are similar (-- 1.7 A). 
From the crystal structure of [( 6-tha)Ru(bipy)Cl] [PF6] H20 (1 . H20), it can be seen 
(Figure 4.2A) that the outer ring of tha is tilted (tilt angle 41.41°) towards the 
chelating ligand. The space-filling and capped-stick models of 1 1120 (Figure 4.4A 
and 4.413, respectively) clearly show the presence of intramolecular CWir interactions 
between CH protons of the outer ring of tha and the centres of the pyridine rings of 
the chelating ligand (distances 2.7 A and 2.8 A). 
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Figure 4.2 ORTEP diagrams for (A) cation of [(q 6 	[PF6] H20 (1 
H20), (B) [(, 6-tha)Ru(bipy(OH)O)Cl] (2), and (C) cation of [(176-
ind)Ru(bipy(OH)2)Cl][PF6] CH30H (8 CH30H), with 50% probability thermal 
ellipsoids. All hydrogens apart from OH hydrogen atoms from chelating ligands, 
bipy(OH)2 and bipy(OH)O, have been omitted for clarity. 
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Figure 4.3 ORTEP diagrams for cations of (A) [(, 6-tha)Ru(bipy(OH)O)(9-EtG-
N7)][PF6] CHOH (10 CH30H), and (B) [(176  -thn)Ru(bipy(OH)O)(N-Melm)][PF6I 
(11), with 50% probability thermal ellipsoids. All hydrogens apart from OH hydrogen 
atom from the chelating ligand (bipy(OH)O), have been omitted for clarity. 
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Table 4.1 X-ray crystal structure data for 1 H20, 2 and 8 CH30H 
1H20 	 2 	 8 CH30H 
Formula C24H24C1F6N20PRu 	C24H21 C1N202Ru C20H22C1F6N203PRu 
Molar mass 637.95 505.95 619.89 
Crystal system triclinic monoclinic triclinic 
Crystal size /mm 0.42 x 0.25  x 0.14 	0.40 x 0.18  x 0.11 0.37 x 0.25  x 0.12 
Space group P-i P211n P-i 
Crystal Yellow / block Yellow / block Orange / block 
a / A 7.4422(3) 7.2697(2) 7.9858(10) 
b/A 11.8685(5) 16.7711(4) 12.1538(15) 
c / A 13.7805(6) 16.0993(4) 12.5825(16) 
a/ deg 94.960(2) 90 67.843(2) 
/3/ deg 101.341(2) 99.6900(10) 83.718(2) 
y/ deg 91.580(2) 90 83.549(2) 
T/K 150 150(2) 150(2) 
Z 2 4 2 
R [F > 4cy (F)] 0.0336 0.0250 0.0464 
RW1' 0.0868 0.0656 0.1248 
GOFC 0.9159 1.077 1.051 
i\p max and mm, 0.81,-0.78 0.599, -0.380 2.784, -1.723 
/ek 
aR = 	IIF0I - IFII/IF0I. bR = [w(F02 - F2)2/wF02)]'. CGOF = [w(F02 - F 2)2/(n- 
1/2, where n = number of reflections and p = number of parameters. 
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Table 4.2 X-ray crystal structure data for 10 CH30H and 11 
10 CH30H 11 
Formula C32H34F6N704PRu C24H25F6N402PRu 
Molar mass 826.70 647.52 
Crystal system monoclinic monoclinic 
Crystal size /mm 0.23 x 0.12  x 0.09 0.44 x 0.40 x 0.18 
Space group P121/ni P21 In 
Crystal Brown I block Yellow / block 
a/A 9.5526(2) 12.7776(2) 
b/A 10.8630(2) 13.4949(3) 
c/A 31.6240(7) 14.4729(3) 
a/deg 90 90 
fi/deg 95.1740(10) 90.7780(10) 
yldeg 90 90 
TIK 150 150(2) 
Z 
R [F> 4a (F)]a 0.0408 0.0331 
R  0.0427 0.0845 
GOFC 1.0967 1.034 
\p max and mm, i 0.90, -0.57 0.879, -0.540 
ek 
aR = 	IIFOI - IFII/IF0I. bR 	= [w(F02 - F2)2/wF02)]'. CGOF = [w(F02 - F2)2/(n- 
p)] 	
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Table 4.3 Selected bond lengths (A) and angles (°) for 
complexes 1, 2, 8, 10 and 11 
Bond/angle' 	1 	 2 	8 	10 	11 
Ru-Cl 2.4047(6) 2.3958(4) 2.4118(8) - - 
Ru-N13 - - - - 2.0971(17) 
Ru-N33 - - - 2.1233(19) - 
Ru-NIB 2.085(2) 2.0701(14) 2.080(3) 2.0786(19) 2.0706(16) 
Ru-N2B 2.0796(19) 2.0659(13) 2.070(3) 2.077(2) 2.0736(16) 
Ru-CIA 2.191(2) 2.1928(15) 2.200(3) 2.195(2) 2.234(2) 
Ru-C2A 2.215(2) 2.2083(15) 2.230(3) 2.225(2) 2.185(2) 
Ru-C3A 2.215(2) 2.2073(16) 2.221(3) 2.220(2) 2.188(2) 
Ru-C4A 2.199(2) 2.2189(17) 2.215(3) 2.217(2) 2.203(2) 
Ru-05A 2.192(2) 2.2124(16) 2.204(3) 2.206(2) 2.204(2) 
Ru-C6A 2.193(2) 2.1934(15) 2.195(3) 2.201(2) 2.2270(19) 
N2B-Ru- 76.89(8) 76.49(5) 76.52(10) 76.27(7) 77.09(6) 
NIB-Ru-Cl 85.85(6) 85.06(4) 87.15(7) - - 
NIB-Ru-N13 - - - - 88.08(6) 
N1B-Ru-N33 - - - 85.71(7) - 
N2B-Ru-C1 85.44(5) 87.03(4) 85.55(8) - - 
N2B-Ru-N13 - - - - 89.23(7) 
N2B-Ru-N33 - - - 85.87(7) - 
aAtom  labelling scheme used for purposes of comparison only. The crystallographic 
atom labelling schemes for individual complexes are different. X = Cl, N13 or N33. 
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In the crystal structure of 2 (Figure 4.213), one of the bipyridinediol oxygens is 
deprotonated, an intramolecular hydrogen bond forms (082" 052; 0-0 distance 
2.3886(19) A). and the complex is neutral. The outer ring from the tricyclic-ring 
system of tha, in the crystal structure of 2, is tilted by 36.900  towards the chelating 
ligand (Figure 4.213). The space-filling and capped-stick models (Figure 4.413 and 
4.4E) clearly show the presence of intramolecular CHIir interactions between CH 
protons of the outer ring of tha and the centres of the pyridine rings of the chelating 
ligand, bipy(OH)0 (distances 2.8 A and 2.9 A). 
Figure 4.4 CH/it interactions in tha complexes 1. 2 and 10. Space-filling and capped-
stick models (A) and (D) the cation of [(, 6-tha)Ru(bipy)Cl][PF6] H0 0 H20), (B) 
and (E) [(, 6-tha)Ru(bipy(OH)0)Cl] (2) and (C) and (F) the cation of [(,6 
tha)Ru(bipy(OH)0)(9-EtG-N7)][PF6] CH30H (10 CH30H), showing interaction 
between CH protons from the outer ring of tha and the centres of the 7t-systems of the 
chelating ligands. 
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The x-ray crystal structure of the cation of [(,7 6-ind)Ru(bipy(OH)2)Cl][PF6] CH 30H 
(8 CH 30H, Figure 4.2C) shows a twisting of the pyridine rings of bipyridinediol 
(twist angle 17.310)  as well as intramolecular H-bonding involving the OH groups 
and intermolecular H-bonding involving methanol to give dimers in the unit cell 
(Figure 4.5A). The two oxygen atoms of the bipy(OH)2 ligand (05A and 08A) are 
2.532(4) A apart. 
Figure 4.5 (A) H-bonding involving the OH groups of [(q 6 
ind)Ru(bipy(OH)2)C1}[PF6] CH 30H (8 CH30H) giving rise to dimers in the unit 
cell. (B) Twisting of the bipy(OH)O ligand in [(1 6-thn)Ru(bipy(OH)O)(N-
MeIm)}[PF6] (11) as a result of H-bond formation between 082 from bipy(OH)O of 
one molecule and C43H from N-Melm of another molecule. 
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1(16-tha)Ru(bipy(OH)O)(9-EtG-N7)] [PF6] (10) crystallized with one molecule of 
solvent (CH30H) in the lattice per molecule of complex. One of the oxygens of the 
chelating ligand in the crystal structure of 10 CH30H is deprotonated and an 
intramolecular hydrogen bond is formed between this oxygen (024) and the hydrogen 
from the other oxygen (023; Figure 4.3A). The two oxygen atoms are 2.389(3) A 
apart. The outer ring from the coordinated tricyclic-ring system of tha is tilted (tilt 
angle 37.21°) towards the chelating bipy(OH)O ligand. The space-filling and capped-
stick models (Figure C and 4.4F) show the presence of intramolecular CH/it 
interactions between CH protons of the outer ring of tha and the centres of the 
pyridine rings of bipy(OH)O (distances 2.8 A and 3.0 A). 
In the crystal structure of [(,1 6-thn)Ru(bipy(OH)0)(N-MeIm)][PF6] (11) one of the 
oxygens of the bipydiol ligand (082) is again deprotonated (Figure 4.313) and an 
intramolecular hydrogen bond is formed between this oxygen and the hydrogen from 
the other oxygen (052). The two oxygen atoms are 2.390(3) A apart. Ru is (Y-bonded 
to N13 of N-methylimidazole. Neither intra- nor inter-molecular it-it stacking nor 
CH/ir interactions are observed in the crystal structure of 11. The non-coordinated 
ring of tim is disordered and bipy(OH)0 ligand is twisted (by 14.43°), as a result of 
the hydrogen bond formed between 082 of bipy(OH)0 of one molecule and the 
C43H hydrogen of N-methylimidazole of another molecule (2.474 A, Figure 4.513). 
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4.3.3 pH dependence 
In order to determine the pK a values of the OH protons of bipyridinediol chelating 
ligand without the complication of deprotonation of coordinated water (aquation of 
chlorido complex), the N-MeIm adduct [(?7 6  -thn)Ru(bipy(OH)O)(N-Melm)][PF6I 
(complex 11) was prepared. 'H NMR spectra of 11 in DMSO-d6 showed a peak at 
17.88 ppm corresponding to the O-H ... O proton from bipy(OH)O. 1 H NMR spectra of 
complex 11 in D20 were recorded over the pH*  range 2-10. None of the peaks shifted 
as a function of pH within this range, indicating that the form of the chelated ligand 
does not change. Therefore, it is reasonable to assume that at physiological pH (pH 
7), the ligand is present in the deprotonated form, bipy(OH)O. 
4.3.4 Aqueous solution chemistry 
The hydrolysis of complexes 4, 7, 8, 13-16 were studied at 37°C, using UV-Vis or by 
'H NMR spectroscopy (complex 4). Due to the small amount of sample required, in 
general it was more convenient to follow hydrolyses by UV-Vis spectroscopy. 
The time dependence of the absorbance of the complexes followed first-order kinetics 
(Figure 4.6A) in each case. ESI-MS spectra were consistent with the formation of the 
aqua complex as the product (observed peaks: [(, 6-thn)Ru(bipy(OH)O)H 2O]' -H2O 
caic. m/z 421.1, found m/z 421.3; [( 6-bip)Ru(bipy(OH)O)H20] ' -H20 calc. mlz 
443.0, found m/z 443.1; [(, 6-ind)Ru(bipy(OH)O)H 2O]' -H20 calc. mlz 407.0, found 
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mlz 407.2; [(,7 6-ind)Ru(4,4'-Me2-bipy)H20] 2 -1120 -H caic. mlz 403.1, found mlz 
403.2; [(16-ind)Ru(j,hen)H20] 2 -1120 -1{' caic. mlz 399.0, found m/z 399.1; [(,6 
bip)Ru(bipy)H20] 2 -1120 -H caic. mlz 411.0, found m/z 411.1; [(,16 
ind)Ru(bipy)H20] 2 -H20 -H caic. mlz 375.0, found mlz 375.1 for the aqua adducts 
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Figure 4.6 (A) Dependence of the absorbance at 434 nm over ca. 4 h during aquation 
of complex 4 at 37°C. (B) Time dependence of the percentage of chiorido and aqua 
species during aquation of complex 4 at 37°C followed by 'H NMR. 
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'H NMR spectra of 4 in 5% MeOD-d4 / 95% DO (for which hydrolysis was also 
monitored using UV-Vis spectroscopy) initially contained one major set of peaks 
(chiorido species), and then a second set of peaks increased in intensity with time. The 
new set of peaks has the same chemical shifts as those of the aqua adduct under the 
same conditions (37°C, 100 p.M solution in 5% MeOD-d4 / 95% DO). The aqua 
adduct was prepared by treating 4 with AgNO 3 in water at room temperature 
overnight and removal of AgC1 by filtration. The time dependence of the increase in 
concentration of aqua adduct or decrease in concentration of chlorido species 
followed first-order kinetics (Figure 4.613), and the corresponding rate constant is 
listed in Table 4.4 together with rate constants determined using UV-Vis 
spectroscopy. 
For complexes [( 6-bip)Ru(bipy(OH)O)Cl] (7) and [(1 6-bip)Ru(bipy)Cl}[PF 6] (15), 
separate sets of peaks were observed in 1 H NMR spectra (in 5% MeOD-& / 95% 
D20) for products which had undergone arene-loss during the aquation. After 24 h, 
33% of 7 and 46% of 15 had undergone arene loss. 
The hydrolysis rates for the complexes which did not undergo arene loss, were 
determined over a period of 4 h. The rate constants for bip complexes that underwent 
arene loss were determined over the period of time before the onset of arene loss (80 
mm, detected by NMR). It can be seen that hydrolysis of the neutral bip complex 7 
containing bipy(OH)O as chelating ligand (t 1/2 = 14.95 mm) is twice as slow as for 
the positively-charged bip complex 15 containing bipy as chelating ligand (t 1/2 = 7.43 
mm), Table 4.4. 
Aqueous solutions of [(I 6_ind)Ru(bipy(OH)2)Cl1[PF61 (8) were found to be acidic 
immediately after dissolution (1 mM, pH 3) consistent with the release of a proton 
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from bipy(OH) 2. Aqueous solutions of [(, 6-thn)Ru(bipy(OH)O)Cl] (4) were 
approximately neutral in pH, consistent with a lack of proton dissociation. 
Table 4.4 Hydrolysis data for complexes 4, 7, 8, 13, 14, 15 and 16 at 37°C 
Complex 103 k0b (min-' )a 	ti/2 (mm) 
[( 6-thn)Ru(bipy(OH)O)Cl] (4) 91.8±0.4" 755 
91 .6±1 .4c 7.57 
[(i6-bip)Ru(bipy(OH)O)Cl]  46.3±0.2" 14.95 
[(,6jnd)Ru(bipy(OH)O)Cl](  164.6±1 0b 4.21 
[(i 6-ind)Ru(4,4'-Me2-bipy)Cl] [PF6}  113.0±2.0" 6.30 
[(j6-ind)Ru(phen)ClJ [PF6]  75.1±1.2 b 9.24 
[(, 6-bip)Ru(bipy)C1] [PF61  8b 7.43 
[( 6-ind)Ru(bipy)C1] [PF6]  121.0±1.0" 573 
aThe errors quoted are fitting errors. bDeteined  by UV-Vis spectroscopy for a 50 
tM solution in 95% H20, 5% MeOH. 'Determined by 'H NMR spectroscopy in 95% 
D20, 5% MeOD-d4 dSpecies  present in aqueous solution; synthesized as 	[(,6 
ind)Ru(bipy(OH)2)Cl] [PF6] 
132 
Chapter 4: Bipyridine Ru" arene complexes 
4.3.5 Interactions with 9-EIG 
Attempts were made to prepare 9-EtG adducts of the bipy complex 1 and the 
bipy(OH)O complexes 2 and 5. Reactions were carried out in water for 2 h at 37CC. 
The 'H NMR spectrum of the product from the reaction of complex 1 with 9-EtG, in 
DMSO-d6 showed that 90 % of complex 1 had reacted with 9-EtG to form [Ø 6-
tha)Ru(bipy)(9-EtG-N7)][PF6]2 (complex 9). Peaks assigned to bound 9-EtG in 
complex 9 are shifted to high field in comparison to those of free 9-EtG, the H8 peak 
(7.4 ppm) by 0.35 ppm. The 111  NMR spectrum of the product in MeOH-d4 showed 
that 98% of complex 2 had reacted with 9-EtG to form [(, 64ha)Ru(bipy(OH)O)(9-
EtG-N7)}[PF6] (complex 10). Peaks assigned to bound 9-EtG in complex 10 were 
again shifted to high field compared to those of free 9-EtG, the 118 peak (7.12 ppm) 
by 0.63 ppm. The 1 H NMR spectrum of complex 5 in DMSO-d6 is shown in Figure 
4.7 and the 'H NMR spectrum of the product from reaction of 5 with 9-EtG ([(q 6 
bz)Ru(bipy(OH)O)(9-EtG-N7)][PF6], complex 12) in DMSO-d6 in Figure 4.8. Under 
the conditions of this reaction almost complete binding of 9-EtG to complex 5 
occurred. Peaks assignable to bound 9-EtG in complex 12 are again shifted to high 
field compared to the peaks of free 9-EtG, the H8 peak (7.01 ppm) by 0.74 ppm. 
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Figure 4.7 Low field region of the 1 H NMR spectrum of [(7 6-bz)Ru(bipy(OH)O)Cl] 
(5) in DMSO-d6. Inset: shows resonance of H-bonded proton from bipy(OH)O ligand. 
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Figure 4.8 Low field region of the 1 11 NMR spectrum of [(1-bz)Ru(bipy(OH)O)(9-
EtG-N7)] [PF6] (12) in DMSO-d6. Low field inset: resonance of H-bonded proton from 
the chelating ligand. High field inset: CH3 resonance of 9-EtG. 
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4.3.6 Computation 
The 	minimum 	energy 	structures 	of 	chiorido 	complexes 	
[(6 
ind)Ru(bipy(OH)2)Cl] [PF6] (8), [()1 6-ind)Ru(bipy(Me)2)C1] [PF 6] (13) and [()7
6
-
ind)Ru(bipy)Cl][PF6] (16) obtained from DTF calculations are shown in Figure 4.9. 
Figure 4.9 Optimized geometries of cations of complexes (A) [(,16 
ind)Ru(bipy)CI][PF6] (16), (B) [(?I 6_ind)Ru(bipy(OH)2)CII[PF6] (8) and (C) 
[(6 
ind)Ru(bipy(Me)2)Cl][PF6] (13). All H-atoms were omitted for clarity apart from the 
H-atoms of the substituents on bipy. 
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The total bonding energy of tha in the optimized structure of 
[06 
tha)Ru(bipy(OH)O)(9-EtG-N7)] (cation of 10, where the arene is interacting with the 
chelating ligand through the intramolecular Cl-Il it interaction) is -313.4 kJ/mol, which 
is 7.5 kJ/mol lower than the bonding energy of tha in the optimized structure of 
modified cation of 10 (-305.9 kJ/mol), in which there is an arenel9-EtG 
intramolecular it-it interaction. The minimum energy structures of complex 10 and 




Figure 4.10 Optimized geometries of cations of complexes (A) modified 10, where 
tha is interacting with 9-EtG through the it-it interaction and (B) [(,16 
tha)Ru(bipy(OH)O)(9-EtG-N7)][PF6I (10), where tha exhibits a CI-Ilit interaction with 
bipy(OH)O. 
To determine the effect of bipy substituents on the electron density on ruthenium, the 
Voronoi Deformation Density (VDD) method for computing atomic charges was 
used. This method has been used previously for transition metals such as Cr and Fe, in 
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complexes Cr(CO)o and Fe(CO)5. 14 Charges on Ru in the bipy(OH)2 complex 8, 
bipy(Me)2 complex 13 and bipy complex 16 were found to be similar, with values of 
+0.268 a.u. for 8 and 13 and +0.270 a.u. for complex 16. For deprotonated complex 8, 
[(, 6-ind)Ru(bipy(OH)O)Cl] the charge on Ru was +0.271 a.u. 
4.3.7 Cancer cell growth inhibition 
The IC50 values for chiorido complexes (1-8) against the A2780 human ovarian and 
A549 human lung cancer cell lines are given in Table 4.2. In general the complexes 
were more active against the A2780 human ovarian cancer cells than against A549 
human lung cancer cells (10 50 values 7-65 tM for A2780 ovarian cells, and 21-62 &M 
for A549 lung cells). The most potent complex against A2780 cells [(?I 6 
tbn)Ru(bipy(OH)O)Cl] (4) had an IC50 value of 7 p.M, comparable to that of cisplatin 
(5 .tM) under the same conditions. In general the most active complexes in ovarian 
cancer cell line contain the most extended arene ring systems in the order tin, tha> 
dha, md > p-terp > bip > bz, a notable exception is the thai bipy complex 1, which is 
inactive not only against A2780 cells but also against A549 cells (10 50 values >100 
tM, Table 4.2). Complexes 5 and 7 containing bz and bip as arenes, respectively, and 
bipy(OH)O as chelating ligand were also inactive against A549 cells. The most active 
complex in this cell line was [(,j 6-tha)Ru(bipy(OH)O)C1} (2) with an IC 50 value of 21 
p.M. The IC50 values for bipy(OH)O complexes showed the following dependence on 
the arene: tin, tha < dha, md <p-terp (Table 4.2). 
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Table 4.2 IC50 values for ruthenium(II) arene complexes against the A2780 human 




% arene loss 
(24 h, 37  
{(,1 6-tha)Ru(bipy)C1]{PF6} (1) > 100 > 100 0 
[(,76-tha)Ru(bipy(OH)O)C1] (2) 8 21 0 
[(,76-dha)Ru(bipy(OH)O)Cl] (3) 17 38 0 
[()16-thn)Ru(bipy(OH)O)Cl] (4) 7 24 0 
[(16-bz)Ru(bipy(OH)O)C1} (5) 65 > 100 0 
[()76-p-terp)Ru(bipy(OH)O)Cl] (6) 21 62 
-b 
[(,16-bip)Ru(bipy(OH)O)Cl] (7) 40 > 100 33 
{(,6ind)Ru(bipy(oH)o)C1]c (8) 18 39 0 
[(,76-bip)Ru(bipy)Cl][PF6] (15) > lood - 46 
cisplatin 5 5 - 
aDete ined by 1 H NMR spectroscopy in 95% D20, 5% MeOH-d4. b  Solubility too 
low to determine arene loss by NMR. 'Species present under test conditions; 
synthesized as [(?1 6-ind)Ru(bipy(OH)2)C1] [PF6]. dPreviously  reported.' 
138 
Chapter 4: Bipyridine Ru" arene complexes 
4.3.8 Binding to calf thymus (CT) DNA 
The experiments were performed at the Institute of Biophysics in Brno (CR) by 
Professor Victor Brabec's research group. 
4.3.8.1 Kinetics of binding 
The extent of binding of complexes [(1 6-ind)Ru(bipy)Cl][PF6] (16) and [(q 6 
ind)Ru(bipy(OH)2)C11 [PF6] (8, under the experimental conditions as neutral [(,6 
ind)Ru(bipy(OH)O)Cl]) to CT DNA was determined at r (molar ratio of free complex 
to nucleotide phosphate) ratios of 0.02 —0.16 in 10 mM NaC10 4 at 37°C, after 48 h of 
the reaction in the dark. Complexes 16 and 8 were incubated with CT DNA for 48 h, 
rapidly cooled, DNA containing bound complex precipitated out by addition of 
ethanol, and the content of free Ru in the supernatant determined by FAAS. 
Intriguingly, both complexes bind to a relatively small extent (only 43% and 11% of 
16 and 8, respectively, after 48 h). 
The binding experiments indicated that modification reactions resulted in the 
irreversible coordination of Ru" arene complexes to CT DNA, which thus facilitated 
sample analysis. Hence, it was possible to prepare samples of DNA modified by 
complexes 16 or 8 at a preselected value of rb.  Thus, except where stated, samples of 
DNA modified by Ru" arene complexes and analyzed further by biophysical or 
biochemical methods were prepared in 10 mM NaC104 at 37°C. After 48 h of the 
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reaction of DNA with complexes, the samples were precipitated in ethanol and 
dissolved in the medium necessary for a particular analysis, and the rb value in an 
aliquot of this sample was checked by FAAS. In this way, all analyses described in 
this Chapter were performed in the absence of unbound (free) complex. 
4.3.8.2 Circular dichroism (CD) 
To gain further information, CD spectra were also recorded of CT DNA modified by 
16 and 8 (Figure 4.11). CD spectral characteristics were compared for CT DNA in the 
absence and in the presence of 16 and 8 at rb values in the range of 0.006 - 0.056 and 
0.017-0.084, respectively. Upon binding of these complexes to CT DNA, the 
conservative CD spectrum normally found for DNA in canonical B-conformation 
transforms at wavelengths below 300 run. There was a slight, but significant increase 
or decrease in the intensity of the positive band around 280 nm if DNA was modified 
by 16 or 8, respectively. 
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Figure 4.11 CD spectra of CT DNA (1 x 	M, the concentration is related to the 
phophorus content) modified by complexes 16 or 8; the medium was 10 mM NaC104, 
pH = 6. (A) DNA was modified by complex 16 at rb = 0, 0.006, 0.026, 0.040, 0.056. 
(B) DNA was modified by complex 8 at rb = 0, 0.017, 0.031, 0.044, 0.084 (curves 1-5, 
respectively). The arrows show a change of CD with increasing rb value. 
Complexes 16 and 8 have no intrinsic CD signals as they are achiral so that any CD 
signal above 300 nm can be attributed to the interaction of complexes with DNA. 
Below 300 nm any change from the DNA spectrum is due either to the DNA induced 
CD (lCD) of the metal complex or the metal complex induced perturbation of the 
DNA spectrum. The signature of complex 16 bound to CT DNA is a strong positive 
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lCD centered at 320 nm (Figure 4.1 1A). On the other hand, the signature of complex 
8 bound to CT DNA includes no such lCD (Figure 4.1 1B). 
4.3.8.3 DNA melting 
CT DNA was modified by [(, 6-ind)Ru(bipy)C1][PF6] (16) and 
[(p6.. 
ind)Ru(bipy(OH)2)Cl] [PF6] (8, under the experimental conditions as neutral [(?I 
6 
ind)Ru(bipy(OH)O)ClJ) to the value of rb = 0.06 and 0.08, respectively in 10 mM 
NaC104 at 37°C for 48 h. The samples were divided into two parts and in one part the 
salt concentration was further adjusted by addition of NaC104 to 0.1 M. Hence, the 
melting curves for DNA modified by 16 and 8 were measured in the two different 
media, at low and high salt concentrations. The effect on the melting temperature (tm) 
is dependent on the salt concentration. At both high and low salt concentration (0.01 
M and 0.1 M) modification of DNA by 16 and 8 affected tm only very slightly (tm was 
changed by less than 1°C). Thus, the melting behavior of DNA was affected by 16 
and 8 only negligibly. 
4.3.8.4 Ethidium bromide (EtBr) fluorescence 
The ability of complexes to displace the DNA intercalator EtBr from CT DNA was 
probed by monitoring the relative fluorescence of the EtBr-DNA adduct after treating 
the DNA with varying concentrations of 16 or 8. Figure 4.12 shows a plot of relative 
fluorescence vs. rb for complexes 16 and 8, cisplatin and monofunctional dienPt. The 
adducts of both Ru" arene complexes competitively replaced intercalated EtBr 
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markedly more effectively than the adducts of monofunctional dienPt and the adducts 
of 16 even more than the adducts of bifunctional cisplatin. Thus, the ability of 
complex 16 to displace the DNA intercalator EtBr from CT DNA was considerably 
greater than that of complex 8. 
Figure 4.12 Plots of the EtBr fluorescence versus rb for DNA modified by cisplatin, 
dienPt and Ru" arene complexes in 10 mM NaC104 at 37°C for 48 h: (x), dienPt; (s), 
cisplatin; (.), complex 16; (o), complex 8. Data points measured in triplicate varied 
on average ± 3% from their mean. 
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4.4 Discussion 
It has been observed previously, a loss of cytotoxicity towards cancer cells for 
complexes of the type [(, 6-arene)Ru(en)Cl] when en, a a-donor, is replaced by 2,2'-
bipyridine.' Bipyridines contain two a-donor nitrogens, and a fully conjugated i-
system which makes them strong ir-acceptors. Incorporation of methyl, 
hydroxymethyl or methylester groups in the 4,4' positions of bipyridine did not 
restore activity. Loss of activity could arise from the absence of NH groups, which are 
known to stabilize nucleobase adducts through strong H-bonding between an NH of 
en and C60 from the guanine (G) nucleobase, 15 or from the back-donation of electron 
density from Run onto bipyridine as a it-acceptor, that would make the metal centre 
more acidic compared to en analogues. This could have an effect on the binding of 
these complexes to DNA. 
Complexes containing 2,2'-bipyridine-3,3'-diol (bipy(OH)2) as the chelating ligand 
showed a dramatic increase in anticancer activity compared to the other bipyridine 
analogues (Table 4.2). NN-chelation of bipy(OH)2 without deprotonation creates 
steric-crowding and distortion of ligand planarity, as observed in the crystal structure 
of 1076-ind)Ru(bipy(OH)2)Clf (8), where the pyridine rings are twisted by 17.3 1°, and 
previously for complexes of 3,3'-dimethyl-2,2'-bipyridine. 16 Chelation of bipyridine 
derivatives to a metal lowers the energy of the form in which the rings of the 
bipyridine are coplanar, 17-19  and the deprotonation of bipy(OH)2 as a chelating ligand 
is favoured as it leads to planarity of the ligand. Furthermore, for 2,2'-bipyridines with 
substituents in the 3,3'-positions, cyclization can occur when substituents are able to 
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react, as observed for —0O 2CH2CF3 and —CONHCH2C6H5 substituents that form - 
CO(NCH2C6H5)OC- with release of CF 3CH20H. 20 
Very stable H-bonding within the deprotonated 2,2'-bipyridine-3,3'-diol (bipy(OH)O) 
ligand gives rise to a large downfield shift of the resonance for the H-bonded proton 
(8-18). "Soft" and "borderline" metal ions usually prefer coordination via nitrogens 
of the heterocycle rather than via oxygens. 2 ' If the bipy(OH)0 ligand was N,0-
chelated instead of NN-chelated, the resonance from the proton involved in the 0— 
H ... N hydrogen-bond would be expected to appear at 815,2224  as observed in the 1 H 
NMR spectrum of 2,2'-bypyridine-3,3'-diol itself, where both hydrogens form 
0—H" N hydrogen bonds. The absence of a resonance with this chemical shift, 
suggests that N,N-chelation is more favourable than N,0-chelation for deprotonated 
bipy(OH)0. The presence of the strong 0-1± 0 intramolecular hydrogen bond 
stabilizes the negative charge on the oxygen of bipy(OH)0 and prevents further 
deprotonation/protonation within the pH range studied by NMR (2-10). It has been 
found previously for [Ru(bipy)2(bipy(OH)0)] that protonation requires pH values of 
ca. 0.4, and of ca. 13.6 for deprotonation. 4 The close contact between two oxygens 
(082 and 052) in the crystal structure of complex 2 confirms formation of a strong 
symmetrical 0 H 0 hydrogen bond, as observed previously in [Ni(Hdmg)]2 (Hdmg 
= dimethylglyoxime)25 and [Ru(bipy)2(bipy(OH)0)]. 4 In the crystal structure of [( 6-
ind)Ru(bipy(OH)2)Cl] [PF6] (8), where the chelating ligand is bipy(OH)2, the distance 
between the two oxygens (05A and 08A) is significantly longer than that observed in 
the crystal structures of [(,1 6-tha)Ru(bipy(OH)0)Cl] (2), [(176-tha)Ru(bipy(OH)0)(9-
EtG-N7)] [PF6] (10) and [(116-thn)Ru(bipy(OH)0)(N-MeIm)] [PF6] (11), where the 
chelating ligands are in the deprotonated, bipy(OH)0 form (see the results section). 
145 
Chapter 4: Bipyridine Ru" arene complexes 
CHIir interactions between the arene and the bipyridine ligand were observed in the 
crystal structures of [(,7 64ha)Ru(bipy)Cl} [PF6] (1), [(17 6-tha)Ru(bipy(OH)O)Cl] (2) 
and [(,16-tha)Ru(bipy(OH)O)(9-EtG-N7)][PF6] (10). The phenomenon of CHIir 
interactions is now well established 26  and the interaction ranges from weak (CH it 
center 2.6-3.0 A) to very strong (CH ... r center < 2.6 A). 27 Such interactions can play 
an important role in protein stability, 26  and in recognition processes. The CH 
interactions observed for complex 1 (2.7 A and 2.8 A), where the chelating ligand is 
bipy (Figure 4.2A), are stronger (0.1 A shorter in each case) than in complex 2 (2.8 A 
and 2.9 A) where the chelating ligand is bipy(OH)O (Figure 4.213). This can be 
attributed to the greater delocalization of the it-electrons in bipy(OH)O through two 




Figure 4.13 Tautomeric forms of bipy(OH)O. 
The space-filling and capped-stick models of [Q 7 6_tha)Ru(bipy(OH)O)C1] (2) (Figure 
4.413 and 4E) show the tilting of the arene towards the chelating ligand in the crystal 
structure, possibly due to an intramolecular CH/it interaction 26-30  between CH protons 
from the outer non-coordinated ring of tha and the centers of the pyridine rings of the 
chelating ligand (vide infra). In such interactions the hydrogen atoms tend to lie above 
the centres of the aromatic rings. 29  In the previously-reported crystal structure of [(i 6- 
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tha)Ru(en)Cl] [PF6], 2  where en = ethylenediamine, the tricyclic ring system of tha is 
nearly flat and the outer ring of the arene is slightly bent away from the Cl ligand. 
Intramolecular it-it arene-nucleobase stacking, observed previously in [(?I 
6 
tha)Ru(en)(9-EtG-N7)][PF6]2, 2  is not present in the crystal structure of complex 10. 
The space-filling and capped-stick models of 10 (Figure 4.4C and 4.4F) clearly show 
that intramolecular CHJir interactions between protons from the outer ring of tha and 
the centres of the it-system of the chelating ligand (distances 2.8 A and 3.0 A), are 
present for the 9-EtG adduct as they are for the chlorido adduct (complex 2). 
DFT calculations show that the total bonding energy of tha in the optimized structure 
Of 1016-tha)Ru(bipy(OH)0)(9-EtG-N7)f' (10), where the arene is interacting with the 
chelating ligand through the intramolecular CH/ it interaction (Figure 4.10B), is 7.5 
kJ/mol lower than the total bonding energy of tha in the optimized structure of 
modified complex 10, in which there is an arene/9-EtG intramolecular it-it interaction 
(Figure 4.10A). This result shows that the it-it interaction between the arene and 9-
EtG observed2 for [(,16-tha)Ru(en)(9-EtG-N7)] [PF6]2, which might play a role in 
stabilizing DNA adducts, is less favoured compared to CHI it interactions in complex 
10. This may lead to less stable DNA adducts. 
Hydrolysis of chlorido complexes also deserves discussion as an important step in 
binding to DNA. Complexes 4, 7, 8 and 13-16 undergo relatively fast hydrolysis with 
half-lives of the order of minutes at 37°C (Table 4.4). The reported half-lives for 
aquation of the chlorido en Ru" arene complexes, [(,j6-dha)Ru(en)Cl][PF6], 
[(,6 
tha)Ru(en)Cl] [PF6] and [(,7 6-bip)Ru(en)Cl] [PF6 1,31 are 1.4 - 8.8 times shorter than 
those of complexes mentioned in this Chapter, under comparable conditions. The 
presence of bipy as a it-acceptor in [(,7 6-arene)Ru(bipy)Cl]Cl complexes where arene 
= benzene (bz), p-cymene (p-cym) and hexamethylbenzene (hmb), has been reported 
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to decrease the rate of hydrolysis by 2 orders of magnitude compared to analogues in 
which bipy is replaced with two aqua ligands. 32 The t-acceptor ligand bipy withdraws 
electron density from Ru and increases the positive charge on the metal, making it 
less favourable for Cl to leave, slowing down the hydrolysis. 
For complexes which contain bip as the arene (7 and 15), loss of the arene is observed 
in aqueous solution (33 and 46%, after 24 h for complexes 7 and 15, respectively). 
The same arene loss was previously observed for Ru" bip complexes containing 
phenylazo-pyridines as it-acceptor ligands (22-50% loss of bip after 24 h in aqueous 
solution).33  No arene loss was observed for the other arene complexes. Biphenyl (bip) 
has a high aromaticity, and competes as a it-acceptor 34 with the it-acceptor chelating 
ligands (bipy(OH)O and bipy in complexes 7 and 15, respectively) for electron 
density. This leads to a weakening of the Ru-arene bonds and loss of bip, which is not 
the case for the other arenes. In 7, the hydroxyl substituents on the chelating ligand 
are electron donors, 35  and the chelating ligand can exist in two tautomeric forms 
(Figure 4.13) one of which places a negative charge on the nitrogen atom. These 
features could make bipy(OH)O a weaker it-acceptor than bipy and stabilize the Ru"-
arene bonds by it-back-donation. As in both complexes (7 and 15) arene loss was 
observed there seems to be no significant difference in the it-acceptor abilities of bipy 
and bipy(OH)O. Attempts to detect arene loss from the p-terp complex (6) were 
hampered by its very low solubility. 
Substituents on bipy have no significant influence on the rates of hydrolysis which 
suggests that their electronic effects on the metal are small. This statement is 
consistent with the DFT calculations. After the geometry optimization of [( q 
6 
ind)Ru(bipy(OH)2)C1] [PF6] (8), [(7 6-ind)Ru(bipy(Me)2)C1] [PF6] (13) and 
[(,6 
ind)Ru(bipy)C1][PF6] (16, Figure 4.9), VDD charges on Ru showed no significant 
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differences among complexes (with values of +0.268 a.u. for complexes 8 and 13 and 
+0.270 a.u. for complex 16). Therefore these results prove that substituents on bipy 
have no significant effect on the charge on the metal. Deprotonation of bipy(OH)2 and 
chelation as bipy(OH)O is expected to reduce the positive charge on Ru" since 
electron density from the oxygen (0) of one pyridine ring can be transferred onto the 
nitrogen of the other pyridine ring (Figure 4.13). However because the H-bonded 
proton stabilises the tautomer in which the negative charge is localised on the oxygen 
atom, this effect is weak,4' 36  as indicated by the VDD charge on Ru in deprotonated 
complex 8 [(i 6-ind)Ru(bipy(OH)O)Cl] of +0.271 a.u., similar to the charges for 8, 13 
and 16. 
Consistent with the results from hydrolysis studies and DFT calculations, no 
significant difference in extent of binding to 9-EtG was observed for bipy and 
bipy(OH)O complexes. As DNA is a potential target for transition metal anticancer 
complexes, 37  reactions of the complexes with 9-EtG as a model nucleobase are 
studied in this Chapter. Ru 1 complexes [(, 6-tha)Ru(bipy)Cl] [PF6] (1) [(p6.. 
tha)Ru(bipy(OH)O)Cl] (2) and [(i 6-bz)Ru(bipy(OH)O)Cl] (5) react relatively rapidly 
with N7 of 9-EtG (90, 98 and 100% of binding of 1, 2 and 5, respectively after 2 h in 
water at 37°C). 9-EtG binds to a greater extent to complexes 2 and 5 containing 
bipy(OH)O than to complex 1 containing bipy. In all three 9-EtG adducts (complexes 
9, 10 and 12), the 'H NMR peaks corresponding to H8 are shifted to high field 
relative to free 9-EtG (making the difference of 0.35, 0.63 and 0.74 ppm for 
complexes 9, 10 and 12, respectively). Usually metallation at the N7 site of purine 
bases produces a low field shift of the H8 resonance by about 0.3 - 1 ppm. 38 
Previously it was observed for en Ru" and Os" arene complexes that 9-EtG H8 peaks 
for bound 9-EtG are shifted to low field relative to those of free 9-EtG." 39 However 
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for 9-EtG in [(i 6-p-cym)Ru(acac)(9-EtG-N7)] (acac = acetylacetonate) the H8 peak 
is shifted to high field compared to the free model nucleobase. 4° The similar H8 
chemical shift behaviour of 9-EtG in complexes 9, 10 and 12 might result from the 
shielding of H8 by one of the pyridine rings from the bipyridine ligands (Figure 4.3A; 
H8 = C2611). 
The polarization of C-H bonds of the bipy rings of bipy(OH)0 and bipy chelating 
ligands could lead to the formation of C-H (of chelating ligand) 0 (of 9-EtG) 
hydrogen bonds. In the crystal structure of complex 10 (Figure 4.3A), a hydrogen 
bond was observed between C20H from bipy(OH)0 and 034 from 9-EtG (2.46 A). 
Such C-H "0 H-bonds observed in other systems commonly have bond lengths of 2.1 
- 2.6 A.4 ' The observed hydrogen bond could lead to the additional stabilization of 9-
EtG adducts. 
Showing no significant difference in extent of binding to 9-EtG bipy and bipy(OH)0 
complexes surprisingly show a significant difference in anti-cancer activity. Complex 
1, containing tha as the arene and bipy as the chelating ligand, showed no activity in 
either the A2780 human ovarian or A549 human lung cancer cell lines, consistent 
with the previous report of the inactivity of bipy/ind and bipy/bip complexes.' 
Complexes containing bipy(OH)0 as the chelating ligand show a dramatic increase in 
cytotoxicity compare to their bipy analogues (Table 4.2).' The higher IC 50 (lower 
cytotoxicity) value for [( 6-bip)RuCl(bipy(OH)0)] (complex 7; 40 gM in A2780 
cells), compared to most of the other complexes containing bipy(OH)0, may be 
related to the facile loss of arene in this case. 
DNA binding studies performed with the bipy complex 16 and the bipy(OH)0 
complex 8 do not explain the significant difference in anti-cancer activity of these 
complexes. Complexes 16 and 8 both bind to DNA to a relatively small extent (43 and 
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11% after 48 h, respectively). CD spectra showed (Figure 4.11) that the binding of 16 
results in conformational alterations in double-helical DNA of a non-denaturational 
character, similar to those induced in DNA by conventional antitumor cisplatin. In 
contrast, the binding of 8 results in conformational alterations in DNA of a 
denaturational character, similar to those induced in DNA by clinically ineffective 
transplatin. 42 The melting behavior of DNA was affected by 16 and 8 only negligibly 
(tm  was changed by less than 1°C) and the ability of complex 16 to displace DNA 
intercalator EtBr from CT DNA was considerably greater than that of complex 8 
(Figure 4.12). These results do not explain the dramatic difference in anti-cancer 
activity of 8 (Table 4.2; IC50 = 18 and 39 tM, against A2780 and A549 cells, 
respectively) and 16 (1050> 100 tM against A2780 cells)' and so it seems likely that 
DNA is not a major target for these complexes. 
4.5 Summary 
In this Chapter it is shown that half-sandwich Ru" arene complexes containing 
deprotonated 2,2'-bipyridine-3,3'-diol (bipy(OH)O) as the chelating ligand can exhibit 
significant cytotoxic activity towards cancer cells, in contrast to analogous complexes 
containing bipyridine or bipyridine with 4,4'-substituents such as Me. X-ray crystal 
structures and 'H NMR spectroscopy have shown that deprotonated bipy(OH)2 
(bipy(OH)O) can form a strong intraligand H-bonding system which enforces 
planarity on bipy(OH)O. It is shown that strong binding to 9-EtG can occur for 
complexes containing bipy(OH)O as well as for those containing bipy. An interesting 
feature of the structures of complexes with tha as arene is the presence of arene CH 
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(bipy(OH)O and bipy) interactions. Using DFT calculations, these interactions were 
found to be more stable compared to it-ir interactions between the arene and 9-EtG. 
The latter are known to stabilize DNA adducts. The work in this Chapter illustrates 
that subtle features in organometallic complexes can exert major effects on biological 
activity. However, DNA binding studies suggest that neither bipy nor bipy(OH)O 
complexes bind strongly to DNA, suggesting that DNA is not the major target for 
these complexes. 
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Chapter 5 
I Ru I  arene complexes with redox 
active diamine ligancis 
"It's an experience like no other experience I can 
describe, the best thing that can happen to a 
scientist, realizing that something that's happened 
in your mind exactly corresponds to something 
that happens in nature. It's startling every time it 
occurs. One is surprised that a construct of one 
own mind can actually be realized in the honest-
to-goodness world out there. A great shock, and a 
great, great joy." 
Professor Leo Kadanoff 
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5.1 Introduction 
The nature of the chelating ligand can play a crucial role in anticancer activity of the 
Ru" arene complexes.' In this Chapter complexes in which the chelating ligand is o-
phenylenediamine (o-pda) are investigated. Transition-metal complexes with the o-
pda as a chelating ligand are of particular interests due to their oxidation properties. 
Dichiorido Pt" complexes containing o-pda were among the first cisplatin analogues 
showing antitumor activity.24  Recently good activity for o-pda complexes of the type 
[(,i6-arene)Ru"(o-pda)ClJ, containing a range of mono-, di- and tn-cyclic 
hydrocarbons (arenes), has been reported.' Complexes containing mono- or di-
methylated o-pda and indan as the arene also exhibit good activity. The incorporation 
of OH groups onto the chelating ligand (o-pda) decreased the activity. It has been 
found that these complexes have the ability to overcome cross-resistance with 
adriamycin (doxorubicin). The reduction in resistance factor (RF) achievable by 
replacing ethylenediamine (en) by o-pda can be dramatic (RF = IC 50(A2780)/ 
1050(A2780) for [(,16-tha)Ru"(en)Cl], tha = tetrahydroanthracefle, reduces from> 100 
to 2 when en is replaced with o-pda to form [(q 
6_tha)RUII(o-pda)Cl]+  and from 92 to 2 
for the analogous dihydroanthracene (dha) complex). 
In this Chapter the preparation and characterization of six Ru" arene complexes 
containing o-pda, o-benzoquinonediimine (o-bqdi) or 4,5-dimethyl-o-
phenylenediamine (dmpda) as chelating ligands, with a variety of arenes and halides 
as other ligands, are reported. The effect of variation of the arene and halides on 
oxidation of coordinated o-pda is investigated, as well as their effect on cytotoxicity 
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against A2780 human ovarian and A549 human lung cancer cell lines. The aqueous 
solution chemistry of complexes containing o-pda and its oxidized form o-bqdi, as 
chelating ligands, is compared. The difference in the solid state structures of the 
diamine and diimine complexes is investigated. The x-ray crystal structures of 
complexes [(ij  [PF6] (1) and [(1 6-hmb)Ru(o-bqdi)Cl] [PF6] (3) 
are reported. The stability of 9-EtG adducts of complexes 1 and 3 is studied using 
DFT calculations. The ability of complex [(,1 6-p-cym)Ru(o-bqdi)I][PF6] (4) to 
undergo ligand-based reduction by glutathione (GSH) in water, to give complex [(17 
6 
p-cym)Ru(o-pda)II [PF6 (8), is also studied in this Chapter. 
5.2 Experimental section 
5.2.1 Materials 
The starting materials [(?7 6-arene)RuC12]2 (arene = p-cymene (p-cym), 
hexamethylbenzene (limb) or biphenyl (bip)) are prepared as described in Chapter 2. 
[(,16-p-cym)Ru12]2 was donated by Dr Holm Petzold. o-Phenylenediamine (o-pda) and 
4,5dimethyl-o-phenyleflediaflhifle (dmpda) were purchased from Sigma-Aldrich, and 
glutathione (GSH) from Acros Organics. Methanol was dried over Mg/12. All other 
reagents were obtained from commercial suppliers. 
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5.2.2 Synthesis of ruthenium complexes 
Complexes 1-4 and 6 were synthesized using a similar procedure. Typically the 
ligand, o-pda or dmpda (2 mol equiv), respectively, was added to a methanolic 
solution of the ruthenium dimer [(?1 6-arene)RuC12]2 and the reaction mixture stirred at 
ambient temperature for 30 mm. lodido and bromido complexes 4 and 5 were 
synthesized in the halide exchange reaction, using the chlorido complex 1 and ca. 5 
mol equiv of KX (X = I or Br). The products were isolated as PF6 salts. Details for 
individual reactions are described below. 
[(i76-p-cym)Ru(o-pda)C11 LPF6J (1). To a suspension of [(i/ 6-p-cym)RuC12]2 (0.05 g, 
0.08 mmol) in dry, freshly-distilled methanol (30 mL) o-pda (0.02 g, 0.16 mmol) was 
added. The reaction mixture turned yellow immediately after addition of o-pda. It was 
stirred at ambient temperature in air for 30 mm. The clear yellow solution was 
filtered, N144PF6 (0.06 g, 0.40 mmol) was added and the flask shaken. A precipitate 
started to appear almost immediately. The fine yellow precipitate was collected by 
filtration, washed with cold methanol and ether, and dried in air. Yield: 0.038 g 
(89%). 
Crystals suitable for x-ray analysis were obtained by slow evaporation of a methanolic 
solution at ambient temperature. The complex crystallized as [(176-p-cym)Ru(o-
pda)Cfl[PF6]. ESI-MS: calcd for RuClN2C16H22 [M] m/z 378.9, found 379.1. Anal. 
calcd for C 16H22C1F6N2PRu (1): C, 36.68; H, 4.23; N, 5.35. Found: C, 36.56; H, 4.16; 
N, 5.32. 'H NMR in DMSO-d6: 6 8.01 (d, 211, NH), 7.21 (m, 414), 6.34 (d, 2H, NH), 
5.75 (d, 2H), 5.52 (d, 2H), 2.28 (m, 1H), 2.21 (s, 3H), 1.18 (d, 6H). 
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I(,16-hmb)Ru(o-pda)C11 [PF6] (2). To a suspension of [(,7 6-hmb)RuC12]2 (0.05 g, 0.07 
mmol) in dry, freshly-distilled methanol (30 mL) o-pda (0.02 g, 0.15 mmol) was 
added. The reaction mixture was stirred at ambient temperature under argon for 30 
mm. The resultant red solution was filtered, NH4PF6 (0.06 g, 0.39 mmol) added and 
the flask shaken. The precipitate, which started to appear almost immediately, was 
collected by filtration, washed with cold methanol and ether, and dried in air to give a 
red solid. Yield: 0.030 (73%). 
1 H NMR in DMSO-d6: 6 7.11 (m, 4H), 6.71 (d, 211, NH), 6.51 (d, 2H, NH), 2.01 (s, 
18H). 
(16 hmb)Ru(o-bqdi)C1] IPF6I (3). To a suspension of [(i 6-bmb)RuCl2]2 (0.05 g, 0.07 
mmol) in dry, freshly-distilled methanol (30 mL) o-pda (0.02 g, 0.15 mmol) was 
added. The reaction mixture was stirred at ambient temperature in air for 30 mm. 
After removing methanol under reduced pressure, the 'H NMR spectrum of the 
remaining solid in DMSO-d6, showed a mixture of complexes 2 and 3 in the ratio 1:1. 
The mixture was redissolved in methanol, NH 4PF6 (0.06 g, 0.39 mmol) was added 
and this left in air overnight. The purple solid which formed was filtered, washed with 
cold methanol, followed by ether, and was dried in air. Yield: 0.028 (67%). 
Crystals suitable for x-ray analysis were obtained by slow evaporation of a methanolic 
solution of 3 at ambient temperature, and the complex crystallized as [(,1 6-hmb)Ru(o-
bqdi)Cl][PF6]. ESI-MS: calcd for RuC1N2Cl8H24 M] mlz 404.9, found 405.1. 1 11 
NMR in DMSO-d6: S 13.97 (s, 2H, NH), 7.11 (m, 4H), 2.03 (s, 18H). 
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(,6_pcym)Ru(o-bqdi)II[PF6J (4). Two methods were used in the preparation of 4. 
Method A: To a suspension of [( 6-p-cym)RuI2]2 (0.05 g, 0.05 mmol) in dry, freshly-
distilled methanol (30 mL), o-pda (0.01 g, 010 mmol) was added. The reaction 
mixture turned purple immediately and was stirred at ambient temperature in air for 
30 mm. The clear dark purple solution was filtered, NH4PF6 (0.04 g, 0.25 mmol) 
added and the flask shaken. The precipitate that appeared was collected by filtration, 
washed with cold methanol and ether, and dried in air to give a dark purple solid. 
Yield: 0.023 g (73%). 
Method B: To a suspension of [(116-p-cym)Ru(o-pda)Cl][PF6] (1, 0.01 g, 0.02 mmol) 
in dry, freshly-distilled methanol (30 mL), KI (0.02 g, 0.09 mmol) was added. The 
reaction mixture was stirred at ambient temperature in air for 30 mm. The yellow 
solution turned dark purple and a dark purple precipitate appeared. The precipitate 
was collected by filtration, washed with cold methanol and ether, and dried in air to 
give a dark purple solid. Yield: 0.004 g (36%). 
ESI-MS: calcd for RuIN2Cl6H20 [M] + mlz 468.3, found 468.9. 'H NMR in DMSO-
d6: 6  14.68 (s, 2H, NH), 7.09 (m, 4H), 6.33 (d, 2H), 6.11 (d, 2H), 2.95 (m, 111), 2.43 
(s, 3H), 1.20 (d, 6H). 
[(ij6_pcym)Ru(o-bqdi)Br1 IPF6I (5). To a suspension of {(i 6-p-cym)Ru(o-
pda)C1][PF6] (1, 0.01 g, 0.02 mmol) in dry, freshly-distilled methanol (30 mL), KBr 
(0.01 g, 0.12 mmol) was added. The reaction mixture was stirred at ambient 
temperature in air for 30 mm. The yellow solution turned purple and a dark purple 
precipitate started to appear. The dark purple precipitate was collected by filtration, 
washed with cold methanol and ether, and dried in air. Yield: 0.003 g (32%). 
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ESI-MS: calcd for RuBrN2C16H20 [M] mlz 421.3, found 421.3. 'H NMR in DMSO-
d6: 8 14.70 (s, 2H, NH), 7.08 (m, 4H), 6.30 (d, 2H), 6.07 (d, 2H), 2.87 (m, 1H), 2.33 
(s, 3H), 1.19 (d, 6H). 
[(11 6-bip)Ru(dmpda)C1] [PF6I (6). To a suspension of [(,1 6-bip)RuC12]2 (0.05 g, 0.08 
mmol) in dry, freshly-distilled methanol (30 mL), dmpda (0.02 g, 0.15 mmol) was 
added. The reaction mixture was stirred at ambient temperature in air for 30 mm. The 
dark violet solution was filtered, NH4PF6 (0.06 g, 0.38 mmol) added, and the flask 
shaken. The precipitate that appeared almost immediately, was collected by filtration, 
washed with cold methanol and ether, and dried in air to give a violet solid. Yield: 
0.022 g (49%). 
ESI-MS: calcd for RuClN2C2oH22 [M] mlz 426.9, found 426.9. Anal. calcd for 
C20H26C1F6N2PO2Ru (6 2 H20): C, 39.51; H, 4.31; N, 4.61. Found: C, 39.11; H, 
3.86; N, 4.44. 'H NMR in DMSO-d6: ö 8.20 (d, 2H, NH), 7.84 (d, 2H), 7.50 (m, 311), 
6.98 (s, 2H), 6.30 (d, 2H, NH), 6.26 (d, 2H), 6.00 (t, 1H), 5.88 (t, 2H), 2.15 (s, 6H). 
5.2.3 X-ray crystalography 
Details of the instrumentation used are described in Chapter 2. Structure 1 was solved 
by Professor Simon Parsons by Patterson method (DIRDIF) 5 and refined with 
SHELXL-976, while structure 3 was solved by Dr Francesca Fabbiani by direct 
method (S1R92) 7  and refined using CRYSTALS 
.8 Hydrogen atoms were placed in 
calculated positions, and all non-H atoms were modelled with anisotropic 
displacement parameters. The final conventional R factor (based on F and 4930 out of 
5671 with F> 4a(1)) was 0.0340 for the structure of 1, and the final conventional R 
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factor (based on F and 2449 out of 4304 with F> 4c(I)) was 0.0407 for the structure 
of 3. Other crystal and refinement data are summarized in Table 5.1. 
5.2.4 Hydrolysis 
The hydrolysis of chlorido Ru" arene complexes was monitored by UV-Vis 
spectroscopy, without explicit control of pH or chloride concentrations. Complexes 
were dissolved in H2O to give Ca. 50 p.M solutions. The absorbance was recorded at 
30 s intervals at the selected wavelength over Ca. 30 min at 37°C. Plots of the change 
in absorbance with time were computer-fitted to the first-order rate equation: A = Co 
+ Cie ' (Co and C1 are computer-fitted constants and A is the absorbance 
corresponding to time t) using Origin version 7.5 (Microcal Software Ltd) to give the 
half-lives (t112) and rate constant values (k). 
5.2.5 Oxidation in methanol 
Oxidation of complex [(i(-p-cym)Ru(o-pda)Cl][PF6] (1) was monitored in methanol 
(50 p.M solution) in the absence, and in the presence of KI (1 mol equiv), by UV-Vis 
spectroscopy. The absorbance was recorded at 30 s intervals at the selected 
wavelength over Ca. 4 h at 37°C. Plots of the change in absorbance with time were 
computer-fitted to the first-order rate equation: A = Co + C,e' (Co and C1 are 
computer-fitted constants and A is the absorbance corresponding to time t) using 
Origin version 7.5 (Microcal Software Ltd) to give the half-lives (t,,2) and rate 
constant values (k). 
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5.2.6 Reaction with GSH 
UV-Vis spectra of complex [(, 6-p-cym)Ru(o-bqdi)I] [PF6] (4) in water (50 tM), in the 
presence of 15 mol equiv GSH, were recorded at 5 min intervals for 1 h, at 37°C. 
The 'H NMR spectra of D20 solution of 4 (200 j.tM), in the presence of 15 mol equiv 
GSH, were recorded 15 mm, 2 h, 4 h, 24 h and 72 h after dissolution at 37°C. 
5.2.7 Computation 
The details are described in Chapter 2. The 9-EtG adducts of complexes 1 and 3 
(MG and MG, respectively) were created by substituting the chiorido ligand with 
9-EtG in the crystal structures of 1 and 3 in Chemcraft (Version 1.5). 9-EtG used in 
substitution was imported into the database of Chemcraft from the previously 
determined x-ray crystal structure of 9-EtG adduct of the Ru" arene complex similar 
in structure to complexes 1 and 3. The coordinates used for the calculations were 
obtained directly from ChemCraft. Estimates of the Ru-{9-EtG} bonding energies in 
1EtG and 3EtG were obtained by subtracting the energies of the separate fragments 
from that of the whole molecule. 
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5.3 Results 
5.3.1 Syntheses and characterization 
The ligands used in this Chapter are shown in Figure 5.1. Ru" arene complexes 1-4 
and 6 (Figure 5.1) were synthesized as PF6 salts by the reaction of [(q 
6_arene)RUX2]2 
(X = Cl or I) and the appropriate chelating ligand, in methanol. The synthesized 
complexes (1-6) were fully characterized by 1D 'H NMR, ESI-MS and CHN analysis. 
Experimental values obtained for Cl-IN analyses of complexes [(q 
6_hmb)Ru(o-
pda)Cl] (2), [( 6-hmb)Ru(o-bqdi)Cl] (3), [(,1 6-p-cym)Ru(o-bqdi)I] (4) and [('i6-p-
cym)Ru(o-bqdi)BrI (5) differ from the calculated values by> 1% for C in each case, 
possibly due to the complexes containing a mixture of counter ions, especially in the 
cases of 4 (Cl, F or PF6) and 5 (Cl -, Bf or PF6). The synthesis of complex 1 as a BF 4 
salt was reported previously. 9  A simplified procedure which isolates the complex as a 
PF6 salt is reported here. 
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H 3  
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Complex Arene 	N-N 	X 
I 	p-cym 	o-pda 	CI 
la 	p-cym 	o-pda 	H20 
2 	hmb 	o-pda 	CI 
3 	hmb 	o-bqdi 	CI 
4 	p-cym 	o-bqdi 	I 
5 	p-cym 	o-bqdi 	Br 
6 	bip 	dmpda 	CI 
7 	p-cym 	o-bqdi 	CI 
7a 	p-cym 	o-bqdi 	H20 
8 	p-cym 	o-pda 	I 
Figure 5.1 General structures of complexes studied in this Chapter as PF6 salts. 
All the Ru" imine complexes described in this Chapter (complexes 3-5), exhibit a 
characteristic broad singlet imine NH resonance at low field (6 Ca. 14 - 15) in 1 H 
NMR spectra in DMSO-d6 (e.g. 6 14.68 for complex 4, Figure 5.2). For all the Ru" 
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amine complexes studied in this Chapter (1, 2 and 6), a characteristic doublet amine 
N112 resonance was observed (8 Ca. 6-8). 




b 	 HNz" 
14.70 14.65 ppm 
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Figure 5.2 Low field region of 'H NMR spectrum of complex [(?7 
6 
 [PF6] (4) in DMSO-d6. Inset: shows resonance of imine NH protons from o- 
bqdi 
The chlorido complex 1 underwent ligand-based oxidation in the presence of Ca. 
mole equiv of KI or KBr in methanol, to afford the diimine iodido and bromido 
complexes 4 and 5, respectively. 
5.3.2 Crystal structures 
The x-ray crystal structures of complexes [(?7 6-p-cym)Ru(o-pda)Cl1[PF6] (1) and [(?7 
6 
hmb)Ru(o-bqdi)Cl][PF6] (3) are determined and their ORTEP diagrams are shown in 
Figure 5.3. The crystallographic data are listed in Table 5. 1, and selected bond lengths 
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and angles in Table 5.2. The crystal structures of complexes 1 and 3 show the typical 
pseudo-octahedral 'piano-stool' geometry. The 'seat' of the stool (it-bonded arene) 
occupies three coordination sites and the two N atoms and Cl fill the remaining three 
sites. 
The distance between the arene centroid and Ru in p-cym complex 1 (1.66 A) is 
shorter than in hmb complex 3 (1.71 A). The Ru-Cl bond lengths in these two 
chlorido Ru" complexes are significantly different, with a values of 2.4039(8) A for 1 
and 2.3936(13) A for 3. In complex 3, which contains o-bqdi as a chelating ligand, the 
Ru-N distances are significantly shorter (2.033(4) A and 2.025(4) A) than those in the 
diamine complex 1 (2.141(2) A and 2.156(2) A). 
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Figure 5.3 ORTEP diagrams for cations of (A) complex [( 6-p-cym)Ru(o-
pda)Cl][PF6] (1), and (B) complex [(116-hmb)Ru(o-bqdi)Cl][PF6] (3) at 50% 
probability thermal ellipsoids. All hydrogens, apart from NH hydrogen atoms from o-
pda and o-bqdi, have been omitted for clarity. 
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Table 5.1 X-ray crystal structure data for complexes 1 and 3 
1 3 
Formula C 16H22C1F6N2PRu C 18H24C1F6N2PRu 
Molar mass 523.85 549.89 
Crystal system orthorhombic monoclinic 
Crystal size /mm. 0.48 x  0.19 x  0.08 0.35 x  0.14 x  0.06 
Space group Pna2l P1211cl 
Crystal Orange I needle red I plate 
a I A 10.6876(4) 12.7647(6) 
b I A 17.0748(8) 10.8910(5) 
c I A 10.8625(5) 15.8629(7) 
a/deg 90 90 
fl/deg 90 113.431(3) 
y/ deg 90 90 
TIK 150(2) 150 
Z 4 4 
R [F > 4c (F)]a 0.0340 0.0407 
R" 0.0838 0.0948 
GOFC 1.056 0.6189 
Ap max and mm, /eA 3 0.893, -0.450 1.39,-1.31 
a R = IIFOI - IFIIIIF0I. b  R = [w(F02 - F2)2IwF02)] . 
C GOF = [w(F02 - F 2)2/(n-
1/2 where n = number of reflections and p = number of parameters. 
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Table 5.2 Selected bond lengths (A) and angles (°) for complexes 1 and 3 
Bond/Angle 	 1 	 3 
Ru-Cl 2.4039(8) 2.3936(13) 
Ru-N12/N2 2.156(2) 2.025(4) 
Ru-N22/N1 2.141(2) 2.033(4) 
Ru-Cu/Cl 2.188(4) 2.263(4) 
Ru-C21/C2 2.195(4) 2.253(4) 
Ru-C311C3 2.166(4) 2.252(4) 
Ru-C411 C4 2.207(4) 2.245(5) 
Ru-051105 2.163(4) 2.176(5) 
Ru-C61/C6 2.186(4) 2.175(5) 
N22/ N2-Ru-N 12/ N  76.18(9) 75.06(15) 
N12/N1-Ru-Cl 86.02(8) 87.90(11) 
N22/N2-Ru-Cl 83.56(8) 86.71(11) 
The C - C and C - N bonds of o-pda in complex 1, and o-bqdi in complex 3, are 
shown in Figure 5.4. It can be seen that the C - C bond lengths of o-bqdi from 3 are in 
the range 1.35 - 1.44 A consistent with the presence of C - C single (average 1.440(6) 
A) and C = C double (average 1.347(6) A) bonds. All C - C bond lengths of o-pda 
from 1 are very similar (1.37 - 1.41 A), average 1.387(5) A. The C - N bonds of o-
bqdi are significantly shorter (1.295(5) A and 1.300(6) A) compared to those of o-pda 
(1.448(4) A and 1.452(4) A). The observed differences in C - C and C - N bond 
lengths can be diagnostic for assignment of the oxidation state of the chelating ligand. 
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Figure 5.4 Bond distances for (A) Ru"(o-pda) unit of complex [( 6-p-cym)Ru(o-
pda)Cl][PF6] (1), and (B) Ru"(o-bqdi) unit of complex [( 6-hmb)Ru(o-bqdi)C1][PF6] 
(3). 
5.3.3 Ligand based-oxidation 
Complex {(?1 6-p-cym)Ru(o-pda)Cl][PF6] (1) is formed as a product of the reaction of 
the dimer ([(16-p-cym)RuC12]2) with o-pda, at ambient temperature in air and 
methanol as a solvent. Complex [( 6-hmb)Ru(o-pda)C1][PF6] (2), however, was 
prepared in methanol from the reaction of [(i 6-hmb)RuCl2]2 with o-pda, under an 
argon atmosphere at ambient temperature. When the preparation of 2 was attempted 
under the same reaction conditions as 1 (in air), the result was the formation of a 
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mixture. The 'H NMR spectrum in DMSO-d6 showed a mixture of 2 and [(I/ 6 
hmb)Ru(o-bqdi)Cl] [PF6] (3) in a 1:1 ratio indicating that changing the arene from p-
cym to hmb has made o-pda more sensitive towards ligand-based oxidation in the 
presence of molecular oxygen from air. 
The extent of ligand-based oxidation process in [(,7 6-p-cym)Ru(o-pda)Cl] (1) and 
formation of [( 6 p-cym)Ru(o-bqdi)Cl (7) in methanol was followed by UV-Vis 
spectroscopy. The data were fitted to the appropriate equation for pseudo-first-order 
kinetics giving the kobs = 10± 0.2 x mind and t1,2 = 68 mm. This is ca. 2 x  slower 
than observed for ligand-based oxidation of the same complex in the presence of 1 
mol equiv of KI (kobs = 24 ± 0.2 x min'; t1,2 = 29 mm). The formation of 7 and 
[(i16-p-cym)Ru(o-bqdi)I] (4) was confirmed by ESI-MS (for complex 7: mlz calc. 
376.9, found 377.2; for complex 4: m/z calc. 468.3, found 468.9) and by 'H NMR (for 
complex 7; Figure 5.5). The resonances of the aromatic protons of p-cym in 7 (two 
doublets at 6.00 ppm and 6.23 ppm) are shifted to lower field, compared to those of 
complex 1 (two doublets at 5.56 ppm and 5.76 ppm). 
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Figure 5.5 Low field region in 'H NMR spectrum of [(,7 6-p-cym)Ru(o-pda)Cl][PF6I 
(1) in MeOH-d4 (A) 10 min after dissolution, and (B) 4 hours after dissolution. 
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Initially the UV-Vis spectrum of 1 in methanol showed no bands in the visible region; 
new bands appeared after 5 mm, at 248 nm, 357 nm, 485 nm and 690 Mn, which 
increased in intensity with time and can be assigned to 7. 
5.3.4 Aquation 
Complex [(,76-hmb)Ru(o-bqdi)Cl][PF6] (3) showed relatively fast hydrolysis, k 0b = 
92.5 ± 1.36xl0 min- ' and ti/2 = 7.49 mm (Figure 5.6). The presence of the aqua 
adduct was confirmed by ESI-MS. The ion peak observed at m/z 369.7 is assignable 
to [(,l6-hmb)Ru(o bqdi)H20]2+  after loss of the aqua ligand and a proton (caic. m/z 
369.4 for [(l6-hmb)Ru(obqdi)H2O] 2+ -H20 -H). 
The 'H NMR spectrum of complex [(,76-p-cym)Ru(o-pda)Cl][PF6] (1) in D20, after 2 
h showed peaks consistent with the presence of 4 species, corresponding to the 
chlorido species 1 (5%) and [(,76-p-cym)Ru(o-bqdi)Cl][PFo] (7, 9%), together with 
peaks for the aqua adducts [(, l6 p cym)Ru(o pda)H2O12+ (la, 38%) and [(p 6-p-
cym)Ru(o-bqdi)H2O] 2 (7a , 48%, Figure 5.7). This is consistent with the formation, 
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Figure 5.6 Hydrolysis studies of complex [(,76-hmb)Ru(o-bqdi)Cl][PF6] (3) at 37°C. 
(A) the UV-Vis difference spectrum shows that the largest change in absorbance 
occurs at 502 nm. (B) The change in absorbance at 502 nm over 30 min during the 
aquation of 3, from which the kinetic data were derived. 
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Figure 5.7 1 H NMR spectrum of complex [(i7 6-p-cym)Ru(o-pda)C1][PF6] (1) in D20, 
2 h after dissolution, showing formation of [(,(-p-cym)Ru(o-bqdi)Cl] [PF6] (7) and 
formation of aqua adducts of both chlorido species (la and 7a). 
The ESI-MS of the same solution in D20 also showed ion peaks that are consistent 
with the presence of 4 species. The peaks corresponding to the two aqua adducts la 
and 7a (calc. mlz 345.4 for {la -1120 —D}, found m/z 345.5; caic. mlz 341.4 for {7a 
-H20 —D}, found mlz 341.5; in which the NH protons of o-pda and o-bqdi 
exchanged with D) overlapped, but a close analysis showed that there were two sets 
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of peaks. The less intense peaks corresponding to two chlorido species 1 and 7 
(Figure 5.8) are still present in solution, again overlapped (caic. mlz 383.0 for 1, with 
ND2, found mlz 383.5; caic. m/z 379.1 for 7, with ND, found mlz 379.4). Thus, 
complex 1 in D20 undergoes hydrolysis as well as ligand-based oxidation, leading to 
the formation of [( 6-p-cym)Ru(o-bqdi)Cl] (7). The formation and increase in 
intensity of bands at: 251 nm, 350 nm, 468 nm and 686 nm in the UV-Vis spectrum of 
1 in water over 1 h is attributable to ligand based oxidation. 
o-Bqdi complexes [(,-hmb)Ru(o-bqdi)C1f (3) and [(1 6-p-cym)Ru(o-bqdi)If (4) in 
water show similar bands in the UV-Vis spectra: at 224, 350, 502 and 678 nm for 3 
and at 260, 397, 493 and 680 nm for complex 4 (Figure 5.9). 
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Figure 5.8 ESI-MS spectrum of D20 solution of [(1-p-cym)Ru(o-pda)C1][PF6] (1, 
lowest spectrum), and isotopic patterns (upper spectra) showing peaks corresponding 
to two species: intact complex 1 (where the NH2 protons have been exchanged with D 
to give ND2) and its oxidized form [(,7 6-p-cym)Ru(o-bqdi)C1][PF6] (7, again with ND, 
instead of NH). 
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Figure 5.9 UV-Vis spectra of an aqueous solution of [( 6-p-cym)Ru(o-bqdi)I][PF6] 
(4), showing no changes during 24 h. 
The appearance and increase in intensity of bands at 251, 347, 475 and 662 nm in the 
UV-Vis spectrum of [(,-bip)Ru(dmpda)Cl] (6) in water over 1 h suggested that 
ligand-based oxidation had occurred, as the species formed absorb at the similar 
wavelengths as complexes 3 and 4. In the 'H NMR spectrum obtained 10 min after 
dissolution of 6 in D20, peaks for free biphenyl were observed (Figure 5.10) 
indicating arene dissociation from the complex. Complex 4 did not undergo 
hydrolysis over a period of 24 h. 
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Figure 5.10 Low field region of the 'H NMR spectrum of [()7 
6 
bip)Ru(dmpda)C1] [PF6] (6) in D20, showing release of bip. 
5.3.5 Reaction with GSH 
UV-Vis spectra of complex [( 6-p-cym)Ru(o-bqdi)I][PF6] (4) in water, in the 
presence of 15 mol equivalents GSH, showed complete disappearance of the bands 
corresponding to 4 after 1 h, and the appearance of an isosbestic point at 299 nm 
(Figure 5.11). This indicated the reduction of o-bqdi to o-pda and the formation of 
[( 
6 -p-cym)Ru(o-pda)I] + (8), as confirmed by ESI-MS (calc. for [M] +  mlz 470.3, 
found 470.9). The resulting colourless solution became purple in colour after more 
than 72 h. Complex 4 dissolved in water gives a purple solution and the UV-Vis 
spectrum showed the complete restoration of bands for 4. 
The 'H NMR spectrum of 4 in D20 and the presence of 15 mol equiv GSH, showed 
resonance peaks at 3.30 (d of d) and 3.00 ppm (d of d, overlapped with the peaks of 
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GSH in the same region, two d of d at 2.95 and 2.98 ppm), corresponded to the -CH2 
protons of GSSG. This suggested that oxidation of GSH to GSSG had occurred.' ° The 





220 	320 	420 	520 	620 	720 
Wavelength / nm 
Figure 5.11 UV-Vis spectra of complex 4 in water 5 min after dissolution (top 
spectra), in the presence of 15 mole equiv GSH, and spectra (bottom) recorded 1 h 
after dissolution, showing complete disappearance of the bands in the visible region 
and the isobestic point at 299 nm, indicating the conversion of the o-bqdi to o-pda and 
formation of [( q 6 -p-cym)Ru(o-pda)l] (8). 
No GSH adduct of 4 in an aqueous solution was detectable by ESI-MS. In negative-
ion mode ion peaks corresponding to GS S -  (caic. mlz 611.2, found 611.1) and GS 
(calc. mlz 305.1, found 304.9) were observed, confirming the formation of GSSG. 
Further confirmation of the origin of the peak at m/z 304.9 was achieved by 
fragmentation. The MS/MS spectrum of this peak showed fragmentation peaks 
consistent with the presence of a glutathionyl unit. 1 ' 
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5.3.6 Computation 
The optimized geometries of the 2+ cations [(i1 6-p-cym)Ru(o-pda)(9-EtG-N7)] 2 
(MG) and [(16-hmb)Ru(o-bqdi)(9-EtG-N7)] 2 (3EtG) are shown in Figure 5.12. A 
hydrogen bond of 1.69 A was formed between 06 of 9-EtG and NH proton (Ha) of o-
pda (Figure 5.12A) in the optimized structure of MG. The distance between 06 
from 9-EtG and Hi from NH of o-bqdi (Figure 5.1 2B) in the optimized structure of 
3EtG is 2.22 A. The binding energy of 9-EtG to the metal fragment in 1EtG is -328.1 
kJ/mol, which is 23.8 kJ/mol lower than the corresponding value for 3EtG (-304.3 
kJ/mol). 
Voronoi Deformation Density (VDD) charges on Ru in 1EtG and 3EtG revealed 
differences in electron density on the metal. In complex 1EtG the atomic charge on 
Ru is +0.25 a.u. and +0.31 a.u. in MG, a difference of 0.06 a.u. 
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Figure 5.12 Optimized geometries of 9-EtG adducts of complexes (A) 1 and (B) 3. 
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5.3.7 Cytotoxicity 
None of the complexes tested (1, 3, 4 or 6) showed activity against A549 human lung 
cancer cells (1050> 100 tM; Table 5.3). Complex 1 containing o-pda as a chelating 
ligand, showed the highest activity against A2780 human ovarian cancer cells (1050 = 
11 tM). In contrast, complexes containing the oxidized form of o-pda (o-bqdi) as a 
chelating ligand (complexes 3 and 4), showed no activity (10 50> 100 .tM) against the 
A2780 cell line. Complex 6 containing dmpda as a chelating ligand showed moderate 
activity against A2780 cells (1050 = 49 p.M). Although the activity of complex [(1 6-p-
cym)Ru(o-bqdi)Br] [PF6] (5), was not determined, it would be predicted to be inactive. 
It is likely that both bromido and iodido ligands in these complexes would be 
substituted by chloride in an extracellular biological media where the concentration of 
chloride is 104 mM, so that these complexes would in any case act as prodrugs.' 2 
IC5 0 of complex 2 in A2780 cells was found to be> 50 jtM. 
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Table 5.3 IC50 values for Ru" complexes described in this Chapter against the A2780 




[(1-p-cym)Ru(o-pda)Cl][PF6]  1 la > 100 
{(,16 hmb)Ru(o pda)Cl][PF6]b  > 50C ND  
[(,16-hmb)Ru(o-bqdi)Cl] [PF6]  > 100 > 100 
[( 6-p-cym)Ru(o-bqdi)I] [PF6]  > 100 > 100 
[( 6-bip)Ru(dmpda)C1} [PF6] (6) 49 > 100 
'The 1050 data of 1 against A2780 human ovarian cancer cell line were previously 
reported. 1 
bComplex  2 is believed to be unstable in solution towards the ligand-based oxidation 
and to be present in the test medium as the oxidized product, complex [(1 6-bmb)Ru(o- 
bqdi)Cl] [PF6] (3). 
cComplex 2 was tested following the same procedure as for the rest of complexes, 
except that this complex was not tested for activity above 50 tM and other complexes 
were tested for activity up to 100 tM. 
dND = not determined. 
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5.4 Discussion 
In this Chapter the oxidation of the diamine ligand o-pda to its diimino form o-bqdi in 
Ru" arene complexes has been investigated, as well as its affect on cytotoxicity 
towards cancer cells. The control of oxidation through changes in the electronic 
properties of the arene and substitution of the halide ligand has also been studied. 
The o-bqdi diimino ligand has been found to exist in solution 13  but has never been 
isolated in any form. For example, o-bqdi was observed as a product from the reaction 
of o-pda with lead dioxide, giving a deep red colour in organic solvents. 
14  This 
reactive ligand can be stabilized by coordination to metal ions. For tris(a-diimine)Fe" 
complexes, theoretical considerations have shown that a significant 7r-electron back-
donation takes place in the ground state and, as a result, unusually stable Fe" 
complexes are formed. 15  Similarly low-spin d6 Ru" complexes containing o-bqdi as 
the a-diimine ligand, are particularly stable. 16  Ru" complexes containing o-bqdi have 
previously been synthesized 16  and structurally characterized. 
17-19  The oxidation of o-
pda and formation of o-bqdi has an effect on the overall physical and chemical 
properties of Ru" arene complexes, including absorption spectra, hydrolysis rates, and 
cytotoxic activity. 
The o-pda complex [(,76-hmb)Ru(o-pda)Cl] (2) contains a strong electron-donating 
arene (hmb) and in methanol solution the absence of oxygen is necessary to prevent 
the formation of the o-bqdi species. On the other hand the less electron-donating arene 
(p-cym) in [(, 6-p-cym)Ru(o-pda)Clj 1 (1) makes it less sensitive to oxidation. 
Therefore the oxidation of o-pda and formation of an 'electron-poor' ligand (o-bqdi) is 
favoured in complexes where the metal center is more 'electron rich'. The stability of 
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the 'electron-poor' o-bqdi ligand in [Ru"(bpy) 2(o-bqdi)] [PF6]2 has been ascribed to its 
it-accepting ability in conjunction with a low-spin 'electron-rich' Ru" as a 7r-donor. 
17 
In contrast rhenium complexes with the oxidation states up to +7 containing (o-pda) 2 
ligands contain a combination of an 'electron-rich' diamine ligand and an 'electron-
poor' metal ion. 20 
The 'H NMR peaks of NH protons from o-bqdi appeared in the low field region of the 
spectra (8 ca. 14-15) compared to those of N112 protons from o-pda (5 ca. 6-8). The 
resonances of the NH protons from o-bqdi were observed at 11.96 ppm for [Ru(o-
bqdi)3[PF6]2 and at 7.0 ppm the resonances of the aromatic protons from the same 
chelating ligand.' 6 This chemical shift is close to that observed for the aromatic 
protons of o-bqdi in complexes 3-5 (8 ca. 7.1). The 'H NMR NH (o-bqdi) peaks of 
[Ru(o-pda)(o-bqdi)2] 2 have different chemical shifts ö, 11.20 and 14.24, as a result of 
different environments of these protons. 21 
o-Pda and o-bqdi species don't only show the difference in 'H NMR spectra; the 
oxidation state can be distinguished by x-ray crystallography as well. The 
significantly shorter Ru-Cl bond in the crystal structure of [(-hmb)Ru(o-
bqdi)Cl] [PF6] (3) compared to that of 1 can be attributed to the strong it-acceptor o-
bqdi in 3. As a consequence of the reduced electron density on the Ru centre, the 
negatively charged chiorido ligand is bound strongly. It has been found that the it-
accepting ability of the ligand L in [Ru(NH3)L] 2 , where n = 4 or 5 and L = pyrazine 
(pyz), 2,2'-bipyridine (bpy), imidazole (im) or o-bqdi, follows the order: o-bqdi>> 
pyz> bpy > im. 22 Therefore the effective charge on Ru in o-bqdi complexes is the 
highest in the series. The presence of significantly shorter Ru-N bonds in the crystal 
structure of 3 (average bond length of 2.029(4) A; Table 5.2) compared to those of 1 
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(average bond length of 2.148(2) A; Table 5.2) again indicates strong it-acceptor 
ability of o-bqdi. 
Structural parameters obtained from several crystal structure determinations can be 
used to assign the oxidation levels of the chelating ligand and enable comparisons to 
be made. 23  The lengths of C = N (av. 1.298(8) A) and C = C (av. 1.347(6) A) bonds of 
o-bqdi in complex 3 (Figure 5.4) are consistent with their identification as localized 
double bonds and are close to C = N (av. 1.300(8) A) and C = C (av. 1.339(9) A) 
bond lengths observed in [(o-bqdi)3Fe"] [PF6] 23  The lengths of C - C bonds of o-bqdi 
in the crystal structures of [(o-bqdi)3Fe"][PF6] (av. 1.437(10) A) and 3 (av. 1.440(6) 
A; Figure 5.4) are very close. 
In the crystal structure of complex 3, the Ru-arene centroid distance is 1.71 A and the 
distance in the crystal structure of [(7 6-hmb)Ru(en)Cl] [PF6] is 1.67 A.24 This indicates 
slightly weaker it-back-bonding between Ru and the arene in complex 3, in which 
more electron density is withdrawn from the metal by o-bqdi than by hmb. 
The two oxidation forms can be distinguished by UV-Vis spectroscopy as well. All 
the o-bqdi complexes studied (3, 4, 7 and the oxidation product of 6) exhibit two 
MLCT bands in UV-Vis spectra (in the range of 468-502 and 224-260 nm in water or 
methanol). The low and high energy MLCT transitions are assigned to Ru (4d 6) 
7[1 * (o-bqdi) and Ru (4d) -* 7L2* (o-bqdi) transitions by analogy with the assignment 
of the bands at 480 and 255 nm for [Ru11(edta)(o-bqdi)] 2 ,25 and at 470 and 258 Mn for 
[Ru"(NH3)4(0-bqdi)] 2 .26  The d-d transition bands for the chlorido complexes (3, 7 
and the oxidation product of 6) in water or methanol appeared in the range of 350-360 
nm, while for the iodido complex 4 (Figure 5.9) the same transition comes at lower 
energy (397 nm). it-Donation increases in the order X = Cl < Br < I for CpRu(PH3)X 
complexes (Cp = cyclopentadiene). 27  This should make the d-d transition energy 
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higher for chiorido Ru" complexes compared to the iodido complexes resulting in 
hypsochromic (blue) shift in the UV-Vis spectrum. 
28 All the complexes show a band 
in the UV-Vis spectra in the region 662-690 nm in water or methanol. This low 
intensity band was similar to that observed previously for [Ru 1'(edta)(o-bqdi)] 2 at Ca. 
575 nm in aqueous solution; its assignment is unclear at the moment, but it is 
suggested that it could be associated with the low energy MLCT transition. 
25 
After being able to distinguish between o-pda and its oxidized form (o-bqdi) an 
important next step is the control of the oxidation. Methanol and aqueous solutions of 
[( 6-hmb)Ru(o-pda)Cl] [PF6] (2) are more sensitive to molecular oxygen (from air) 
compared to the solutions of [(?1 6  -p-cym)Ru(o-pda)CIj[PF61 (1), due to the difference 
in the arene (vide infra). These solutions react with 02 to yield very intense purple 
products. In the 1 H NMR spectrum of 1 in MeOH-d4 (Figure 5.5), the formation of 
[(76-p-cym)Ru(o-bqdi)Cl] [PF6] (7) was detected. The intensity of the peaks 
corresponding to the protons of 7 increased with time, indicating increase in the 
concentration of the oxidized product (7). After 4 h the ratio of 7 and 1 was 3:1 
(Figure 5.513). For 7, the aromatic p-cym peaks are shifted to low field due to the 
deshielding of these protons by the it-accepting o-bqdi ligand (6.00 and 6.23 ppm). 
The aquation of 1, followed by UV-Vis spectroscopy showed the formation of 7. 
Isobestic points were not apparent, indicated a multi-step reaction pathway, as 
suggested by Bednarski for the ligand based oxidation of o-pda Pt" chlorido 
complexes in water. 29 
The ease with which 2 is oxidized compared to 1 is related to the increased number of 
electron-donating substituents on the arene in 2. The presence of electron-pushing 
alkyl groups on the arene has been found to strengthen the Ru-arene bond 30 and 
effectively increase the electron density on the Ru centre. The same effect is observed 
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when substituting Cl with the less electronegative Br or I (in complexes 4 and 5), 
resulting in less polarized Ru - Br/I bonds. Therefore the increased electron density 
on the Ru centre makes the chelating ligand in complexes 4 and 5, more susceptible 
towards oxidation (vide infra). 
Simultaneous oxidation and arene loss occurred during the aquation of complex [(q 
6 
bip)Ru(dmpda)Cl] [PF6] (6), even though the replacement of the arene (p-cym, hmb) 
by more electron-deficient bip,31' 32  should make the Ru centre even more acidic and 
this should stabilize the chelating ligand and make the oxidation less likely. Arene 
loss (detected in 'H NMR in D20; Figure 5.10) occurs possibly due to the oxidation of 
the chelating ligand resulting in a strong it-acceptor (dmbqdi), which competes with 
the bip arene (weak it-acceptor) for electron density from Ru. This destabilizes the Ru 
- arene bond through lack of it-back donation resulting in the dissociation of the arene 
from Ru. Arene loss was not observed for other complexes studied here. 
The difference in behaviour of o-pda and o-bqdi species in aqueous solutions deserves 
discussion as well. 'H NMR spectrum of [( 6-p-cym)Ru(o-pda)C1][PF61 (1), in D20 
(Figure 5.7) showed the formation of [(,76-p-cym)Ru(o-bqdi)Cl][PF6] (7), as well as 
formation of aqua adducts [( 6 p cym)Ru(o pda)H2O12+ (la) and [(i 6-p-cym)Ru(o-
bqdi)H2O] 2 (7a). Thus complex 1 hydrolyses as it undergoes ligand based oxidation 
(vide infra). 
For Ru" complexes, the presence of it-acceptors as chelating ligands decreases the 
rate of hydrolysis compared to the ethylenediamine analogues, 
33  by decreasing the 
electron density on Ru and reducing Cl lability. Thus the hydrolysis of [(ii -
hmb)Ru(o-bqdi)Cl] [PF6] (3) was found to be 17 times slower than previously 
observed for [(,1 6-hmb)Ru(en)Cl] [PF6] 
24  The iodido complex [(i 6-p-cym)Ru(o-
bqdi)I][PF6] (4) was found not to undergo hydrolysis. The absence of hydrolyses for 
192 
Chapter 5: Ru" arene complexes with redox active diamine ligands 
iodido [(,76-arene)Ru(azpy)I] [PF6] complexes, where arene = bip or p-cym and azpy = 
N,N-dimethylphenyl- or hydroxyphenyl-azopyridine, had also been reported. 
34 
The stabilization of the divalent Ru centre by the it-acceptor o-bqdi 35 suggests that 
reduction of o-bqdi back to o-pda is not favourable. However the ligand-based 
reduction of o-bqdi complex 4 occurred in the presence of glutathione (GSH). GSH is 
the primary cellular antioxidant and is present in cells in concentrations of Ca. 2-10 
mM. In many cases cancer cell resistance to drugs is correlated with an increased 
level of GSH in cancer cells compare to the healthy ones. 
12  For this reason, reactions 
of Ru" arene complexes with GSH are of particular importance. In the presence of 15 
mol equiv GSH, complex [(,-p-cym)Ru(o-bqdi)I][PF6] (4) underwent ligand-based 
reduction to form [(j6-p-cym)Ru(o-pda)I][PF6] (8). Leaving the aqueous solution for 
over 72 h, resulted in the complete conversion of 8 back to complex 4, indicating that 
once all the GSH has been oxidized to GSSG, dissolved oxygen in water goes on to 
cause ligand-based oxidation and formation of stable complex 4. The rate of oxidation 
of GSH is probably too slow to be important under physiological conditions 
(complete oxidation of GSH to GSSG requires more than 72 h). 
The stability of 9-EtG adducts of o-pda and o-bqdi complexes, as an important feature 
for potential DNA binding, was examined using DFT calculations. The o-bqdi ligand 
in the crystal structure of [(,7 6-hmb)Ru(o-bqdi)Clf' (3, Figure 5.313), and the 
optimized structure of (3EtG, Figure 5.12B) has a 
planar geometry and the H atoms of NH lie in the same plane. This results in the 06 
atom of 9-EtG in 3EtG being farther away from the NH protons of o-bqdi. The H-
bond formed between Hi and 06 is weaker (Figure 5.1213; 2.22 A) compared to the 
one formed between NH proton of o-pda and 06 of 9-EtG in [(, 6-pcym)Ru(o-pda)(9-
EtG-N7)] 2  (MG). The tetrahedral geometry around the N donors of o-pda in 1EtG 
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(Figure 5.12A) resulted in one hydrogen (Ha) pointing towards 06 making the H-
bond strong (1.69 A). The H-bond between Ha and 06 in 1EtG appears to be stronger 
than observed in en complexes of the type [(, l6 arene)Ru(en)(9EtGN7)1 2+, where 
arene = bip, tetrahydroanthracene (tha) and dihydroanthracene (dha). H-bonds in en 
complexes had values of 1.868 A for the bip complex, 1.919 A for the tha complex 
and 2.081 A for the dha complex. 36  The H-bond in 1EtG is similar in length to the H-
bond between the NH proton of en and 06 in the energy minimized structure of [(I 
6 
p-cym)Ru(en)(9-EtG-N7)1 2 (1.67 A).37 
The total bonding energy of 9-EtG in the structure of 1EtG (-328.1 kJ/mol) is 23.8 
kJ/mol lower than the bonding energy of 9-EtG in 3EtG (-304.3 kJ/mol). This could 
mainly be attributed to the more stabilized 9-EtG adduct of 1 through the stronger H-
bond described above. The charge on the metal centre in 3EtG (+0.31 a.u.) is 0.06 
more positive than in 1EtG (+0.25 a.u.) which is consistent with o-bqdi acting as a it-
acceptor. Considering the arenes, hmb in 3EtG with 6 CH3 groups would have more 
electron pushing effect compared to the p-cym of MG. Still the effect of the arene is 
noticeably smaller compared to the effect of the chelating ligand, and this leaves Ru 
in complex 3EtG with higher positive charge compared to Ru in MG. 
For complexes containing o-bqdi as the chelating ligand, no cytotoxic activity was 
achieved. Inactive [( 6-hmb)Ru(o-bqdi)Cl] (3) showed relatively fast hydrolysis and 
potential ability to bind to DNA. However as the 9-EtG adduct of 3 was found to be 
not as stable as the adduct of 1, the stability of the adduct formed contributes more 
towards cytotoxic activity than the actual ability of binding. Complex 2 is believed to 
be unstable in solution towards the ligand based oxidation, and tested as the oxidized 
product, complex 3, or at least partially. This explains the inactivity of 2. The 
inactivity of iodido complex [(,16-p-cym)Ru(o-bqdi)If (4) could be attributed to the 
194 
Chapter 5: Ru" arene complexes with redox active diamine ligands 
absence of hydrolysis. This could be a good reason for loss of ability of binding to 
DNA and loss of cytotoxic activity. The relatively fast hydrolysis of [(p 6-p-
cym)Ru(en)I] (t112 = 12.2 mm)24 resulted in relatively good cytotoxic activity of the 
complex (10 5 0 = 9 p.M against A2780 cells) .38 Complexes containing mono- or 
dimethylated o-pda and indan as arene, exhibited good activity, with IC50 values of 4 
and 14 p.M, respectively.' The loss of activity for 6, which contains dimethylated 
pda, might arise from the dissociation of the bip arene from the complex (vide infra). 
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5.5 Summary 
In this Chapter it is shown, for the first time, that Ru" arene complexes containing o-
pda as the chelating ligand can lose cytotoxic activity towards cancer cells upon 
oxidation of the chelating ligand to o-bqdi. This oxidation can be controlled through 
changes in electronic properties of the other ligands in the complex. The ligand based 
oxidation can be followed by UV-Vis and 'H NMR spectroscopy and the oxidation 
state of the diamine/diimine ligand can be distinguished in the x-ray crystal structure. 
The loss of anticancer activity for the dmpda complex containing bip as the arene is 
attributed to the dissociation of the arene ligand from the complex. It is suggested that 
the loss of activity for o-bqdi complexes can be attributed to the absence of hydrolysis 
or as well to the formation of the less stable adducts with 9-EtG, which would lead to 
the weakened binding to DNA. it-Accepting ability of the o-bqdi ligand is confirmed 
by the higher charge on Ru in the o-bqdi complex compared to that in the o-pda 
complex. It is shown that o-bqdi complexes can be reduced back to the original o-pda 
form by an excess of the intracellular reducing agent GSH. Once all the GSH is 
oxidized to form GSSG, the o-pda complex again undergoes ligand-based oxidation to 
form very stable o-bqdi Ru" species. 
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Chapter 6 
Isomer separation by ion mobility 
mass spectrometry 
"Man's mind, once stretched by a new idea, never regains its original dimensions." 
Oliver Wendell Holmes 
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6.1 Introduction 
In this Chapter the separation of isomeric terphenyl complexes of the type [( q  6 
arene)Ru(en)Cl], where en = ethylenediamine and arene = para- (1), ortho- (2) or 
meta-terphenyl (3) (p-, o- or m-terp; Figure 6.1, synthesis and characterization are 














Figure 6.1 Chemical structures of terphenyl complexes 1, 2 and 3. 
6.1.1 Ruthenium(II) terphenyl complexes 
DNA binding properties of 1, 2 and 3 were investigated in Chapter 3, and the data are 
consistent with a combined intercalative and monofunctional (coordination) binding 
mode of complex 1, while the two other complexes showed preferential binding 
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through the coordination. Intercalative binding mode of 1 seems therefore to make a 
major contribution to the high potency of this complex (1050 = 4[LM against A2780 
ovarian cancer cell line) compared to complexes 2 and 3 (1050 = 30 and 42 l.LM, 
respectively against A2780 cells; Chapter 3). 
6.1.2 Mass Spectrometry (MS) 
Due to its speed, selectivity and sensitivity modem mass spectrometry (MS) is 
becoming an essential tool for chemical, biological and medical research. Recent 
applications have allowed the stoichiometry of heterogeneous protein complexes to be 
defined based on their differences in mass-to-charge ratios (m/z). 1,2  The application of 
electrospray mass spectrometry (ES-MS) to organometallic chemistry and its 
development towards the characterization of organometallic compounds have been 
discussed in the literature. 3-5  Electrospray ionization mass spectrometry (ESI-MS) is 
described in Chapter 2. 
MS however cannot separate isomeric species as a stand-alone technique. It is often 
common to distinguish isomers using tandem MS since differences in the relative 
abundance of product ions, formed by fragmentation of individual selected isomeric 
precursor ions, may often be observed. It would be highly advantageous if the 
separation of isomeric species could be achieved on a time-scale compatible with the 
MS acquisition time-scale, and also provide an insight into the physical dimension of 
the separated species. 
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6.1.3 Ion mobility (IM) 
Ion mobility (IM) has the ability to rapidly separate isomeric and isobaric species 
based on differences in their collision cross-sections (physical size and shape) in the 
gas-phase and thus provide specific information on ionic conformation. IM separates 
ionic species based on their drift time through a gas-filled cell under the influence of 
an applied electric field (Figure 6.2). Drift time is dependent on factors such as mass, 
charge, together with physical size and shape (collision cross-section) and 
instrumental operating parameters. It is therefore possible to separate isomeric and 
isobaric species using IM if they have sufficiently different collision cross-sections. 6,7 
6.1.4 Ion mobility (IM) in combination with mass spectrometry (MS) 
In combination with MS, IM represents a powerful analytical tool since m/z and 
structural information can rapidly be obtained from a single experiment. A variety of 
IM methods are commonly used in combination with MS but they cannot all provide 
absolute collision cross-section (CC S) measurements directly from kinetic theory 
(attempts to explain macroscopic properties such as pressure, temperature, or volume, 
by considering the molecular composition and motion). 2 
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Figure 6.2 Schematic diagram illustrating ion mobility separation (A) starting point 
(B) the achieved separation (based on the previously published scheme). 8 
To take advantage of the IM-MS technique, an instrument based on 'travelling-wave' 
(T-Wave) technology has been developed . 7-9 The instrument (Synapt HDMS, Waters 
UK; Figure 6.3) uses a radio-frequency (RF) stacked ring ion guide (consists of a 
series of ring electrodes and adjacent rings have opposite phases of RF voltage 
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applied to them; Figure 6.4) as the mobility cell with a continuous train of transient 
voltages (travelling waves) to propel ions through the N2 drift gas (vide supra). The 
lower mobility ion rolls over the wave more often and takes longer to traverse the cell 
(Figure 6.2). For more details see Experimental section. 
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Figure 6.3 A schematic diagram of the Synapt HDMS system (reproduced from the 
previously published scheme). 7  All the turbomolecular pumps have pumping speed of 
2201/s and are backed by 35 m3/h scroll pump. 
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Figure 6.4 A schematic diagram of an RF-only stacked ring ion guide (based on the 
previously published scheme). 8 
6.2 Experimental Section 
6.2.1 Preparation of Complexes 
All complexes were synthesized using a similar procedure. Typically 2 mol equiv of 
en was added to a methanolic solution of [(116-arene)RuC12]2, where arene = 
terphenyl (o-terp), m-terphenyl (m-terp) or p-terphenyl (p-terp). Details for individual 
reactions and characterization of complexes (1 [(, 6-p-terp)Ru(en)Cl}, 2 
terp)Ru(en)Cl} and 3 [(,1 6-m-terp)Ru(en)Clf 4 ) are described in Chapter 3. 
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6.2.2 Preparation of samples 
Complexes 1,2 and 3 were dissolved in methanol to a concentration of 1 ng/p.L (ca. 2 
M) prior for analysis. 
6.2.3 Hybrid quadrupole-lion mobility/oa-ToF MS instrumentation 
Experiments were performed using the Waters (Manchester, UK) Synapt HDMS 
(high definition mass spectrometer) instrument shown in Figure 6.3. This instrument 
has been described in detail elsewhere. 7, 8 In brief, the instrument has a hybrid 
quadrupole/ion mobility/orthogonal acceleration time-of-flight (oa-T0F) geometry. 
Ions are transported to the mobility separation section through the quadrupole 
analyser, which in this work was operated in both resolving and non-resolving mode 
depending on the experiment. The mobility section comprises three consecutive, gas 
filled, travelling wave (T-Wave) RF ion guides. Ions are accumulated in the first 
(Trap) T-Wave and periodically released into the second (Mobility) T-Wave, where 
they separate according to their mobility through action of a continuous train of 
transient voltage pulses (travelling waves; vide infra). The separated ions are then 
propelled through the third (Transfer) T- Wave into the oa-ToF analyser for mass 
analysis. 
The Mobility 1-Wave consists of 61 electrode pairs, while Trap and Transfer T- 
Waves consist of 33 electrode pairs each. Ion drift times or arrival time distributions 
(ATDs) are recorded by synchronisation of the oa-ToF mass spectral acquisition with 
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the release of ions from the Trap to the Mobility device. In this study ions were 
released from the Trap for 100 p.s every 10 ms. Mass spectra were acquired in positive 
ion mode. The instrument was operated with a capillary voltage of 3.0 kV. The ion 
source block and nitrogen desolvation gas temperature were set to 80 °C and 150°C, 
respectively. The Trap and Transfer T-Waves were operated at approximately 10.2 
mbar of argon and the ion mobility T-Wave optimised between 2.05 mbar of nitrogen. 
The Mobility T-wave was operated at 300 m/s and the pulse height optimised between 
28.4 V for separation. 
Data acquisition and processing were carried out using MassLynx (V4. 1) software 
supplied with the instrument. The data were acquired and processed by Dr. Jonathan 
P. Williams (University of Warwick) and Kevin Giles (Waters MS Technologies 
Centre, Micromass UK Ltd., Manchester). 
6.2.4 Estimation of collision cross-section (CCS) measurement using the T- Wave 
based ion mobility device 
The experiments were performed by Dr Jonathan P. Williams. Instrument mobility 
calibration was performed by measuring the arrival times of ionic species whose 
absolute CCS have previously been determined using drift-cell technology as 
explained in detail previously.9' 10  CCS calibration of the Synapt was undertaken using 
the tryptic peptide ions produced from human hemoglobin whose absolute CCS 
values are known from drift-tube studies." Drift time measurements obtained from a 
single pulse height were normalised with respect to the square root of the reduced 
mass and charge. Reduced mass is defined as, p. = Mon x m5 / M,0 + mg ). A 
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correction factor is applied to the ATDs for ions obtained from the reference tryptic 
peptides such that their differences correspond to those measured using a DC system. 
This corrects for potential non-linear relationships between an ion's ATD and 
collision cross-section together with flight time offsets in the system as previously 
discussed. 12 
6.3 Results 
IM in combination with MS has been used in this study to probe the differences in 
size and shape of the isomeric ruthenium terphenyl complexes 1, 2 and 3. The 
difference in size and shape of complexes could influence, for example, their 
diffusion into cells and cellular uptake. If complexes are entering the cell by passive 
diffusion smaller size should aid uptake. 13 
Isomeric complexes 1, 2 and 3 were detected at m/z 427.06 (Figure 6.5) corresponding 
to [M]+ (calcd for C201122ClRuN2 [M] m/z 426.90). The peak observed at m/z 391.08 
corresponded to [M-HCl] + (calcd for C20H21RuN2 [M-HCl] mlz 390.44). 
0 
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391.08 
m / z -+ 
Figure 6.5 ESI mass spectrum of a 1 ng/pL (ca. 2 pM) methanol solution of complex 
1 
Arrival-time distributions (ATDs) of m/z 427.1 from a mixture of complexes 2 and 1 
showed a significant difference in arrival time of 550 us (4.17 ms for 2 and 4.72 ms 
for 1; Figure 6.6A). A slightly smaller difference of 500 uis in arrival time was 
observed for the mixture of 3 and 1 (4.22 ms for 3 and 4.72 ms for 1; Figure 6.6B). 
When all three isomeric complexes are mixed together, 2 and 3 merge into one peak 
and have an ATD centred around 4.22 ms. The ATD for complex 2 (dashed line; 
Figure 6.6C) is compared with the ATD of the mixture of 3 and 1 in Figure 6.6C 
highlighting the small but reproducible difference in arrival time of complexes 2 and 
3. For a more detailed analysis of the IM data the arrival times were converted into 
CCS values, shown in Table 6.1. 
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Figure 6.6 (A) Ion mobility (IM) arrival time distribution (ATD) of 1 ng/p.L 
(methanol) solution of the mixture of complexes 2 and 1 (1:1) (B) IM ATD of 1 
ng/.tL (methanol) solution of complexes 3 and 1 (1:1 mixture) and (C) IM ATD of the 
mixture (1:1) of complexes 3 and 1 (solid line) in methanol (1 ng/.i.L) overlaid with 
IM ATD of the solution (1 ng/tL in methanol) of complex 2 (dotted line), 
highlighting the subtle differences in arrival times of 2 and 3. 
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Table 6.1 The estimated collision cross-section (CCS) measurements of complexes 1, 
2 and 3, obtained using ion mobility (IM) 
Complex 	Estimated CCS (A2) 
1 	 120.6 
2 	 113.0 
3 	 113.6 
6.4 Discussion 
The separation of some isomeric aromatic hydrocarbons (arenes) has been explored 
previously with a differential mobility spectrometer without MS.' TM-MS data 
obtained previously for Cu(DAC) 2 , where DAC = 1 ,8-bis(9-methylanthracyl)cyclam 
and cyclam = 1,4,8,11 -tetraazacyclotetradecane, showed that this powerful technique 
can be used to probe the shape and number of existing conformers of the complex, 
which can be separated as a function of differences in collision cross-section. 
14 
Here it has been possible for the first time, to separate a mixture of Ru" isomeric 
arene anticancer complexes 1 and 3, and 1 and 2, but similarities in conformation 
(shape) of complexes 2 and 3 render them difficult to separate using the present ion 
mobility approach. Furthermore, similar in their size and shape complexes 2 and 3 
(more compact) showed reduced anti-cancer activity, while the complex that differs 
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the most in size and shape (complex 1, more elongated) showed the best potency 
(Chapter 3). 
6.5 Summary 
Ruthenium(II) anti-cancer isomer complexes have the same mass and charge and 
measured differences in ion mobility arrival times were a result of differences in 
collision cross-section (CCS), which relates to structural conformation in the gas-
phase. Overall, here we have shown that isomeric Ru" terphenyl anticancer 
complexes can be separated as a function of a difference in CCS. Arrival-time 
distributions of m/z 427.1 from a mixture of isomeric complexes 2 and 1, and 3 and 1 
showed significant differences, while similarities in conformation of 2 and 3 render 
them difficult to separate. These observations correlate with the fact that the 
differences in shape of these complexes cause differences in anticancer activity. More 
similar in shape, complexes 2 and 3 showed reduced anti-cancer activity, and the one 
that differs the most in shape (complex 1) showed the best potency (Chapter 3). 
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Conclusions and Future work 
"The real voyage of discovery consists 
not in seeking new landscapes but in 
having new eyes." 
Marcel Proust 
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7.1 Conclusions 
This thesis is concerned with synthesis and characterization of ruthenium(II) arene 
complexes of the general formula [(Y7 6_arene)Ru(N,N)X] O/+, where arene = benzene or 
benzene derivative, N,N = chelating ligand and X = leaving group. Synthesis and 
characterization of starting materials, ruthenium dimers of the type [(,6 
arene)RuC12]2, reduction of arenes as well as purification of diene products used in 
synthesis of the dimmers, are reported. The focus is on the synthesis of novel Ru" 
arene complexes containing features such as arene ligands capable of intercalation 
into DNA bases or redox active chelating ligands. The control of stereochemistry of 
chelating ligands and examination of solid and solution state structures are attempted. 
Determination of the cytotoxicity and potential cellular targets for these complexes 
are attempted as well. The structure-activity relationships are investigated. 
Preparation and characterization of complexes [(, 6-arene)Ru(en)Cl] 1 , where arene 
ortho-, meta- or para-terphenyl (o-, m- or p-terp) are reported, together with those of 
appropriate dimers and diene ligands used in their preparation. The separation and 
purification of dienes are reported as well. The cancer cell cytotoxicity, cell uptake 
and DNA binding properties of the terphenyl complexes are investigated. The 
complex containing p-terp showed higher activity against cancer cell lines, compared 
to the analogues where arene = o- or m-terp. The extent of the complex uptake into 
A2780 or A2780cis cells shows that higher amounts of [(, 6-o-terp)Ru(en)C1f or 
m-terp)Ru(en)C1] complexes are needed compared to the p-terp analogue in cells to 
induce the same cytotoxic effect. [(, 6-p-terp)Ru(en)Clf binds to DNA rapidly and 
217 
Chapter 7: Conclusions and Future work 
quantitatively, and causes significant DNA unwinding. Circular dichroism, 
competitive binding experiments with ethidium bromide and DNA melting data are 
consistent with combined intercalative and monofunctional (coordination) binding 
mode of p-terp complex, while o- and m-terp analogues bind preferentially through 
the coordination. The unusual DNA binding mode of [(, 6-p-terp)Ru(en)Cl] therefore 
makes a major contribution towards the high potency of the complex. 
Arrival-time distributions of m/z 427.1 from mixtures of these isomeric terphenyl 
complexes showed that similarities in conformation of [(i 6-o-terp)Ru(en)Cl] and 
[(116-m-terp)Ru(en)C1f render them difficult to separate using ion mobility in 
combination with mass spectrometry. Both o- and m-terp complexes are well 
separated from the p-terp analogue. 
Changing the en chelating ligand in [(,i6-arene)Ru(en)Cl]  to bipyridine (bipy) or 
deprotonated 2,2'-bipyridine-3,3'-diol (bipy(OH)O) and the arene from terphenyl to 
indane, leads to reduction in extent of binding of these complexes to DNA. DNA 
6 binding studies of [(, -indane)Ru(N,N)Cl] 01+  , where N,N = bipy or bipy(OH)O, 
suggest that DNA is not the major target for this type of complexes. Neither [(,? 6 
indane)Ru(bipy)Cl} nor [(?I 6_indane)Ru(bipy(OH)O)CI] bind strongly to DNA. In 
general Ru" arene bipy(OH)O complexes showed the significant cytotoxic activity 
towards cancer cells, in contrast to analogous complexes containing bipy or bipy with 
4,4'-substituents such as Me. X-ray crystal structures and 'H NMR spectroscopy has 
shown that deprotonated 2,2'-bipyridine-3,3'-diol (bipy (OH)O) can form a strong 
intraligand H-bonding system which enforces planarity on bipy(OH)O. Strong 
binding to 9-EtG can occur for complexes containing bipy(OH)O as well as for those 
containing bipy. An interesting feature of the structures of complexes with 
tetrahydroanthracene (tha) as arene is the presence of arene CH (bipy(OH)O and 
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bipy) interactions. Using DFT calculations these interactions were found to be more 
stable compared to ir-t interactions between the arene and 9-EtG. As the latter are 
known to stabilize DNA adducts, this contributes towards the statement that the DNA 
adducts of the tha complexes wouldn't be additionally stabilized. 
The stability of 9-EtG adducts was as well investigated for complexes containing o-
benzoquinonediimine (o-bqdi) and o-phenylenediamine (o-pda) as chelating ligands. 
The formation of less stable 9-EtG adducts of [(,-hmb)Ru(o-bqdi)Cl][PF6] compared 
to the adducts of [(1 6-p-cym)Ru(o-pda)Cl] [PF6] is suggested to be a reason for the 
inactivity of [(,7 6-hmb)Ru(o-bqdi)Cl][PF6]. The formation of the less stable adduct 
would lead to the weakened binding to DNA, which explains inactivity of the 
complex. In general complexes containing o-pda as the chelating ligand have shown 
loss of cytotoxic activity towards cancer cells when the chelating ligand is oxidized to 
o-bqdi. It is shown that the loss of activity can be attributed as well to the absence of 
hydrolysis, as found for [(, 6-p-cym)Ru(o-bqdi)I] [PF6] and loss of ability of binding to 
DNA, as a potential target. The ligand-based oxidation can be controlled through 
changes in electronic properties of the other ligands in the complex. The ligand-based 
oxidation can be followed by UV-Vis and 1 H NMR spectroscopy and the oxidation 
form can be distinguished in the x-ray crystal structure, based on differences in bond 
lengths within o-pda and o-bqdi ligands. o-Bqdi complex [(, 6-p-cym)Ru(o-
bqdi)I] [PF6] is involved in redox reactions with glutathione, and as a result 
glutathione is oxidized and the complex reduced to form [(, 6-p-cym)Ru(o-
pda)I][PF6]. Once all glutathione is oxidized, [(q 6  -p-cym)Ru(o-pda)l][PF6] undergoes 
ligand-based oxidation under oxygen from air and [(, 6-p-cym)Ru(o-bqdi)I] [PF 6] is 
recovered. 
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7.2 Future work 
The following experiments would lead to the synthesis of novel mono- and di-nuclear 
complexes, to further insight into the cellular mechanism of action of Ru" arene 
complexes and further exploration of the structure-activity relationships. 
7.2.1 DNA structural distortion induced by terphenyl Ru" arene complexes 
Studies of the interactions of terphenyl complexes (o-, m- and p-terp, Chapter 3) with 
double-stranded DNA and the characterization of the resulting structural perturbations 
could be performed by ab initio and classical molecular dynamics simulations. This 
could provide more information on differences in induced structural distortions in 
6 DNA by [( 6  -o-terp)Ru(en)Cl]+ , [( ii6  -m-terp)Ru(en)Cl] +  and [(q -p-terp)Ru(en)Cl] +  
Previously, the binding processes were investigated for [(q6-p-cymene)Ru(en)X] and 
[(i 6-p-cymene)Ru(pta)X2] complexes, where X = leaving group, en = 
ethylenediamine and pta = monodentate phosphine 1,3,5-triaza-7-
phosphaadamantane, by the means of ab initio and classical molecular dynamics 
simulations. It was found that both complexes bind easily through the Ru centre to the 
N7 of guanine (G) bases, but once bound these two complexes induce different 
structural distortions. It was found that the strain induced in the DNA backbone from 
en complex is released by a local break of a Watson-Crick base-pair (local 
denaturation). The bulkier pta complex bends the DNA helix towards the major 
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groove, resembling the characteristic DNA distortion like that induced by cisplatin.' 
As o- and m-terp complexes are bulkier compared to the p-terp analogue, the expected 
differences in structural distortion of DNA induced by these complexes would be of a 
great importance to confirm. 
7.2.2 Sandwich bis-p-lerp complex 
[('16-p-terp)Ru(en)Cl] is the most potent complex in the series of isomeric terphenyl 
complexes, and the one that shows combined coordinative and intercalative binding 
modes (Chapter 3). Therefore, it would be of a great interest to prepare bis-p-terp 
complex [( 6-p-terp)2Ru] 2 , study DNA binding properties and examine the 
contribution of only intercalative mode of binding versus the combined (coordination 
and intercalation) observed for [( 6-p-terp)Ru(en)Clf. Sandwich FeCp complexes of 
o-, m-, and p-terp have been synthesized previously by ligand exchange reactions  
between ferrocene and terphenyl. 3 
7.2.3 Din uclear terphenyl complexes 
1 ',4', 1 ",4"-Tetrahydro-p-terphenyl (th-p-terp, Chapter 2) can be used in the synthesis 
of dinuclear Ru" complex [(1 6-p-terp)Ru2(en)2Cl2] 2 . As there is a possibility for Ru 
being coordinated to only one terminal ring of th-p-terp, forming a mononuclear [(I 6_ 
dh-p-terp)Ru(en)Cl] (dh = dihydro) complex, the separation of these might be 
required. This should not create additional problems as these two complexes would 
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have a different charge, which would lead to differences in their solubility. Mass 
spectra of FeCp o-, m-, and p-terp complexes showed the existence of mononuclear 
and dinuclear complexes for all isomers. The mononuclear and dinuclear products 
have been isolated by using the difference in solubility; the mononuclear complex is 
soluble in dichioromethane, while the dinuclear complex is soluble in acetone. 3 
The DNA binding studies of [(, 6-p-terp)Ru2(en)2Cl2]2 could be performed in order to 
examine a possibility of interstrand cross links. The Ru" mer-[Ru(terpy)C 131 (terpy = 
2,2':6',2"-terpyridine) is reported to be exceptionally cytotoxic in comparison to Ru" 
complexes [Ru(terpy)(bpy)Cl]Cl and cis-[Ru(bpy)2C12] (bpy = 2,2'-bipyridine) . 4 The 
reason for such behaviour is suggested to be that in a cell-free medium, the Ru" 
trichlorido complex coordinates to DNA preferentially at guanine residues forming 
interstrand cross-links. Thus, an important feature for biological activity of ruthenium 
complexes can be DNA interstrand cross-linking. 
7.2.4 Cellular uptake studies of bipyridine complexes 
For 	positively 	charged 	[(, 6-indane)Ru(bipy)Clf 	and 	neutral 	[(16- 
indane)Ru(bipy(OH)O)Cl], cellular uptake studies could provide additional 
information to help understand the difference in activity (Chapter 4). The cellular 
uptake of small molecules can be critical to their application as drugs. The cellular 
uptake of [Ru(bipy)2(N,N)]C1 2, where N,N = bipyridine (bipy), phenantralene or other 
bipy derivatives (with more extended aromatic system), by human cancer cells in 
general showed that enlargement of the aromatic ring system results in an increase in 
the cellular uptake. 5 This is in agreement with the higher affinity of the more 
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hydrophobic systems for the cell membrane. If complexes are entering the cell by 
passive diffusion, neutral charge, smaller size and greater hydrophobicity should aid 
uptake. 6 For cisplatin analogues, the complexes with the greatest lipophilicity exhibit 
the highest uptake (all the complexes studied were hydrophilic, with octanollwater 
partition coefficients of <l). It has been reported that ligand hydrophobicity 
outweighs the influence of the charges. 8 Subtle features in organometallic complexes 
can exert major effects on cellular uptake. Therefore it would be of a great interest to 
determine the uptake of [( q 6_indane)Ru(bipy)Cl] +  and its bipy(OH)O analogue, to 
examine the effect of the overall charge of the complex, influence of the substituents 
and differences in 7t-systems of the chelating ligands. 
7.2.5 o-Semiquinonediimine (o-sqdi) as a possible intermediate in the oxidation of 
o-phenylenediamine 
7.2.5.1 Detection of the o-sqdi species 
The mechanism of the oxidation of o-phenylenediamine (o-pda) to o-
benzoquinonediimine (o-bqdi) in water is believed to occur via a multi-step 
mechanism (Chapter 5) as suggested for o-pda Pt" chlorido complexes. 9 This 
behaviour is not apparent in methanol, and the different oxidation mechanism 
pathways might arise from the difference in oxygen solubility in these two solvents; 
oxygen is around 25 times more soluble in methanol than in water. 10 The oxidation 
pathway in water, therefore, might involve the formation of o-semiquinonediimine (o-
sqdi) as an intermediate. In the literature there are several examples of complexes 
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containing o-sqdi." 12  The existence of o-sqdi in water, could be examined by EPR 
spectroscopy. As the oxidation in water is relatively slow (Chapter 5), the detection of 
o-sqdi as an intermediate, could be possible. The EPR spectra of the previously 
described [Ru"(bipy)2(0-sqdi)] showed that the unpaired electron is located primarily 
on the o-sqdi ligand and therefore the description of the Ru-ligand species is Ru"-o-
sqdi.' 2 An EPR study in water could confirm the presence of o-sqdi species, and 
provide the information on where the unpaired electron is located. Another technique 
for the examination of the mechanism of the oxidation is cyclic voltammetry (CV). 
With CV it could be distinguished if the process is a one or two electron process and 
if the oxidation is reversible. 
7.2.5.2 The ability of o-phenylenediamine (o-pda) complexes to overcome cross-
resistance towards A278U41 cell line 
o-Pda complexes have the ability to overcome cross-resistance with adriamycin 
(doxorubicin).' 3 The reduction in resistance factor (RF) achievable by replacing 
ethylenediamine (en) in Ru" arene complexes by o-pda can be dramatic (Chapter 5). 
Multi-drug resistance A2780' cells over-express the plasma membrane transporter 
P-i 70 glycoprotein. Proteins of the p-glycoprotein class, which are responsible for 
pumping drugs out of cells, appear to possess binding cavities lined on opposite faces 
with nonpolar (e.g. Phe) and negatively charged (e.g. Asp) residues. 14  Such a cavity 
might accommodate favourably positively charged complexes. Neutral or negatively 
charged compounds have a better chance to overcome cross-resistance towards 
A2780AD cells. Therefore it is of particular importance to understand the mechanism 
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of o-pda oxidation (Chapter 5), in order to further investigate the mechanism of cross-
resistance towards A2780' cells. 
7.2.6 Dinuclear mixed valent Ru complexes 
The use of the 3,3 ',4,4'-tetraimino-3 ,3 ',4,4'-tetrahydrobiphenyl (L, Figure 7.1), as a 
chelating ligand for a dinuclear Ru complex of the type [(, 6-arene)2Ru2(L)C12] 
could possibly lead to the mixed valent complex as observed previously for 
{Ru"(L)Ru" } *- {Ru'(L 2 )Rum } species. 15 The evidence for the presence or the 
absence of the mixed valent situation usually comes from EPR spectroscopy. 
Figure 7.1 Chemical structure of 3,3',4,4'-tetraamino-3,3 ',4,4'-tetrahydrobiphenyl (L). 
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